



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



# **PHILIPPINE BIDDING DOCUMENTS**

(As Harmonized with Development Partners)

## **SUPPLY AND DELIVERY OF VARIOUS MEDICINES FOR NBP AND CIW 2019**

**Fifth Edition  
October 2016**

**Bids and Awards Committee 2019**

# TABLE OF CONTENTS

<b>SECTION I. INVITATION TO BID .....</b>	<b>3</b>
<b>SECTION II. INSTRUCTIONS TO BIDDERS .....</b>	<b>22</b>
<b>SECTION III. BID DATA SHEET .....</b>	<b>54</b>
<b>SECTION IV. GENERAL CONDITIONS OF CONTRACT .....</b>	<b>81</b>
<b>SECTION V. SPECIAL CONDITIONS OF CONTRACT .....</b>	<b>98</b>
<b>SECTION VI. SCHEDULE OF REQUIREMENTS.....</b>	<b>103</b>
<b>SECTION VII. TECHNICAL SPECIFICATIONS.....</b>	<b>105</b>
<b>SECTION VIII. BIDDING FORMS .....</b>	<b>135</b>

## *Section I. Invitation to*



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**INVITATION TO BID FOR  
SUPPLY AND DELIVERY OF VARIOUS MEDICINES FOR NBP AND  
CIW 2019**

1. The **Bureau of Corrections**, through the **General Appropriation Act (GAA) of 2019** intends to apply the sum of **Two Hundred Three Million One Hundred Forty-Seven Thousand Two Hundred Three Pesos and 81/100 (₱203,147,203.81)** for the following;

<b>Item No.</b>	<b>Contract Name</b>	<b>Identification Number</b>	<b>ABC</b>
1	8% w/v Amino Acid Soln w/ 3% w/v Branched Chain Amino Acids content 500ml		1,391,390.00
2	A1(OH) 200 mg+ +Mg(OH)2 100 mg, 120 ml		5,280.00
3	A1OH + MgOH mg, Simethicone 30 mg		231,380.00
4	Aciclovir + Zinc Oxide Ointment 50mg/100mg		1,228,920.00
5	Aciclovir 200 mg		8,310.00
6	Aciclovir 400 mg		240,000.00
7	Aciclovir 5%, 5 g		447,000.00
8	Ademetionine Butane Disulfonate 500mg		1,230,000.00
9	Ademetionine Butane Disulfonate 500mg IV/IM		525,000.00
10	Agmatine Sulfate		202,500.00
11	Alendronic Acid (as Alendronate Na Trihydrate) 70 mg		206,960.00
12	Allopurinol 300 mg		45,375.00
13	Alpha- lipoic Acid, Gamma-Linoleic Acid, Vit E & Selenium with Vit B Complex 920 mg		412,500.00
14	Alprazolam 250 mcg		11,200.00
15	Aluminum Magnesium Hydroxide 200/100		1,052,700.00
16	Ambroxol HCl 30 mg		19,468.00
17	Amino Acid + M-Vit + Mineral (Oral) 50 g		528,000.00
18	Amino Acid + Sorbitol Solution for I.V. 500 ml		1,800,000.00
19	Amino Acid and Glucose Inj. With Electrolytes and Vitamins B1, 1 L		4,200,000.00

20	Amino Acid and Glucose Inj. With Electrolytes and Vitamins B1, 500 ml		2,526,000.00
21	AminoLock Collagen		336,000.00
22	Amlodipine Besilate 10 mg		220,190.00
23	Amlodipine Besilate 5 mg		115,770.00
24	Amoxicillin 500 mg		41,400.00
25	Aripiprazole 10mg Discmelt ODT 30's		1,300,000.00
26	Aripiprazole 15mg Discmelt ODT 30's		1,300,000.00
27	Aripiprazole 400mg (box of 1)		388,550.00
28	Aspirin 80 mg		33,060.00
29	Atorvastatin 10 mg + Ezetimibe 10 mg FC		3,360,000.00
30	Atorvastatin 40 mg		93,500.00
31	Atorvastatin Calcium 20 mg		600,000.00
32	ATS 1,500 IU		1,250,700.00
33	Azelastine HCl 1mg/ml (0.1% w/v) Nasal Spray14ml		1,560,000.00
34	Azithromycin Monohydrate 500 mg		136,730.00
35	Bacillus Clausii Oral Solution 5ml		240,000.00
36	Beclomethasone 100 mcg + Formoterol 6 mcg PMDI inhaler		1,741,500.00
37	Betahistine HCl 16 mg		234,210.00
38	Betamethasone Dipropionate 1ml		45,300.00
39	Betamethasone Dipropionate 640 mcg 5 g Ointment		580,500.00
40	Betamethasone Dipropionate 640mcg + Gentamicin 1mg 5 g Cream		457,000.00
41	Betamethasone Valerate 1mg/g, 1 g Cream		525,000.00
42	Biperiden 5mg		120,000.00
43	Biperiden HCl 2 mg		51,765.00
44	Biperiden Injection		88,000.00
45	Bisacodyl 10 mg (Adult)		35,790.00
46	Bisacodyl 5 mg		23,188.00
47	Blumea Balsamifera 500 mg		35,880.00
48	Brimonidine tabs 1.5 mg/ml topical ocular hypertensive agent solution		37,290.00
49	Bromhexine HCl 8 mg		154,000.00

50	Bucizine HCl + FeSO4 + MV		154,350.00
51	Budesonide + Formeterol 160 mcg + 4.5 mcg, 120 doses dry powder inhaler		1,588,400.00
52	Budesonide 500 mcg/ml, 2ml respiratory solution		890,000.00
53	Budesonide Singhaler 200 mcg/dose		248,325.00
54	Butamirate Citrate 50 mg		293,370.00
55	Calamine plus Zinc Oxide 40/30 mg/g, 5g		133,000.00
56	Calcium with Vitamin D		333,300.00
57	Calcium with Vitamins and Minerals		201,500.00
58	Candesartan Cilexetil 8 mg		151,800.00
59	Captopril 25 mg		199,144.00
60	Captopril 50 mg		523,200.00
61	Carb Steady Renal Nutrition Formula for Dialysis Patient 237ml		510,000.00
62	Carb Steady Renal Nutrition Formula for Pre-Dialysis Patient w/ CKD 237ml		1,045,000.00
63	Carbamazepine 200 mg tab		81,620.00
64	Carbocisteine 500 mg		338,040.00
65	Carvedilol 25 mg		77,000.00
66	Castor Oil (Sweet Orange Flavor), 60 ml.		27,500.00
67	Cefaclor 500 mg		347,000.00
68	Cefalexin 500 mg		234,960.00
69	Ceftriaxone 1 g		177,135.00
70	Cefuroxime 500 mg		421,385.00
71	Cefuroxime 750 mg		363,869.10
72	Cefoxitin 1 g. IM/IV		300,000.00
73	Celecoxib 200 mg		98,335.00
74	Cetirizine 10 mg		60,610.00
75	Chloramphenicol Eyedrops 0.5% x 5 ml		5,500.00
76	Chlorphenamine Maleate 10mg/ml , 1 ml injection		61,260.00
77	Chlorphenamine Maleate 4 mg		11,560.00
78	Chlorpromazine HCl 100 mg		51,192.00
79	Chlorpromazine HCl 200 mg		76,140.00

80	Cilostazol 100 mg SR		3,223,440.00
81	Cimetidine 200 mg		4,950.00
82	Cinnarizine 25 mg		27,500.00
83	Ciprofloxacin 200 mg/100 ml I.V.		11,011,000.00
84	Ciprofloxacin 500 mg		107,640.00
85	Citicoline 1g/4ml Injection		858,000.00
86	Citicoline 500 mg		913,484.00
87	Citicoline Adult Oral Drops 100 mg/ml		563,200.00
88	Clarithromycin 500 mg		159,500.00
89	Clindamycin 300 mg		205,700.00
90	Clobetasol Propionate 0.05% Cream, 5 g		469,000.00
91	Clobetasol Propionate 0.05% Ointment 5 g		420,000.00
92	Clonidine HCl 75 mcg		32,450.00
93	Clopidrogel 75 mg		171,760.00
94	Clopidrogel Bisulfate 75mg, Aspirin 100mg		295,300.00
95	Clotrimazole 10 mg + Beclomethasone 250 mcg, 5 g		544,500.00
96	Clotrimazole 100 mg (vaginal tab)		20,400.00
97	Clotrimazole Cream 1.0%, 5 g		266,000.00
98	Cloxacillin 500 mg		77,440.00
99	Clozapine 100 mg		244,000.00
100	Co-Amoxiclav 1.2 g		440,000.00
101	Co-Amoxiclav 625 mg		450,000.00
102	Colchicine 500 mcg		9,800.00
103	Complete and Balanced Diabetes Nutrition Supplement Formula Powder with Sucromalt and Fibersol, 900 g		2,458,750.00
104	Complete and Balanced Nutrition Formula for Adult with HMB, 850 g		4,498,000.00
105	Cotrimoxazole 800/160mg		24,465.00
106	Dapagliflozin 10 mg		540,750.00
107	Dapagliflozin 10 mg / Metformin 1000 mg		912,000.00
108	Dapagliflozin 10 mg / Metformin 500 mg		855,000.00
109	Dapagliflozin 5 mg / Metformin 500 mg		600,000.00

110	Depotrust 50 mg/ml x 3 ml		5,280.00
111	Desloratidine 5 mg		92,400.00
112	Dexamethasone 1mg Neomycin SO4 3,500 IU mg Polymyxin B SO4 6,000u		82,600.00
113	Dexamethasone 500 mg		6,900.00
114	Dextrose + Vitamins for I.V. 500 ml		1,200,000.00
115	Dextrose 5% Lactated Ringer Solution 1L		67,868.60
116	Dextrose 5% Normal Saline Solution 1L		89,008.00
117	Dextrose 5% Water 1L		61,193.00
118	Dextrose 50%, 50 ml		18,450.00
119	Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate		98,000.00
120	Di-Alpha Tocopheryl Acetate (Vitamin E) + Selenium 400/IU 50mcg Softgel Capsule + Mineral (30cap / bot)		3,120,000.00
121	Diazepam 10 mg / 2 ml		19,966.80
122	Diazepam 5 mg		7,040.00
123	Diclofenac Sodium 25 mg/ml, 3 ml		12,796.60
124	Diclofenac Sodium 50 mg		14,030.00
125	Dicycloverine HCl 10 mg		3,520.00
126	Digoxin 0.25 mg		50,875.00
127	Digoxin 250 mcg/ml		117,975.00
128	Diltiazem 60 mg		241,440.00
129	Diosmin 450 mg + Hesperidin 50 mg		237,930.00
130	Diphenhydramine HCl 50 mg		162,130.00
131	Diphenhydramine HCl 50 mg/ml		38,005.20
132	Divalproex Na 250 mg IR (Immediate Release)		149,600.00
133	Divalproex Sodium 500 mg		55,110.00
134	Domperidone 10 mg		41,886.00
135	Donepezil 5mg		444,000.00
136	Dopamine 40 mg/ml, 5 ml		377,600.00
137	Doxofylline 400 mg		253,440.00
138	Doxycycline 100 mg		11,340.00
139	Drospirenone estradiol		23,694.00



140	Dutasteride 500 mcg + Tamsulosin HCl 400 mcg		14,080.00
141	Enalapril Maleate 10 mg		58,695.00
142	Energy Dense Nutritional Powder Formula w/ Increased Protein Content w/ Omega 3 EPA & Antioxidant 380g		800,000.00
143	Eperisone HCl 50 mg		246,000.00
144	Epinephrine SO4 1mg/ml, 1 ml		85,345.00
145	Epoetin Alpha, 4000 iu/ml		165,000.00
146	Epoietin Beta 5,000 IU/0.3 ml		295,625.00
147	Erythromycin 500 mg		10,373.00
148	Escitalopram Oxalate 10 mg		34,300.00
149	Esomeprazole 40 mg		675,000.00
150	Essential Phospholipids softgel 300 mg		814,000.00
151	Eterocoxib 60 mg		91,800.00
152	Ethambutol 300 mg		7,920.00
153	Ethambutol 400 mg		17,500.00
154	Etoricoxib 120 mg		276,250.00
155	Evening Primrose Oil Capsule		7,383.00
156	Eye Vitamins, Alpha Lipoic Acid 200 mg, Vit C 75 mg, Lutein powder 20 mg, Vie E 12 mg, Copper		252,000.00
157	Febuxostat 40 mg		30,250.00
158	Febuxostat 80 mg		325,000.00
159	Fenofibrate 145 mg		1,050,280.00
160	Ferrous Sulfate 300 mg + Folic Acid 250mg		725,880.00
161	Floucinolone cream 0.03%		97,500.00
162	Flucinolone 0.25%, Neomycin SO4 3.5 mg, Polymycin B SO4 10,000 Units Ear Drops		226,840.00
163	Fluconazole 150 mg		187,000.00
164	Flunarizine HCl 5 mg		577,600.00
165	Fluocinolone acetoneide 250 mcg, neomycin sulfate 3.5 mg, polymyxin B sulfate 10,000 unit Otic, 5 ml		460,200.00
166	Fluoxetine HCl 20 mg		18,800.00
167	Fluticasone Propionate Nasal Spray 50 mcg		84,480.00
168	Formula powder with Glutamine, Argine & Fish Oil 400 g/can (vanilla/melon flavor)		4,293,000.00

169	Furosemide 10mg/ml, 2 ml		212,960.00
170	Furosemide 40 mg		33,600.00
171	Fusidate Sodium 10cm x 10cm Intertulle		224,400.00
172	Fusidate Sodium 2% Ointment 5 g		750,000.00
173	Fusidic Acid 2% + Betamethasone Dipropionate oint., 5 g		2,164,800.00
174	Fusidic Acid 2% Cream 5 g		293,109.00
175	Fusidic Acid 2% w/ Betamethasone w/ 0.064% Dip. Cream, 5 g		371,624.00
176	Gabapentin 100 mg		19,625.00
177	Gentamicin Sulfate 0.3% Ophthalmic/Otic drops, 5 ml		600,000.00
178	Gingko Biloba + Nattokinase Extract + Policosanol and fish Oil		3,200,000.00
179	Glibenclamide 5 mg		46,900.00
180	Gliclazide 30 mg		30,800.00
181	Gliclazide 60 mg MR		176,220.00
182	Glimiperide 2 mg		31,790.00
183	Glipizide 5 mg		112,200.00
184	Glucosamine HCl, Boswella Extract, Chondroitin SO4, Bioflavanoids & Vitamin C 620mg		1,500,000.00
185	Glucosamine Sulfate 495mg + Chondroitin Sulfate 400mg		512,000.00
186	Glucosamine Sulfate 500mg (Calcium Citrate, chondroitin, colecalciferol)		619,850.00
187	Glucosamine Sulfate, Sodium Chloride 1.884g		1,215,000.00
188	Guiafenesin 500mg		35,800.00
189	Guiafenesin 50mg / Salbutamol 1mg		32,232.00
190	Hydralazine HCl 20mg/ml		52,440.00
191	Hydrocortisone 1% Cream 5g		113,300.00
192	Hydrocortisone Sodium Succinate 100mg		114,900.00
193	Hydrocortisone Sodium Succinate 250mg		556,800.00
194	Hydroxyzine diHCl 10mg		147,433.00
195	Hyoscine N Butylbromide 10mg		149,160.00
196	Hyoscine N Butylbromide 20 mg/ml x 1ml		66,861.00
197	Hypromellose 0.3% x 10ml		637,432.00

198	Ibuprofen 400mg		12,980.00
199	Inosine Dipepranol Immunosin 500mg		36,256.00
200	Insulin 70/30 100 IU/ml		385,000.00
201	Insulin Biphasic Isophane Human (70/30) 100 IU/ml, 10ml		651,000.00
202	Insulin Glargine 100 U/ml, 10 ml		1,833,000.00
203	Insulin Glargine 100 U/ml, 3 ml		1,354,500.00
204	Insulin Glargine U 300		649,995.00
205	Insulin Glulisine 100 U/ml, 10 ml		1,140,000.00
206	Insulin N Isophane Human 100 IU/ml, 10 ml		54,500.00
207	Ipratropium B 20 mcg + Salbutamol 120 mcg inhaler		1,822,204.50
208	Ipratropium B 500 mcg + Salbutamol 120 mcg, 2.5 ml		364,320.00
209	Iron Sucrose 20 mg/ml		231,000.00
210	Isosorbide Dinitrate 1mg/1ml, 10 ml		572,000.00
211	Isosorbide Dinitrate 5 mg sublingual/oral		451,000.00
212	Isosorbide Mononitrate 60 mg MR		254,250.00
213	Itopride HCl 50mg		210,000.00
214	Itraconazole 100 mg		44,000.00
215	Ketoanalogues + Essential Amino Acids 630mg		463,792.00
216	Ketoconazole Cream 2%, 5 g		525,000.00
217	Ketorolac 30 mg/ml		26,400.00
218	Lactated Ringer Solution 1L		230,350.00
219	Lactulose 3.3g/5ml, 120 ml syrup		60,000.00
220	Lagundi 600 mg		41,250.00
221	Lansoprazole 30 mg		106,920.00
222	Levocetirizine 5 mg		220,000.00
223	Levodopa 250 mg + Carbidopa 25 mg		52,000.00
224	Levofloxacin 500 mg		64,000.00
225	Levothyroxine Na 100 mg		148.50
226	Lidocaine 2% + Epinephrine Injection		600,000.00
227	Lidocaine HCl 2%, 50 ml		98,670.00
228	Lidocaine HCl Topical Anesthesia		35,000.00

229	Linagliptin 2.5 mg + Metformin 500 mg		1,463,000.00
230	Linagliptin 5 mg		1,500,000.00
231	Loperamide 2 mg		58,850.00
232	Loratadine 10 mg		52,030.00
233	Losartan 50 mg		108,360.00
234	Losartan K 50mg + HCTZ 12.5mg		72,450.00
235	Losartan Potassium 50mg + Amlodipine Besylate 5 mg		770,000.00
236	Mannitol 20%, 250 ml		200,000.00
237	Mebendazole 100 mg		11,550.00
238	Mebendazole 500 mg		60,720.00
239	Meclizine HCl 25mg		9,405.00
240	Mecobalamin 500 mcg		69,650.00
241	Mefenamic Acid 500 mg		210,800.00
242	Meloxicam 15 mg		46,750.00
243	Memantine 10 mg		67,950.00
244	Metformin 500 mg		129,600.00
245	Methimazole 20 mg		92,000.00
246	Methimazole 5 mg		106,020.00
247	Methisoprinol 500 mg		217,300.00
248	Methylprednisolone 40 mg		87,500.00
249	Methylprednisolone 5 mg		3,025.00
250	Metoclopramide 5mg/ml, 2 ml		25,042.50
251	Metoclopramide HCl 10 mg		12,430.00
252	Metoprolol Tartrate 100 mg		17,325.00
253	Metoprolol Tartrate 50 mg		99,000.00
254	Metronidazole + Miconazole (vaginal suppository)		161,920.00
255	Metronidazole 500 mg		53,025.00
256	Metronidazole 500 mg/100 ml Infusion		16,230.00
257	Miconazole Nitrate + Hydrocortisone Cream 15 g		34,430.00
258	Miconazole Nitrate 2 cream, 5 g		270,000.00

259	Modular Amino Acid for healing and Immune Enchancing, Powder scht, 80 Kcal, Glutamine 10.0 G, CHO 9.6 G. Lipid 13.4 G with Fibre 1.2 g. Vitamin C 250mg, Vit E 83mg a-TE, Zn 3.4mg, Selenium 50 u.g. 22.4 g.		100,500.00
260	Mometasone Furoate 0.1% Ointment 5 g		870,000.00
261	Montelukast 10 mg + Levocetirizine 5 mg		612,720.00
262	Montelukast Na 10 mg		198,660.00
263	Muconase Nasal 60 ml		120,505.00
264	Multivitamins & Minerals Tablet with Natural Extract Amino Acid 820mg		2,800,000.00
265	Multivitamins / Minerals with Lecithin 50mg + Citrus Bioflavanoids 25mg L-lysine HCl 25mg		600,000.00
266	Multivitamins + Minerals + Iron		1,416,100.00
267	Mupirocin 2% Ointment 5 g		418,824.00
268	N-Acetylcysteine 600 mg		376,090.00
269	N-Acetylcysteine 600 mg		907,500.00
270	NaCl 0.65% Nasal Spray		9,750.00
271	Nalbuphine 10 mg/ml		15,369.60
272	Naphazoline HCl 0.12 mg/ml eye drops		18,000.00
273	Naproxen 500 mg		26,400.00
274	Neem, Glycyrrhiza Glabra Extract, Polyethylene Glycol, Ficus Infectoria Extract, Pongamia Pinnata Extract, Cassia Tora Extract, Zinc Oxide Celastrus Panniculatus Extract Cream 25g.		1,125,000.00
275	Nicardepine 1mg/ml, 2 ml		275,535.40
276	Nicotinamide + Phosphatidyl + B Complex Forte		220,000.00
277	Nifedipine 10 mg		211,200.00
278	Nifedipine 5 mg		13,860.00
279	Norfloxacin 400 mg		33,456.00
280	Normal Saline Solution 1L		256,762.50
281	Normal Saline Solution 1L (Irrigating Solution)		4,840.00
282	Nutritional Drink with Glutamine, Oligosaccharide, Dietary Fiber - Refreshing Lemon Flavor		3,834,000.00
283	Nystatin Oral Gel		66,192.50
284	Ofloxacin 200 mg		49,830.00
285	Ofloxacin 3mg/ml Ophthalmic/Otic Drops,5ml		417,450.00

286	Ofloxacin 400 mg		77,000.00
287	Olanzapine 10 mg		69,300.00
288	Olanzapine 5 mg oral dispersable		197,100.00
289	Olmesartan + Amlodipine 5 mg		90,000.00
290	Olmesartan 20 mg + Amlodipine 5 mg + HCTZ 12.5 mg		360,595.00
291	Olmesartan Medoxomil 20 mg		172,400.00
292	Omeprazole 20 mg		38,475.00
293	Omeprazole 40 mg powder		137,088.00
294	Oral Rehydration Salt, Powder for Oral Solution 5.125g		162,855.00
295	Oxymetazoline HCl 0.05%		23,364.00
296	Pantoprazole 40mg		179,550.00
297	Pantoprazole 40mg		87,750.00
298	Paracetamol 150 mg Injection		35,563.00
299	Paracetamol 325 mg + Ibuprofen 200 mg		65,000.00
300	Paracetamol 325 mg + Tramadol 37.5 mg		47,610.00
301	Paracetamol 500 mg		60,500.00
302	Paracetamol 650 mg + Orphenadine Citrate 50 mg		1,032,000.00
303	Permethrin Lotion 5%, 60 ml		1,031,550.00
304	Petroleum Jelly 200 g		283,140.00
305	Phenobarbital 60mg		11,000.00
306	Phenobarbital 90mg		12,100.00
307	Phenylpropanolamine 325mg + Paracetamol 25mg + Chlorphenamine Maleate 2mg		495,000.00
308	Phenytoin Sodium 100 mg		53,200.00
309	Phenytoin Sodium 50mg/ml 2ml		11,365.00
310	Phosphatidyl Choline 300mg, Nicotinamide 30mg, DL-A Tocopheryl Acetate 10mg + Vitamin B2 6mg, B6 10mg,		375,000.00
311	Pinaverium Br 50mg		4,020.00
312	Pinene 17mg + Camphene 5mg + Cineol 2mg + Menthone 6mg + Methol 32mg + Borneol 5 mg + Olive Oil 33mg		296,434.00
313	Pinene 31mg + Camphene 15mg + Cineol 3mg + Frenchone 4mg + Borneol 10mg, Anethol 4mg, Olive Oil 33mg		231,000.00
314	Pioglitazone 15 mg		300,000.00

315	Pioglitazone 15 mg + Glimeperide 2mg		340,000.00
316	Pioglitazone 15 mg + Metformin 500 mg		175,000.00
317	Pioglitazone 30 mg		360,000.00
318	Pioglitazone 30 mg + Glimeperide 2mg		420,000.00
319	Pioglitazone 30 mg + Metformin 500 mg		170,000.00
320	Piperacillin Sodium 4g + Tazobactam Sodium 500mg		211,744.50
321	Piracetam 400 mg		11,000.00
322	Pirenoxine Na eye solution 0.85mg, 15ml solvent		137,500.00
323	Piroxicam 20mg		15,400.00
324	Pizotifen, Vit B, Nicotinamide		1,093,750.00
325	Policresulen 50mg, Cinchocaine HCl 10mg 20g ointment		233,590.00
326	Potassium Chloride 2 meq/ml, 20 ml injection		44,000.00
327	Potassium Chloride 600 mg		236,280.00
328	Potassium Citrate 10 mEq		59,840.00
329	Povidone Iodine gargle, 120 ml		44,700.00
330	Pramipexole diHCl 1mg		91,000.00
331	Prasugrel 10mg		2,420,000.00
332	Prednisolone Acetate Eye Drops 1%, 5 ml		52,500.00
333	Prednisone		18,920.00
334	Prednisone 10 mg		110,166.00
335	Prednisone 5 mg		32,004.00
336	Pregabalin 150 mg		24,750.00
337	Pregabalin 75 mg		283,250.00
338	Procaterol HCl 50 mcg Swinghaler 5 ml		1,560,000.00
339	Procaterol HCl 50 mcg		810,000.00
340	Propranolol 10mg		88,550.00
341	Propranolol 40mg		33,220.00
342	Propylthiouracil 50 mg		52,500.00

343	Protein 5 g, fat 2.3 g (saturated fatty acid 0.9 g), carbohydrate 15.7 g (dietary fiber 1.2 g), Na 177 mg (salt equiv 0.44 g), vit B1 0.32 mg, vit B2 0.35 mg, vit B6 0.45 mg, vit B12 0.45 mcg, vit C 80 mg, vit A 82 mcg-RE, vit E 3.5 mg α-TE, vit D 2 mcg, Cl 72 mg, K 156 mg, Ca 94 mg, P 75 mg, Fe 1.1 mg, Zn 1.8 mg. Energy: 100 kCal (Jelly Corn Flavor) 100g		439,500.00
344	Psyllium		54,000.00
345	Purified Vero Cell 0.5ml		750,000.00
346	Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated)		1,500,000.00
347	Quetiapine Fumarate 200mg		66,000.00
348	Racicotril 100mg x 20's		19,315.00
349	Ranitidine 50 mg/ml		1,925.00
350	Ranitidine HCl 150 mg		225.00
351	Ranitidine HCl 300 mg		30,800.00
352	Ranitidine Injection		24,750.00
353	Rebamipide 100 mg		310,000.00
354	Rifaximin 200 mg		513,500.00
355	Risperidone 2 mg		163,000.00
356	Rosuvastatin 10 mg		420,000.00
357	Salbutamol + Ipratropium 2.5mg/500mg, 2.5ml		230,000.00
358	Salbutamol 100 mcg inhaler		1,254,150.00
359	Salbutamol 2 mg		166,155.00
360	Salbutamol 2.5 mg / 2.5 ml		453,435.00
361	Salmeterol + Fluticasone 25/125 mcg Inhaler		2,161,400.00
362	Salmeterol + Fluticasone 25/250 mcg Inhaler		1,276,450.00
363	Selegiline HCl 5mg		27,000.00
364	Serrapeptase 10 mg		525,000.00
365	Silver Sulfadiazine 1% Cream 20 g		73,408.56
366	Silymarine + Thiamine + Pyridoxine		44,000.00
367	Silymarine 125mg + Vit B (1.0000mg) + Vit B2 (1.0000mg) + Vit B6 (0.5000mg) + Vit B12 (0.0005mg)		4,400,000.00
368	Silymarine 150mg + Thiamine Mononitrate 4mg + Pyridoxine HCl 4mg + Cyanocobalamin 1.2mcg + Nicotinamide 12mg + Calcium Pantothenate 8mg + Lecithin 8mg (30cap / bot)		4,500,000.00



369	Simeticone 300 mg		10,472.00
370	Simvastatin 20 mg		4,628.00
371	Simvastatin 40 + Fenofibrate 145mg		420,000.00
372	Simvastatin 40 mg		176,580.00
373	Sitagliptin 100mg		300,000.00
374	Sitagliptin 50 mg + Metformin 1 g		700,000.00
375	Sitagliptin 50 mg + Metformin 500 mg		850,000.00
376	Sodium Ascorbate 568 mg		4,598,000.00
377	Sodium Bicarbonate 1 meq, 50 ml		66,000.00
378	Sodium Bicarbonate 1760mg Sodium Citrate 630mg Citric Acid 720mg Tartaric Acid		900,000.00
379	Sodium Bicarbonate 650 mg		6,380.00
380	Sodium Chloride 0.9% Solution for Irrigation 1L		92,600.70
381	Sodium Chloride 1 g		55,000.00
382	Spirolactone 25 mg		91,814.00
383	Spirolactone 25 mg / Butizide 2.5 mg		4,265.00
384	Spirolactone 50 mg		156,420.00
385	Standardized Senna Concentrate 374mg		12,000.00
386	Sterile Water for Injection, 100 cc		312,500.00
387	Sterile Water for Injection, 50 cc		281,531.25
388	Sucralfate 1 g		141,625.00
389	Sulfur Soap, 135 g		1,470,000.00
390	Sulodexide 250 mg		1,323,000.00
391	Sulodexide 600mg, 2 ml		169,400.00
392	Sultamicillin 1.5 g (Ampicillin + Sulbactam 1g/500mg)		107,800.00
393	Sultamicillin 750 mg		165,000.00
394	Tamsulosin 400 mg		174,700.00
395	Terazosin HCl 2 mg		550,000.00
396	Terazosin HCl 5 mg		2,405,900.00
397	Terbinafine Cream 10 g		132,000.00
398	Terbutaline 2.5 mg		549,000.00

399	Terbutaline 2.5 mg		44,000.00
400	Tetanus Toxoid 0.5 ml		349,650.00
401	Tetracycline 500 mg		605.00
402	Thiamine HCl Vit B1 (100mg) Riboflavin - 5 Phosphate Na Vit B2 5mg, Nicotinamide Vit B3 (100mg)		240,000.00
403	Tibolone pack (28's)		84,975.00
404	Timolol Maleate Ophthalmic Drops 0.5% x 5 ml		187,500.00
405	Tioconazole ointment 5 g		34,100.00
406	Tiotropium 18 mcg inhaler		875,000.00
407	Tobramycin 0.3% + Dexamethasone 0.5%, 5 ml Ophthalmic Drops		1,497,200.00
408	Tobramycin Ophthalmic Drops 3mg/ml, 5 ml Ophthalmic Drops		695,300.00
409	Tolnaftate 1% cream, 5 g		33,000.00
410	Tolvaptan 15 mg		3,080,000.00
411	Tramadol 50 mg		24,156.00
412	Tramadol 50 mg/ml		36,350.00
413	Tranexamic Acid 50 mg/5 ml		34,868.00
414	Tranexamic Acid 500 mg		579,700.00
415	Trimetazidine 20 mg		114,450.00
416	Trimetazidine 35 mg		33,260.00
417	Ursodeoxycholic Acid 300 mg		563,300.00
418	Valproic Acid Solution for Injection 500mg / 5ml		461,500.00
419	Valsartan 80 mg + Amlodipine 5 mg		185,000.00
420	Valsartan 80 mg + HCTZ 12.5 mg		240,000.00
421	Vildagliptin 50 mg tab		868,000.00
422	Vildagliptin 50 mg + Metformin 1 g		900,000.00
423	Vildagliptin 50 mg + Metformin 500 mg		936,000.00
424	Vildagliptin 50 mg + Metformin 850 mg		900,000.00
425	Vitamin B Complex 3 ml IV.		300,000.00
426	Vitamin B1 250mg + B6 250mg + B12 1000mcg		1,615,000.00
427	Vitamin C		9,240.00
428	Vitamin D		6,550.00

429	Vitamin E		6,600.00
430	Zolpidem Tartrate 10 mg		17,958.00

being the Approved Budget for the Contract (ABC) to payments under the contract for each item. Bids received in excess of the ABC for each item shall be automatically rejected at bid opening.

2. The **Bureau of Corrections** now invites bids for **Medicines**. Delivery of the Goods is required within 30 calendar days from the receipt of Notice to Proceed (NTP) and Contract Agreement. Bidders should have completed, within the last two (2) years from the date of submission and receipt of bids, a contract similar to the Project equivalent to at least twenty-five percent (25%) of the ABC to be bid. Partial bids are allowed. All Goods are grouped in items listed below. Bidders shall have the option of submitting a proposal on any or all items and evaluation and contract award will be undertaken on a per line basis. Lots shall not be divided further into sub-lots for the purpose of bidding, evaluation, and contract award.

In all cases, the NFCC computation, if applicable, must be sufficient for all the lots or contracts to be awarded to the Bidder.

The description of an eligible bidder is contained in the Bidding Documents, particularly, in Section II. Instructions to Bidders.

3. Bidding will be conducted through open competitive bidding procedures using a non-discretionary “pass/fail” criterion as specified in the 2016 Revised Implementing Rules and Regulations (IRR) of Republic Act (RA) 9184, otherwise known as the “Government Procurement Reform Act”.

Bidding is restricted to Filipino citizens/sole proprietorships, partnerships, or organizations with at least sixty percent (60%) interest or outstanding capital stock belonging to citizens of the Philippines, and to citizens or organizations of a country the laws or regulations of which grant similar rights or privileges to Filipino citizens, pursuant to RA 5183.

4. Interested bidders may obtain further information from **Bureau of Corrections** and inspect the Bidding Documents at the address given below during Monday to Friday from 8:00am to 5:00pm.
5. A complete set of Bidding Documents may be acquired by interested Bidders on June 26, 2019-8:00am-5:00pm to July 17, 2019-8:59pm from the address below and upon payment of a nonrefundable fee for the Bidding Documents pursuant to the latest guidelines issued by the GPPB; provided that the total fees for the Bidding Documents of all items shall not exceed the maximum fee prescribed in the Guidelines for the sum of the ABC of all items.

<b>Approved Budget for the Contract</b>	<b>Maximum Cost of Bidding Documents (in Philippine Peso)</b>
<b>500,000 and below</b>	<b>500.00</b>

<b>More than 500,000 up to 1 Million</b>	<b>1,000.00</b>
<b>More than 1 Million up to 5 Million</b>	<b>5,000.00</b>
<b>More than 5 Million up to 10 Million</b>	<b>10,000.00</b>
<b>More than 10 Million up to 50 Million</b>	<b>25,000.00</b>
<b>More than 50 Million up to 500 Million</b>	<b>50,000.00</b>
<b>More than 500 Million</b>	<b>75,000.00</b>

It may also be downloaded free of charge from the website of the Philippine Government Electronic Procurement System (PhilGEPS) and the website of the Procuring Entity, provided that Bidders shall pay the applicable fee for the Bidding Documents not later than the submission of their bids.

6. The **Bureau of Corrections** will hold a Pre-Bid Conference on July 04, 2019-01:00pm at BAC Conference Room NBP Reservation Muntinlupa City, which shall be open to prospective bidders.
7. Bids must be duly received by the BAC Secretariat at the address below on or before July 17, 2019-9:00am All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in **ITB** Clause 18.


Bid opening shall be on July 17, 2019-9:00am at BAC Conference Room NBP Reservation Muntinlupa City. Bids will be opened in the presence of the bidders' representatives who choose to attend at the address below. Late bids shall not be accepted.

8. *The Schedule of Bidding Activities shall be as follows:*

<b>ACTIVITES</b>	<b>DATE/TIME</b>	<b>VENUE</b>
1. Sale and Issuance of Bid Documents	June 26, 2019-8:00am-5:00pm to July 17, 2019-8:59pm	Supply Division Bureau of Corrections Muntinlupa City
2. Pre-bid Conference	July 04, 2019-01:00pm	BAC Conference Room Bureau of Corrections Muntinlupa City
3. Submission and Opening of Bid Documents	July 17, 2019-9:00am	BAC Conference Room Bureau of Corrections Muntinlupa City

9. The **Bureau of Corrections** reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Section 41 of RA 9184 and its IRR, without thereby incurring any liability to the affected bidder or bidders.

For further information, you can call the BAC Secretariat c/o *WILLIAM M. TERRADO* at the Supply Office, Bureau of Corrections, Muntinlupa City at Tel # 809-8587/478-0907 from 8:00 am to 5:00pm, Monday to Friday.

  
**CTCSUPT. MA. LOURDES M. RAZON, MD.**  
*Chairperson, Bids and Awards Committee*

## ***Section II. Instructions to Bidders***

## TABLE OF CONTENTS

<b>A. GENERAL</b> .....	25
1. Scope of Bid.....	25
2. Source of Funds .....	25
3. Corrupt, Fraudulent, Collusive, and Coercive Practices.....	25
4. Conflict of Interest .....	26
5. Eligible Bidders .....	28
6. Bidder’s Responsibilities.....	29
7. Origin of Goods .....	31
8. Subcontracts .....	31
<b>B. CONTENTS OF BIDDING DOCUMENTS</b> .....	31
9. Pre-Bid Conference .....	31
10. Clarification and Amendment of Bidding Documents.....	32
<b>C. PREPARATION OF BIDS</b> .....	32
11. Language of Bid.....	32
12. Documents Comprising the Bid: Eligibility and Technical Components .....	33
13. Documents Comprising the Bid: Financial Component .....	35
14. Alternative Bids .....	35
15. Bid Prices .....	36
16. Bid Currencies .....	37
17. Bid Validity .....	38
18. Bid Security.....	38
19. Format and Signing of Bids.....	40
20. Sealing and Marking of Bids .....	41
<b>D. SUBMISSION AND OPENING OF BIDS</b> .....	42
21. Deadline for Submission of Bids .....	42
22. Late Bids.....	42
23. Modification and Withdrawal of Bids .....	42
24. Opening and Preliminary Examination of Bids .....	43
<b>E. EVALUATION AND COMPARISON OF BIDS</b> .....	44
25. Process to be Confidential .....	44
26. Clarification of Bids .....	45
27. Domestic Preference.....	45

<b>28. Detailed Evaluation and Comparison of Bids.....</b>	<b>45</b>
<b>29. Post-Qualification.....</b>	<b>47</b>
<b>30. Reservation Clause.....</b>	<b>37</b>
<b>F. AWARD OF CONTRACT.....</b>	<b>50</b>
<b>31. Contract Award.....</b>	<b>50</b>
<b>32. Signing of the Contract.....</b>	<b>51</b>
<b>33. Performance Security.....</b>	<b>51</b>
<b>34. Notice to Proceed.....</b>	<b>52</b>
<b>35. Protest Mechanism.....</b>	<b>53</b>



## **A. General**

### **1. Scope of Bid**

- 1.1. The Procuring Entity named in the **BDS** invites bids for the supply and delivery of the Goods as described in Section VII. Technical Specifications.
- 1.2. The name, identification, and number of lots specific to this bidding are provided in the **BDS**. The contracting strategy and basis of evaluation of lots is described in **ITB** Clause 28.

### **2. Source of Funds**

The Procuring Entity has a budget or has received funds from the Funding Source named in the **BDS**, and in the amount indicated in the **BDS**. It intends to apply part of the funds received for the Project, as defined in the **BDS**, to cover eligible payments under the contract.

### **3. Corrupt, Fraudulent, Collusive, and Coercive Practices**

- 3.1. Unless otherwise specified in the **BDS**, the Procuring Entity as well as the bidders and suppliers shall observe the highest standard of ethics during the procurement and execution of the contract. In pursuance of this policy, the Procuring Entity:
  - (a) defines, for purposes of this provision, the terms set forth below as follows:
    - (i) “corrupt practice” means behavior on the part of officials in the public or private sectors by which they improperly and unlawfully enrich themselves, others, or induce others to do so, by misusing the position in which they are placed, and includes the offering, giving, receiving, or soliciting of anything of value to influence the action of any such official in the procurement process or in contract execution; entering, on behalf of the government, into any contract or transaction manifestly and grossly disadvantageous to the same, whether or not the public officer profited or will profit thereby, and similar acts as provided in RA 3019.
    - (ii) “fraudulent practice” means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Procuring Entity, and includes collusive practices among Bidders (prior to or after bid submission) designed to establish bid prices at artificial, non-competitive levels and to deprive the Procuring Entity of the benefits of free and open competition.
    - (iii) “collusive practices” means a scheme or arrangement between two or more Bidders, with or without the knowledge of the

Procuring Entity, designed to establish bid prices at artificial, non-competitive levels.

(iv) “coercive practices” means harming or threatening to harm, directly or indirectly, persons, or their property to influence their participation in a procurement process, or affect the execution of a contract;

(v) “obstructive practice” is

(aa) deliberately destroying, falsifying, altering or concealing of evidence material to an administrative proceedings or investigation or making false statements to investigators in order to materially impede an administrative proceedings or investigation of the Procuring Entity or any foreign government/foreign or international financing institution into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the administrative proceedings or investigation or from pursuing such proceedings or investigation; or

(bb) acts intended to materially impede the exercise of the inspection and audit rights of the Procuring Entity or any foreign government/foreign or international financing institution herein.

(b) will reject a proposal for award if it determines that the Bidder recommended for award has engaged in any of the practices mentioned in this Clause for purposes of competing for the contract.

3.2. Further, the Procuring Entity will seek to impose the maximum civil, administrative, and/or criminal penalties available under applicable laws on individuals and organizations deemed to be involved in any of the practices mentioned in **ITB** Clause 3.1(a).

3.3. Furthermore, the Funding Source and the Procuring Entity reserve the right to inspect and audit records and accounts of a bidder or supplier in the bidding for and performance of a contract themselves or through independent auditors as reflected in the **GCC** Clause 3.

#### **4. Conflict of Interest**

4.1. All Bidders found to have conflicting interests shall be disqualified to participate in the procurement at hand, without prejudice to the imposition of appropriate administrative, civil, and criminal sanctions. A Bidder may be considered to have conflicting interests with another Bidder in any of the events described in paragraphs (a) through (c) below and a general conflict of

interest in any of the circumstances set out in paragraphs (d) through (g) below:

- (a) A Bidder has controlling shareholders in common with another Bidder;
- (b) A Bidder receives or has received any direct or indirect subsidy from any other Bidder;
- (c) A Bidder has the same legal representative as that of another Bidder for purposes of this bid;
- (d) A Bidder has a relationship, directly or through third parties, that puts them in a position to have access to information about or influence on the bid of another Bidder or influence the decisions of the Procuring Entity regarding this bidding process;
- (e) A Bidder submits more than one bid in this bidding process. However, this does not limit the participation of subcontractors in more than one bid;
- (f) A Bidder who participated as a consultant in the preparation of the design or technical specifications of the Goods and related services that are the subject of the bid; or
- (g) A Bidder who lends, or temporarily seconds, its personnel to firms or organizations which are engaged in consulting services for the preparation related to procurement for or implementation of the project, if the personnel would be involved in any capacity on the same project.

4.2. In accordance with Section 47 of the IRR of RA 9184, all Bidding Documents shall be accompanied by a sworn affidavit of the Bidder that it is not related to the Head of the Procuring Entity (HoPE), members of the Bids and Awards Committee (BAC), members of the Technical Working Group (TWG), members of the BAC Secretariat, the head of the Project Management Office (PMO) or the end-user unit, and the project consultants, by consanguinity or affinity up to the third civil degree. On the part of the Bidder, this Clause shall apply to the following persons:

- (a) If the Bidder is an individual or a sole proprietorship, to the Bidder himself;
- (b) If the Bidder is a partnership, to all its officers and members;
- (c) If the Bidder is a corporation, to all its officers, directors, and controlling stockholders;
- (d) If the Bidder is a cooperative, to all its officers, directors, and controlling shareholders or members; and
- (e) If the Bidder is a joint venture (JV), the provisions of items (a), (b), (c), or (d) of this Clause shall correspondingly apply to each of the members of the said JV, as may be appropriate.

Relationship of the nature described above or failure to comply with this Clause will result in the automatic disqualification of a Bidder.

## 5. Eligible Bidders

- 5.1. Unless otherwise provided in the **BDS**, the following persons shall be eligible to participate in this bidding:
- (a) Duly licensed Filipino citizens/sole proprietorships;
  - (b) Partnerships duly organized under the laws of the Philippines and of which at least sixty percent (60%) of the interest belongs to citizens of the Philippines;
  - (c) Corporations duly organized under the laws of the Philippines, and of which at least sixty percent (60%) of the outstanding capital stock belongs to citizens of the Philippines;
  - (d) Cooperatives duly organized under the laws of the Philippines; and
  - (e) Persons/entities forming themselves into a Joint Venture (JV), *i.e.*, a group of two (2) or more persons/entities that intend to be jointly and severally responsible or liable for a particular contract: Provided, however, that Filipino ownership or interest of the JV concerned shall be at least sixty percent (60%).
- 5.2. Foreign bidders may be eligible to participate when any of the following circumstances exist, as specified in the **BDS**:
- (a) When a Treaty or International or Executive Agreement as provided in Section 4 of RA 9184 and its IRR allow foreign bidders to participate;
  - (b) Citizens, corporations, or associations of a country, the laws or regulations of which grant reciprocal rights or privileges to citizens, corporations, or associations of the Philippines;
  - (c) When the Goods sought to be procured are not available from local suppliers; or
  - (d) When there is a need to prevent situations that defeat competition or restrain trade.
- 5.3. Government owned or –controlled corporations (GOCCs) may be eligible to participate only if they can establish that they (a) are legally and financially autonomous, (b) operate under commercial law, and (c) are not attached agencies of the Procuring Entity.
- 5.4. Unless otherwise provided in the **BDS**, the Bidder must have completed a Single Largest Completed Contract (SLCC) similar to the Project and the value of which, adjusted, if necessary, by the Bidder to current prices using the Philippine Statistics Authority (PSA) consumer price index, must be at least equivalent to a percentage of the ABC stated in the **BDS**.

For this purpose, contracts similar to the Project shall be those described in the **BDS**, and completed within the relevant period stated in the Invitation to Bid and **ITB** Clause 12.1(a)(ii).

- 5.5. The Bidder must submit a computation of its Net Financial Contracting Capacity (NFCC), which must be at least equal to the ABC to be bid, calculated as follows:

NFCC = [(Current assets minus current liabilities) (15)] minus the value of all outstanding or uncompleted portions of the projects under ongoing contracts, including awarded contracts yet to be started, coinciding with the contract to be bid.

The values of the domestic bidder's current assets and current liabilities shall be based on the latest Audited Financial Statements submitted to the BIR.

For purposes of computing the foreign bidders' NFCC, the value of the current assets and current liabilities shall be based on their audited financial statements prepared in accordance with international financial reporting standards.

If the prospective bidder opts to submit a committed Line of Credit, it must be at least equal to ten percent (10%) of the ABC to be bid. If issued by a foreign universal or commercial bank, it shall be confirmed or authenticated by a local universal or commercial bank.

## **6. Bidder's Responsibilities**

- 6.1. The Bidder or its duly authorized representative shall submit a sworn statement in the form prescribed in Section VIII. Bidding Forms as required in **ITB** Clause 12.1(b)(iii).
- 6.2. The Bidder is responsible for the following:
- (a) Having taken steps to carefully examine all of the Bidding Documents;
  - (b) Having acknowledged all conditions, local or otherwise, affecting the implementation of the contract;
  - (c) Having made an estimate of the facilities available and needed for the contract to be bid, if any;
  - (d) Having complied with its responsibility to inquire or secure Supplemental/Bid Bulletin(s) as provided under **ITB** Clause 10.4.
  - (e) Ensuring that it is not "blacklisted" or barred from bidding by the GOP or any of its agencies, offices, corporations, or LGUs, including foreign government/foreign or international financing institution whose blacklisting rules have been recognized by the GPPB;

- (f) Ensuring that each of the documents submitted in satisfaction of the bidding requirements is an authentic copy of the original, complete, and all statements and information provided therein are true and correct;
- (g) Authorizing the HoPE or its duly authorized representative/s to verify all the documents submitted;
- (h) Ensuring that the signatory is the duly authorized representative of the Bidder, and granted full power and authority to do, execute and perform any and all acts necessary and/or to represent the Bidder in the bidding, with the duly notarized Secretary's Certificate attesting to such fact, if the Bidder is a corporation, partnership, cooperative, or joint venture;
- (i) Complying with the disclosure provision under Section 47 of RA 9184 and its IRR in relation to other provisions of RA 3019;
- (j) Complying with existing labor laws and standards, in the case of procurement of services; Moreover, bidder undertakes to:
  - (i) Ensure the entitlement of workers to wages, hours of work, safety and health and other prevailing conditions of work as established by national laws, rules and regulations; or collective bargaining agreement; or arbitration award, if and when applicable.

In case there is a finding by the Procuring Entity or the DOLE of underpayment or non-payment of workers' wage and wage-related benefits, bidder agrees that the performance security or portion of the contract amount shall be withheld in favor of the complaining workers pursuant to appropriate provisions of Republic Act No. 9184 without prejudice to the institution of appropriate actions under the Labor Code, as amended, and other social legislations.

- (ii) Comply with occupational safety and health standards and to correct deficiencies, if any.

In case of imminent danger, injury or death of the worker, bidder undertakes to suspend contract implementation pending clearance to proceed from the DOLE Regional Office and to comply with Work Stoppage Order; and

- (iii) Inform the workers of their conditions of work, labor clauses under the contract specifying wages, hours of work and other benefits under prevailing national laws, rules and regulations; or collective bargaining agreement; or arbitration award, if and when applicable, through posting in two (2) conspicuous places in the establishment's premises; and

- (k) Ensuring that it did not give or pay, directly or indirectly, any commission, amount, fee, or any form of consideration, pecuniary or otherwise, to any person or official, personnel or representative of the government in relation to any procurement project or activity.

Failure to observe any of the above responsibilities shall be at the risk of the Bidder concerned.

- 6.3. The Bidder is expected to examine all instructions, forms, terms, and specifications in the Bidding Documents.
- 6.4. It shall be the sole responsibility of the Bidder to determine and to satisfy itself by such means as it considers necessary or desirable as to all matters pertaining to the contract to be bid, including: (a) the location and the nature of this Project; (b) climatic conditions; (c) transportation facilities; and (d) other factors that may affect the cost, duration, and execution or implementation of this Project.
- 6.5. The Procuring Entity shall not assume any responsibility regarding erroneous interpretations or conclusions by the prospective or eligible bidder out of the data furnished by the procuring entity. However, the Procuring Entity shall ensure that all information in the Bidding Documents, including bid/supplemental bid bulletin/s issued, are correct and consistent.
- 6.6. Before submitting their bids, the Bidder is deemed to have become familiar with all existing laws, decrees, ordinances, acts and regulations of the Philippines which may affect this Project in any way.
- 6.7. The Bidder shall bear all costs associated with the preparation and submission of his bid, and the Procuring Entity will in no case be responsible or liable for those costs, regardless of the conduct or outcome of the bidding process.
- 6.8. The Bidder should note that the Procuring Entity will accept bids only from those that have paid the applicable fee for the Bidding Documents at the office indicated in the Invitation to Bid.

## **7. Origin of Goods**

Unless otherwise indicated in the **BDS**, there is no restriction on the origin of goods other than those prohibited by a decision of the United Nations Security Council taken under Chapter VII of the Charter of the United Nations, subject to **ITB** Clause 27.1.

## **8. Subcontracts**

- 8.1. Unless otherwise specified in the **BDS**, the Bidder may subcontract portions of the Goods to an extent as may be approved by the Procuring Entity and stated in the **BDS**. However, subcontracting of any portion shall not relieve the Bidder from any liability or obligation that may arise from the contract for this Project.

- 8.2. Subcontractors must submit the documentary requirements under **ITB** Clause 12 and comply with the eligibility criteria specified in the **BDS**. In the event that any subcontractor is found by the Procuring Entity to be ineligible, the subcontracting of such portion of the Goods shall be disallowed.
- 8.3. The Bidder may identify the subcontractor to whom a portion of the Goods will be subcontracted at any stage of the bidding process or during contract implementation. If the Bidder opts to disclose the name of the subcontractor during bid submission, the Bidder shall include the required documents as part of the technical component of its bid.

## **B. Contents of Bidding Documents**

### **9. Pre-Bid Conference**

- 9.1. (a) If so specified in the **BDS**, a pre-bid conference shall be held at the venue and on the date indicated therein, to clarify and address the Bidders' questions on the technical and financial components of this Project.  
  
(b) The pre-bid conference shall be held at least twelve (12) calendar days before the deadline for the submission and receipt of bids, but not earlier than seven (7) calendar days from the posting of the invitation to bid/bidding documents in the PhilGEPS website. If the Procuring Entity determines that, by reason of the method, nature, or complexity of the contract to be bid, or when international participation will be more advantageous to the GOP, a longer period for the preparation of bids is necessary, the pre-bid conference shall be held at least thirty (30) calendar days before the deadline for the submission and receipt of bids, as specified in the **BDS**.
- 9.2. Bidders are encouraged to attend the pre-bid conference to ensure that they fully understand the Procuring Entity's requirements. Non-attendance of the Bidder will in no way prejudice its bid; however, the Bidder is expected to know the changes and/or amendments to the Bidding Documents as recorded in the minutes of the pre-bid conference and the Supplemental/Bid Bulletin. The minutes of the pre-bid conference shall be recorded and prepared not later than five (5) calendar days after the pre-bid conference. The minutes shall be made available to prospective bidders not later than five (5) days upon written request.
- 9.3. Decisions of the BAC amending any provision of the bidding documents shall be issued in writing through a Supplemental/Bid Bulletin at least seven (7) calendar days before the deadline for the submission and receipt of bids.

### **10. Clarification and Amendment of Bidding Documents**

- 10.1. Prospective bidders may request for clarification on and/or interpretation of any part of the Bidding Documents. Such request must be in writing and submitted to the Procuring Entity at the address indicated in the **BDS** at least ten (10) calendar days before the deadline set for the submission and receipt of Bids.



- 10.2. The BAC shall respond to the said request by issuing a Supplemental/Bid Bulletin, to be made available to all those who have properly secured the Bidding Documents, at least seven (7) calendar days before the deadline for the submission and receipt of Bids.
- 10.3. Supplemental/Bid Bulletins may also be issued upon the Procuring Entity's initiative for purposes of clarifying or modifying any provision of the Bidding Documents not later than seven (7) calendar days before the deadline for the submission and receipt of Bids. Any modification to the Bidding Documents shall be identified as an amendment.
- 10.4. Any Supplemental/Bid Bulletin issued by the BAC shall also be posted in the PhilGEPS and the website of the Procuring Entity concerned, if available, and at any conspicuous place in the premises of the Procuring Entity concerned. It shall be the responsibility of all Bidders who have properly secured the Bidding Documents to inquire and secure Supplemental/Bid Bulletins that may be issued by the BAC. However, Bidders who have submitted bids before the issuance of the Supplemental/Bid Bulletin must be informed and allowed to modify or withdraw their bids in accordance with **ITB** Clause 23.

### **C. Preparation of Bids**

#### **11. Language of Bids**

The eligibility requirements or statements, the bids, and all other documents to be submitted to the BAC must be in English. If the eligibility requirements or statements, the bids, and all other documents submitted to the BAC are in foreign language other than English, it must be accompanied by a translation of the documents in English. The documents shall be translated by the relevant foreign government agency, the foreign government agency authorized to translate documents, or a registered translator in the foreign bidder's country; and shall be authenticated by the appropriate Philippine foreign service establishment/post or the equivalent office having jurisdiction over the foreign bidder's affairs in the Philippines. The English translation shall govern, for purposes of interpretation of the bid.

#### **12. Documents Comprising the Bid: Eligibility and Technical Components**

12.1. Unless otherwise indicated in the **BDS**, the first envelope shall contain the following eligibility and technical documents:

- (a) Eligibility Documents –

Class "A" Documents:

- (i) PhilGEPS Certificate of Registration and Membership in accordance with Section 8.5.2 of the IRR. For procurement to be performed overseas, it shall be subject to the Guidelines to be issued by the GPPB, OR combination of a valid PhilGEPS Platinum Certificate of Registration and Membership and the

valid and updated Class A Eligibility Documents pursuant to Section 8.5.2 of the 2016 Revised IRR; OR the following eligibility documents

- a) Registration certificate from SEC, Department of Trade and Industry (DTI) for sole proprietorship, or CDA for cooperatives;
- b) Mayor's/Business permit issued by the city or municipality where the principal place of business of the prospective bidder is located, or the equivalent document for Exclusive Economic Zones or Areas.

In cases of recently expired Mayor's/Business permits, it shall be accepted together with the official receipt as proof that the bidder has applied for renewal within the period prescribed by the concerned local government unit, provided that the renewed permit shall be submitted as a postqualification requirement in accordance with Section 34.2 of this IRR;

- c) Tax clearance per E.O. 398, s. 2005, as finally reviewed and approved by the Bureau of Internal Revenue (BIR); and
- d) Audited financial statements, showing, among others, the prospective bidder's total and current assets and liabilities, stamped "received" by the BIR or its duly accredited and authorized institutions, for the preceding calendar year which should not be earlier than two (2) years from the date of bid submission.

Provided that the bidder having the Lowest/Single Calculated Bid shall submit within five (5) calendar days from receipt of the BAC notice, a valid and updated PhilGEPS Platinum Certificate of Registration and Membership

- (ii) Statement of all its ongoing government and private contracts, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid; and

Statement of the Bidder's SLCC similar to the contract to be bid, in accordance with ITB Clause 5.4, within the relevant period as provided in the **BDS**.

The two statements required shall indicate for each contract the following:

- (ii.1) name of the contract;

- (ii.2) date of the contract;
  - (ii.3) contract duration;
  - (ii.4) owner's name and address;
  - (ii.5) kinds of Goods;
  - (ii.6) For Statement of Ongoing Contracts - amount of contract and value of outstanding contracts;
  - (ii.7) For Statement of SLCC - amount of completed contracts, adjusted by the Bidder to current prices using PSA's consumer price index, if necessary for the purpose of meeting the SLCC requirement;
  - (ii.8) date of delivery; and
  - (ii.9) end user's acceptance or official receipt(s) or sales invoice issued for the contract, if completed, which shall be attached to the statements.
- (iii) NFCC computation in accordance with ITB Clause 5.5 or a committed Line of Credit from a universal or commercial bank.

Class "B" Document:

- (iv) If applicable, the Joint Venture Agreement (JVA) in case the joint venture is already in existence, or duly notarized statements from all the potential joint venture partners in accordance with Section 23.1(b) of the IRR.
- (b) Technical Documents –
- (i) Bid security in accordance with **ITB** Clause 18. If the Bidder opts to submit the bid security in the form of:
    - (i.1) a bank draft/guarantee or an irrevocable letter of credit issued by a foreign bank, it shall be accompanied by a confirmation from a Universal or Commercial Bank; or
    - (i.2) a surety bond, it shall be accompanied by a certification by the Insurance Commission that the surety or insurance company is authorized to issue such instruments;
  - (ii) Conformity with technical specifications, as enumerated and specified in Sections VI and VII of the Bidding Documents; and

- (iii) Sworn statement in accordance with Section 25.3 of the IRR of RA 9184 and using the form prescribed in Section VIII. Bidding Forms.
- (iv) For foreign bidders claiming eligibility by reason of their country's extension of reciprocal rights to Filipinos, a certification from the relevant government office of their country stating that Filipinos are allowed to participate in their government procurement activities for the same item or product.

### **13. Documents Comprising the Bid: Financial Component**

13.1. The financial component of the bid shall contain the following:

- (a) Financial Bid Form, which includes bid prices and the applicable Price Schedules, in accordance with **ITB** Clauses 15.1 and 15.4;
- (b) If the Bidder claims preference as a Domestic Bidder, a certification from the DTI issued in accordance with **ITB** Clause 27, unless otherwise provided in the **BDS**; and
- (c) Any other document related to the financial component of the bid as stated in the **BDS**.

13.2. (a) Unless otherwise stated in the **BDS**, all bids that exceed the ABC shall not be accepted.

(b) Unless otherwise indicated in the **BDS**, for foreign-funded procurement, a ceiling may be applied to bid prices provided the following conditions are met:

- (i) Bidding Documents are obtainable free of charge on a freely accessible website. If payment of Bidding Documents is required by the procuring entity, payment could be made upon the submission of bids.
- (ii) The procuring entity has procedures in place to ensure that the ABC is based on recent estimates made by the responsible unit of the procuring entity and that the estimates reflect the quality, supervision and risk and inflationary factors, as well as prevailing market prices, associated with the types of works or goods to be procured.
- (iii) The procuring entity has trained cost estimators on estimating prices and analyzing bid variances.
- (iv) The procuring entity has established a system to monitor and report bid prices relative to ABC and engineer's/procuring entity's estimate.

- (v) The procuring entity has established a monitoring and evaluation system for contract implementation to provide a feedback on actual total costs of goods and works.

## **14. Alternative Bids**

- 14.1 Alternative Bids shall be rejected. For this purpose, alternative bid is an offer made by a Bidder in addition or as a substitute to its original bid which may be included as part of its original bid or submitted separately therewith for purposes of bidding. A bid with options is considered an alternative bid regardless of whether said bid proposal is contained in a single envelope or submitted in two (2) or more separate bid envelopes.
- 14.2 Each Bidder shall submit only one Bid, either individually or as a partner in a JV. A Bidder who submits or participates in more than one bid (other than as a subcontractor if a subcontractor is permitted to participate in more than one bid) will cause all the proposals with the Bidder's participation to be disqualified. This shall be without prejudice to any applicable criminal, civil and administrative penalties that may be imposed upon the persons and entities concerned.

## **15. Bid Prices**

- 15.1. The Bidder shall complete the appropriate Schedule of Prices included herein, stating the unit prices, total price per item, the total amount and the expected countries of origin of the Goods to be supplied under this Project.
- 15.2. The Bidder shall fill in rates and prices for all items of the Goods described in the Schedule of Prices. Bids not addressing or providing all of the required items in the Bidding Documents including, where applicable, Schedule of Prices, shall be considered non-responsive and, thus, automatically disqualified. In this regard, where a required item is provided, but no price is indicated, the same shall be considered as non-responsive, but specifying a zero (0) or a dash (-) for the said item would mean that it is being offered for free to the Government, except those required by law or regulations to be accomplished.
- 15.3. The terms Ex Works (EXW), Cost, Insurance and Freight (CIF), Cost and Insurance Paid to (CIP), Delivered Duty Paid (DDP), and other trade terms used to describe the obligations of the parties, shall be governed by the rules prescribed in the current edition of the International Commercial Terms (INCOTERMS) published by the International Chamber of Commerce, Paris.
- 15.4. Prices indicated on the Price Schedule shall be entered separately in the following manner:
  - (a) For Goods offered from within the Procuring Entity's country:
    - (i) The price of the Goods quoted EXW (ex works, ex factory, ex warehouse, ex showroom, or off-the-shelf, as applicable);

- (ii) The cost of all customs duties and sales and other taxes already paid or payable;
  - (iii) The cost of transportation, insurance, and other costs incidental to delivery of the Goods to their final destination; and
  - (iv) The price of other (incidental) services, if any, listed in the **BDS**.
- (b) For Goods offered from abroad:
- (i) Unless otherwise stated in the **BDS**, the price of the Goods shall be quoted DDP with the place of destination in the Philippines as specified in the **BDS**. In quoting the price, the Bidder shall be free to use transportation through carriers registered in any eligible country. Similarly, the Bidder may obtain insurance services from any eligible source country.
  - (ii) The price of other (incidental) services, if any, listed in the **BDS**.
- (c) For Services, based on the form which may be prescribed by the Procuring Entity, in accordance with existing laws, rules and regulations

15.5. Prices quoted by the Bidder shall be fixed during the Bidder's performance of the contract and not subject to variation or price escalation on any account. A bid submitted with an adjustable price quotation shall be treated as non-responsive and shall be rejected, pursuant to **ITB** Clause 24.

All bid prices for the given scope of work in the contract as awarded shall be considered as fixed prices, and therefore not subject to price escalation during contract implementation, except under extraordinary circumstances. Upon the recommendation of the Procuring Entity, price escalation may be allowed in extraordinary circumstances as may be determined by the National Economic and Development Authority in accordance with the Civil Code of the Philippines, and upon approval by the GPPB. Nevertheless, in cases where the cost of the awarded contract is affected by any applicable new laws, ordinances, regulations, or other acts of the GOP, promulgated after the date of bid opening, a contract price adjustment shall be made or appropriate relief shall be applied on a no loss-no gain basis.

## 16. Bid Currencies

16.1. Prices shall be quoted in the following currencies:

- (a) For Goods that the Bidder will supply from within the Philippines, the prices shall be quoted in Philippine Pesos.
- (b) For Goods that the Bidder will supply from outside the Philippines, the prices may be quoted in the currency(ies) stated in the **BDS**. However, for purposes of bid evaluation, bids denominated in foreign currencies

shall be converted to Philippine currency based on the exchange rate as published in the *Bangko Sentral ng Pilipinas* (BSP) reference rate bulletin on the day of the bid opening.

- 16.2. If so allowed in accordance with **ITB** Clause 16.1, the Procuring Entity for purposes of bid evaluation and comparing the bid prices will convert the amounts in various currencies in which the bid price is expressed to Philippine Pesos at the foregoing exchange rates.
- 16.3. Unless otherwise specified in the **BDS**, payment of the contract price shall be made in Philippine Pesos.

**17. Bid Validity**

- 17.1. Bids shall remain valid for the period specified in the **BDS** which shall not exceed one hundred twenty (120) calendar days from the date of the opening of bids.
- 17.2. In exceptional circumstances, prior to the expiration of the bid validity period, the Procuring Entity may request Bidders to extend the period of validity of their bids. The request and the responses shall be made in writing. The bid security described in **ITB** Clause 18 should also be extended corresponding to the extension of the bid validity period at the least. A Bidder may refuse the request without forfeiting its bid security, but his bid shall no longer be considered for further evaluation and award. A Bidder granting the request shall not be required or permitted to modify its bid.

**18. Bid Security**

- 18.1. The Bidder shall submit a Bid Securing Declaration or any form of Bid Security in the amount stated in the **BDS**, which shall be not less than the percentage of the ABC in accordance with the following schedule:

Form of Bid Security	Amount of Bid Security (Not Less than the Percentage of the ABC)
(a) Cash or cashier's/manager's check issued by a Universal or Commercial Bank.  <i>For biddings conducted by LGUs, the Cashier's/Manager's Check may be issued by other banks certified by the BSP as authorized to issue such financial instrument.</i>	Two percent (2%)

<p>(b) Bank draft/guarantee or irrevocable letter of credit issued by a Universal or Commercial Bank: Provided, however, that it shall be confirmed or authenticated by a Universal or Commercial Bank, if issued by a foreign bank.</p> <p><i>For biddings conducted by LGUs, Bank Draft/Guarantee, or Irrevocable Letter of Credit may be issued by other banks certified by the BSP as authorized to issue such financial instrument.</i></p>	
<p>(c) Surety bond callable upon demand issued by a surety or insurance company duly certified by the Insurance Commission as authorized to issue such security.</p>	<p>Five percent (5%)</p>

The Bid Securing Declaration mentioned above is an undertaking which states, among others, that the Bidder shall enter into contract with the procuring entity and furnish the performance security required under ITB Clause 33.2, within ten (10) calendar days from receipt of the Notice of Award, and commits to pay the corresponding amount as fine, and be suspended for a period of time from being qualified to participate in any government procurement activity in the event it violates any of the conditions stated therein as provided in the guidelines issued by the GPPB.

- 18.2. The bid security should be valid for the period specified in the **BDS**. Any bid not accompanied by an acceptable bid security shall be rejected by the Procuring Entity as non-responsive.
- 18.3. No bid securities shall be returned to Bidders after the opening of bids and before contract signing, except to those that failed or declared as post-disqualified, upon submission of a written waiver of their right to file a request for reconsideration and/or protest, or upon the lapse of the reglementary period to file a request for reconsideration or protest. Without prejudice on its forfeiture, bid securities shall be returned only after the Bidder with the Lowest Calculated Responsive Bid (LCRB) has signed the contract and furnished the performance security, but in no case later than the expiration of the bid security validity period indicated in **ITB** Clause 18.2.
- 18.4. Upon signing and execution of the contract pursuant to **ITB** Clause 32, and the posting of the performance security pursuant to **ITB** Clause 33, the successful Bidder's bid security will be discharged, but in no case later than the bid security validity period as indicated in the **ITB** Clause 18.2.



18.5. The bid security may be forfeited:

- (a) if a Bidder:
  - (i) withdraws its bid during the period of bid validity specified in **ITB** Clause 17;
  - (ii) does not accept the correction of errors pursuant to **ITB** Clause 28.3(b);
  - (iii) has a finding against the veracity of any of the documents submitted as stated in **ITB** Clause 29.2;
  - (iv) submission of eligibility requirements containing false information or falsified documents;
  - (v) submission of bids that contain false information or falsified documents, or the concealment of such information in the bids in order to influence the outcome of eligibility screening or any other stage of the public bidding;
  - (vi) allowing the use of one's name, or using the name of another for purposes of public bidding;
  - (vii) withdrawal of a bid, or refusal to accept an award, or enter into contract with the Government without justifiable cause, after the Bidder had been adjudged as having submitted the LCRB;
  - (viii) refusal or failure to post the required performance security within the prescribed time;
  - (ix) refusal to clarify or validate in writing its bid during post-qualification within a period of seven (7) calendar days from receipt of the request for clarification;
  - (x) any documented attempt by a Bidder to unduly influence the outcome of the bidding in his favor;
  - (xi) failure of the potential joint venture partners to enter into the joint venture after the bid is declared successful; or
  - (xii) all other acts that tend to defeat the purpose of the competitive bidding, such as habitually withdrawing from bidding, submitting late Bids or patently insufficient bid, for at least three (3) times within a year, except for valid reasons.
- (b) if the successful Bidder:
  - (i) fails to sign the contract in accordance with **ITB** Clause 32; or
  - (ii) fails to furnish performance security in accordance with **ITB** Clause 33.

## 19. Format and Signing of Bids

- 19.1. Bidders shall submit their bids through their duly authorized representative using the appropriate forms provided in Section VIII. Bidding Forms on or before the deadline specified in the **ITB** Clauses 21 in two (2) separate sealed bid envelopes, and which shall be submitted simultaneously. The first shall contain the technical component of the bid, including the eligibility requirements under **ITB** Clause 12.1, and the second shall contain the financial component of the bid. This shall also be observed for each lot in the case of lot procurement.
- 19.2. Forms as mentioned in **ITB** Clause 19.1 must be completed without any alterations to their format, and no substitute form shall be accepted. All blank spaces shall be filled in with the information requested.
- 19.3. The Bidder shall prepare and submit an original of the first and second envelopes as described in **ITB** Clauses 12 and 13. In addition, the Bidder shall submit copies of the first and second envelopes. In the event of any discrepancy between the original and the copies, the original shall prevail.
- 19.4. Each and every page of the Bid Form, including the Schedule of Prices, under Section VIII hereof, shall be signed by the duly authorized representative/s of the Bidder. Failure to do so shall be a ground for the rejection of the bid.
- 19.5. Any interlineations, erasures, or overwriting shall be valid only if they are signed or initialed by the duly authorized representative/s of the Bidder.

## 20. Sealing and Marking of Bids

- 20.1. Bidders shall enclose their original eligibility and technical documents described in **ITB** Clause 12 in one sealed envelope marked “ORIGINAL - TECHNICAL COMPONENT”, and the original of their financial component in another sealed envelope marked “ORIGINAL - FINANCIAL COMPONENT”, sealing them all in an outer envelope marked “ORIGINAL BID”.
- 20.2. Each copy of the first and second envelopes shall be similarly sealed duly marking the inner envelopes as “COPY NO. \_\_\_ - TECHNICAL COMPONENT” and “COPY NO. \_\_\_ - FINANCIAL COMPONENT” and the outer envelope as “COPY NO. \_\_\_”, respectively. These envelopes containing the original and the copies shall then be enclosed in one single envelope.
- 20.3. The original and the number of copies of the Bid as indicated in the **BDS** shall be typed or written in ink and shall be signed by the Bidder or its duly authorized representative/s.
- 20.4. All envelopes shall:
  - (a) contain the name of the contract to be bid in capital letters;

- (b) bear the name and address of the Bidder in capital letters;
- (c) be addressed to the Procuring Entity's BAC in accordance with **ITB** Clause 21;
- (d) bear the specific identification of this bidding process indicated in the **ITB** Clause 1.2; and
- (e) bear a warning "DO NOT OPEN BEFORE..." the date and time for the opening of bids, in accordance with **ITB** Clause 21.

20.5. Bid envelopes that are not properly sealed and marked, as required in the bidding documents, shall not be rejected, but the Bidder or its duly authorized representative shall acknowledge such condition of the bid as submitted. The BAC or the Procuring Entity shall assume no responsibility for the misplacement of the contents of the improperly sealed or marked bid, or for its premature opening.

## **D. Submission and Opening of Bids**

### **21. Deadline for Submission of Bids**

Bids must be received by the Procuring Entity's BAC at the address and on or before the date and time indicated in the **BDS**. *In case the deadline for submission of bids falls on a non-working day duly declared by the president, governor or mayor or other government official authorized to make such declaration, the deadline shall be the next working day.*

### **22. Late Bids**

Any bid submitted after the deadline for submission and receipt of bids prescribed by the Procuring Entity, pursuant to **ITB** Clause 21, shall be declared "Late" and shall not be accepted by the Procuring Entity. The BAC shall record in the minutes of bid submission and opening, the Bidder's name, its representative and the time the late bid was submitted.

### **23. Modification and Withdrawal of Bids**

23.1. The Bidder may modify its bid after it has been submitted; provided that the modification is received by the Procuring Entity prior to the deadline prescribed for submission and receipt of bids. The Bidder shall not be allowed to retrieve its original bid, but shall be allowed to submit another bid equally sealed and properly identified in accordance with **ITB** Clause 20, linked to its original bid marked as "TECHNICAL MODIFICATION" or "FINANCIAL MODIFICATION" and stamped "received" by the BAC. Bid modifications received after the applicable deadline shall not be considered and shall be returned to the Bidder unopened.

23.2 A Bidder may, through a Letter of Withdrawal, withdraw its bid after it has been submitted, for valid and justifiable reason; provided that the Letter of Withdrawal is received by the Procuring Entity prior to the deadline

prescribed for submission and receipt of bids. The Letter of Withdrawal must be executed by the duly authorized representative of the Bidder identified in the Omnibus Sworn Statement, a copy of which should be attached to the letter.

- 23.3. Bids requested to be withdrawn in accordance with **ITB** Clause 23.1 shall be returned unopened to the Bidders. A Bidder, who has acquired the bidding documents, may also express its intention not to participate in the bidding through a letter which should reach and be stamped by the BAC before the deadline for submission and receipt of bids. A Bidder that withdraws its bid shall not be permitted to submit another bid, directly or indirectly, for the same contract.
- 23.4. No bid may be modified after the deadline for submission of bids. No bid may be withdrawn in the interval between the deadline for submission of bids and the expiration of the period of bid validity specified by the Bidder on the Financial Bid Form. Withdrawal of a bid during this interval shall result in the forfeiture of the Bidder's bid security, pursuant to **ITB** Clause 18.5, and the imposition of administrative, civil and criminal sanctions as prescribed by RA 9184 and its IRR.

## **24. Opening and Preliminary Examination of Bids**

- 24.1. The BAC shall open the bids in public, immediately after the deadline for the submission and receipt of bids, as specified in the **BDS**. In case the Bids cannot be opened as scheduled due to justifiable reasons, the BAC shall take custody of the Bids submitted and reschedule the opening of Bids on the next working day or at the soonest possible time through the issuance of a Notice of Postponement to be posted in the PhilGEPS website and the website of the Procuring Entity concerned.
- 24.2. Unless otherwise specified in the **BDS**, the BAC shall open the first bid envelopes and determine each Bidder's compliance with the documents prescribed in **ITB** Clause 12, using a non-discretionary "pass/fail" criterion. If a Bidder submits the required document, it shall be rated "passed" for that particular requirement. In this regard, bids that fail to include any requirement or are incomplete or patently insufficient shall be considered as "failed". Otherwise, the BAC shall rate the said first bid envelope as "passed".
- 24.3. Unless otherwise specified in the **BDS**, immediately after determining compliance with the requirements in the first envelope, the BAC shall forthwith open the second bid envelope of each remaining eligible bidder whose first bid envelope was rated "passed". The second envelope of each complying bidder shall be opened within the same day. In case one or more of the requirements in the second envelope of a particular bid is missing, incomplete or patently insufficient, and/or if the submitted total bid price exceeds the ABC unless otherwise provided in **ITB** Clause 13.2, the BAC

shall rate the bid concerned as “failed”. Only bids that are determined to contain all the bid requirements for both components shall be rated “passed” and shall immediately be considered for evaluation and comparison.

- 24.4. Letters of Withdrawal shall be read out and recorded during bid opening, and the envelope containing the corresponding withdrawn bid shall be returned to the Bidder unopened.
- 24.5. All members of the BAC who are present during bid opening shall initial every page of the original copies of all bids received and opened.
- 24.6. In the case of an eligible foreign bidder as described in **ITB** Clause 5, the following Class “A” Documents may be substituted with the appropriate equivalent documents, if any, issued by the country of the foreign Bidder concerned, which shall likewise be uploaded and maintained in the PhilGEPS in accordance with Section 8.5.2 of the IRR:
  - (a) Registration certificate from the Securities and Exchange Commission (SEC), Department of Trade and Industry (DTI) for sole proprietorship, or CDA for cooperatives;
  - (b) Mayor’s/Business permit issued by the local government where the principal place of business of the bidder is located; and
  - (c) Audited Financial Statements showing, among others, the prospective bidder’s total and current assets and liabilities stamped “received” by the Bureau of Internal Revenue or its duly accredited and authorized institutions, for the preceding calendar year which should not be earlier than two years from the date of bid submission.
- 24.7. Each partner of a joint venture agreement shall likewise submit the requirements in **ITB** Clause 12.1(a)(i). Submission of documents required under **ITB** Clauses 12.1(a)(ii) to 12.1(a)(iii) by any of the joint venture partners constitutes compliance.
- 24.8. The Procuring Entity shall prepare the minutes of the proceedings of the bid opening that shall include, as a minimum: (a) names of Bidders, their bid price (per lot, if applicable, and/or including discount, if any), bid security, findings of preliminary examination, and whether there is a withdrawal or modification; and (b) attendance sheet. The BAC members shall sign the abstract of bids as read.
- 24.8. The bidders or their duly authorized representatives may attend the opening of bids. The BAC shall ensure the integrity, security, and confidentiality of all submitted bids. The Abstract of Bids as read and the minutes of the bid opening shall be made available to the public upon written request and payment of a specified fee to recover cost of materials.
- 24.9. To ensure transparency and accurate representation of the bid submission, the BAC Secretariat shall notify in writing all bidders whose bids it has received through its PhilGEPS-registered physical address or official e-mail address.

The notice shall be issued within seven (7) calendar days from the date of the bid opening.

## **E. Evaluation and Comparison of Bids**

### **25. Process to be Confidential**

- 25.1. Members of the BAC, including its staff and personnel, as well as its Secretariat and TWG, are prohibited from making or accepting any kind of communication with any bidder regarding the evaluation of their bids until the issuance of the Notice of Award, unless otherwise allowed in the case of **ITB** Clause 26.
- 25.2. Any effort by a bidder to influence the Procuring Entity in the Procuring Entity's decision in respect of bid evaluation, bid comparison or contract award will result in the rejection of the Bidder's bid.

### **26. Clarification of Bids**

To assist in the evaluation, comparison, and post-qualification of the bids, the Procuring Entity may ask in writing any Bidder for a clarification of its bid. All responses to requests for clarification shall be in writing. Any clarification submitted by a Bidder in respect to its bid and that is not in response to a request by the Procuring Entity shall not be considered.

### **27. Domestic Preference**

- 27.1. Unless otherwise stated in the **BDS**, the Procuring Entity will grant a margin of preference for the purpose of comparison of bids in accordance with the following:
  - (a) The preference shall be applied when the lowest Foreign Bid is lower than the lowest bid offered by a Domestic Bidder.
  - (b) For evaluation purposes, the lowest Foreign Bid shall be increased by fifteen percent (15%).
  - (c) In the event that the lowest bid offered by a Domestic Bidder does not exceed the lowest Foreign Bid as increased, then the Procuring Entity shall award the contract to the Domestic Bidder at the amount of the lowest Foreign Bid.
  - (d) If the Domestic Bidder refuses to accept the award of contract at the amount of the Foreign Bid within two (2) calendar days from receipt of written advice from the BAC, the Procuring Entity shall award to the bidder offering the Foreign Bid, subject to post-qualification and submission of all the documentary requirements under these Bidding Documents.
- 27.2. A Bidder may be granted preference as a Domestic Bidder subject to the certification from the DTI that the Bidder is offering unmanufactured articles,

materials or supplies of the growth or production of the Philippines, or manufactured articles, materials, or supplies manufactured or to be manufactured in the Philippines substantially from articles, materials, or supplies of the growth, production, or manufacture, as the case may be, of the Philippines.

## **28. Detailed Evaluation and Comparison of Bids**

- 28.1. The Procuring Entity will undertake the detailed evaluation and comparison of bids which have passed the opening and preliminary examination of bids, pursuant to **ITB** Clause 24, in order to determine the Lowest Calculated Bid.
- 28.2. The Lowest Calculated Bid shall be determined in two steps:
- (a) The detailed evaluation of the financial component of the bids, to establish the correct calculated prices of the bids; and
  - (b) The ranking of the total bid prices as so calculated from the lowest to the highest. The bid with the lowest price shall be identified as the Lowest Calculated Bid.
- 28.3. The Procuring Entity's BAC shall immediately conduct a detailed evaluation of all bids rated "passed," using non-discretionary pass/fail criteria. The BAC shall consider the following in the evaluation of bids:
- (a) Completeness of the bid. Unless the **BDS** allows partial bids, bids not addressing or providing all of the required items in the Schedule of Requirements including, where applicable, Schedule of Prices, shall be considered non-responsive and, thus, automatically disqualified. In this regard, where a required item is provided, but no price is indicated, the same shall be considered as non-responsive, but specifying a zero (0) or a dash (-) for the said item would mean that it is being offered for free to the Procuring Entity, except those required by law or regulations to be provided for; and
  - (b) Arithmetical corrections. Consider computational errors and omissions to enable proper comparison of all eligible bids. It may also consider bid modifications. Any adjustment shall be calculated in monetary terms to determine the calculated prices.
- 28.4. Based on the detailed evaluation of bids, those that comply with the above-mentioned requirements shall be ranked in the ascending order of their total calculated bid prices, as evaluated and corrected for computational errors, discounts and other modifications, to identify the Lowest Calculated Bid. Total calculated bid prices, as evaluated and corrected for computational errors, discounts and other modifications, which exceed the ABC shall not be considered, unless otherwise indicated in the **BDS**.
- 28.5. The Procuring Entity's evaluation of bids shall be based on the bid price quoted in the Bid Form, which includes the Schedule of Prices.

- 28.6. Bids shall be evaluated on an equal footing to ensure fair competition. For this purpose, all bidders shall be required to include in their bids the cost of all taxes, such as, but not limited to, value added tax (VAT), income tax, local taxes, and other fiscal levies and duties which shall be itemized in the bid form and reflected in the detailed estimates. Such bids, including said taxes, shall be the basis for bid evaluation and comparison.
- 28.7. If so indicated pursuant to **ITB** Clause 1.2, Bids are being invited for individual lots or for any combination thereof, provided that all Bids and combinations of Bids shall be received by the same deadline and opened and evaluated simultaneously so as to determine the Bid or combination of Bids offering the lowest calculated cost to the Procuring Entity. Bid prices quoted shall correspond to all items specified for each lot and to all quantities specified for each item of a lot. Bid Security as required by **ITB** Clause 18 shall be submitted for each contract (lot) separately. The basis for evaluation of lots is specified in **BDS** Clause 28.3.

## **29. Post-Qualification**

- 29.1. The BAC shall determine to its satisfaction whether the Bidder that is evaluated as having submitted the Lowest Calculated Bid complies with and is responsive to all the requirements and conditions specified in **ITB** Clauses 5, 12, and 13.
- 29.2. Within a non-extendible period of five (5) calendar days from receipt by the bidder of the notice from the BAC that it submitted the Lowest Calculated Bid, the Bidder shall submit its latest income and business tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) and other appropriate licenses and permits required by law and stated in the **BDS**.  
  
Failure to submit any of the post-qualification requirements on time, or a finding against the veracity thereof, shall disqualify the bidder for award. Provided in the event that a finding against the veracity of any of the documents submitted is made, it shall cause the forfeiture of the bid security in accordance with Section 69 of the IRR of RA 9184.
- 29.3. The determination shall be based upon an examination of the documentary evidence of the Bidder's qualifications submitted pursuant to **ITB** Clauses 12 and 13, as well as other information as the Procuring Entity deems necessary and appropriate, using a non-discretionary "pass/fail" criterion, which shall be completed within a period of twelve (12) calendar days.
- 29.4. If the BAC determines that the Bidder with the Lowest Calculated Bid passes all the criteria for post-qualification, it shall declare the said bid as the LCRB, and recommend to the HoPE the award of contract to the said Bidder at its submitted price or its calculated bid price, whichever is lower.
- 29.5. A negative determination shall result in rejection of the Bidder's Bid, in which event the Procuring Entity shall proceed to the next Lowest Calculated Bid with a fresh period to make a similar determination of that Bidder's capabilities to perform satisfactorily. If the second Bidder, however, fails the



post qualification, the procedure for post qualification shall be repeated for the Bidder with the next Lowest Calculated Bid, and so on until the LCRB is determined for recommendation for contract award.

- 29.6. Within a period not exceeding fifteen (15) calendar days from the determination by the BAC of the LCRB and the recommendation to award the contract, the HoPE or his duly authorized representative shall approve or disapprove the said recommendation.
- 29.7. In the event of disapproval, which shall be based on valid, reasonable, and justifiable grounds as provided for under Section 41 of the IRR of RA 9184, the HoPE shall notify the BAC and the Bidder in writing of such decision and the grounds for it. When applicable, the BAC shall conduct a post-qualification of the Bidder with the next Lowest Calculated Bid. A request for reconsideration may be filed by the bidder with the HoPE in accordance with Section 37.1.3 of the IRR of RA 9184.

### **30. Reservation Clause**

- 30.1. Notwithstanding the eligibility or post-qualification of a Bidder, the Procuring Entity concerned reserves the right to review its qualifications at any stage of the procurement process if it has reasonable grounds to believe that a misrepresentation has been made by the said Bidder, or that there has been a change in the Bidder's capability to undertake the project from the time it submitted its eligibility requirements. Should such review uncover any misrepresentation made in the eligibility and bidding requirements, statements or documents, or any changes in the situation of the Bidder which will affect its capability to undertake the project so that it fails the preset eligibility or bid evaluation criteria, the Procuring Entity shall consider the said Bidder as ineligible and shall disqualify it from submitting a bid or from obtaining an award or contract.
- 30.2. Based on the following grounds, the Procuring Entity reserves the right to reject any and all bids, declare a Failure of Bidding at any time prior to the contract award, or not to award the contract, without thereby incurring any liability, and make no assurance that a contract shall be entered into as a result of the bidding:
  - (a) If there is *prima facie* evidence of collusion between appropriate public officers or employees of the Procuring Entity, or between the BAC and any of the Bidders, or if the collusion is between or among the bidders themselves, or between a Bidder and a third party, including any act which restricts, suppresses or nullifies or tends to restrict, suppress or nullify competition;
  - (b) If the Procuring Entity's BAC is found to have failed in following the prescribed bidding procedures; or
  - (c) For any justifiable and reasonable ground where the award of the contract will not redound to the benefit of the GOP as follows:

- (i) If the physical and economic conditions have significantly changed so as to render the project no longer economically, financially or technically feasible as determined by the HoPE;
  - (ii) If the project is no longer necessary as determined by the HoPE; and
  - (iii) If the source of funds for the project has been withheld or reduced through no fault of the Procuring Entity.
- 30.3. In addition, the Procuring Entity may likewise declare a failure of bidding when:
- (a) No bids are received;
  - (b) All prospective Bidders are declared ineligible;
  - (c) All bids fail to comply with all the bid requirements or fail post-qualification; or
  - (d) The bidder with the LCRB refuses, without justifiable cause to accept the award of contract, and no award is made in accordance with Section 40 of the IRR of RA 9184.

## **F. Award of Contract**

### **31. Contract Award**

- 31.1. Subject to **ITB** Clause 29, the HoPE or its duly authorized representative shall award the contract to the Bidder whose bid has been determined to be the LCRB.
- 31.2. Prior to the expiration of the period of bid validity, the Procuring Entity shall notify the successful Bidder in writing that its bid has been accepted, through a Notice of Award duly received by the Bidder or its representative personally or sent by registered mail or electronically, receipt of which must be confirmed in writing within two (2) days by the Bidder with the LCRB and submitted personally or sent by registered mail or electronically to the Procuring Entity.
- 31.3. Notwithstanding the issuance of the Notice of Award, award of contract shall be subject to the following conditions:
- (a) *Submission of a valid JVA, if applicable, within ten (10) calendar days from receipt of the Notice of Award;*
  - (b) Posting of the performance security in accordance with **ITB** Clause 33;
  - (c) Signing of the contract as provided in **ITB** Clause 32; and

- (d) Approval by higher authority, if required, as provided in Section 37.3 of the IRR of RA 9184.

31.4. At the time of contract award, the Procuring Entity shall not increase or decrease the quantity of goods originally specified in Section VI. Schedule of Requirements.

## **32. Signing of the Contract**

32.1. At the same time as the Procuring Entity notifies the successful Bidder that its bid has been accepted, the Procuring Entity shall send the Contract Form to the Bidder, which contract has been provided in the Bidding Documents, incorporating therein all agreements between the parties.

32.2. Within ten (10) calendar days from receipt of the Notice of Award, the successful Bidder shall post the required performance security, sign and date the contract and return it to the Procuring Entity.

32.3. The Procuring Entity shall enter into contract with the successful Bidder within the same ten (10) calendar day period provided that all the documentary requirements are complied with.

32.4. The following documents shall form part of the contract:

- (a) Contract Agreement;
- (b) Bidding Documents;
- (c) Winning bidder's bid, including the Technical and Financial Proposals, and all other documents/statements submitted (*e.g.*, bidder's response to request for clarifications on the bid), including corrections to the bid, if any, resulting from the Procuring Entity's bid evaluation;
- (d) Performance Security;
- (e) Notice of Award of Contract; and
- (f) Other contract documents that may be required by existing laws and/or specified in the **BDS**.

## **33. Performance Security**

33.1. To guarantee the faithful performance by the winning Bidder of its obligations under the contract, it shall post a performance security within a maximum period of ten (10) calendar days from the receipt of the Notice of Award from the Procuring Entity and in no case later than the signing of the contract.

33.2. The Performance Security shall be denominated in Philippine Pesos and posted in favor of the Procuring Entity in an amount not less than the percentage of the total contract price in accordance with the following schedule:

Form of Performance Security	Amount of Performance Security (Not less than the Percentage of the Total Contract Price)
<p>(a) Cash or cashier's/manager's check issued by a Universal or Commercial Bank.</p> <p><i>For biddings conducted by the LGUs, the Cashier's/Manager's Check may be issued by other banks certified by the BSP as authorized to issue such financial instrument.</i></p>	Five percent (5%)
<p>(b) Bank draft/guarantee or irrevocable letter of credit issued by a Universal or Commercial Bank: Provided, however, that it shall be confirmed or authenticated by a Universal or Commercial Bank, if issued by a foreign bank.</p> <p><i>For biddings conducted by the LGUs, the Bank Draft/ Guarantee or Irrevocable Letter of Credit may be issued by other banks certified by the BSP as authorized to issue such financial instrument.</i></p>	
<p>(c) Surety bond callable upon demand issued by a surety or insurance company duly certified by the Insurance Commission as authorized to issue such security.</p>	Thirty percent (30%)

33.3. Failure of the successful Bidder to comply with the above-mentioned requirement shall constitute sufficient ground for the annulment of the award and forfeiture of the bid security, in which event the Procuring Entity shall have a fresh period to initiate and complete the post qualification of the second Lowest Calculated Bid. The procedure shall be repeated until the LCRB is identified and selected for recommendation of contract award. However if no Bidder passed post-qualification, the BAC shall declare the bidding a failure and conduct a re-bidding with re-advertisement, if necessary.

#### **34. Notice to Proceed**

Within seven (7) calendar days from the date of approval of the contract by the appropriate government approving authority, the Procuring Entity shall issue the Notice to Proceed (NTP) together with a copy or copies of the approved contract to the successful Bidder. All notices called for by the terms of the contract shall be effective only at the time of receipt thereof by the successful Bidder.

### **35. Protest Mechanism**

Decisions of the procuring entity at any stage of the procurement process may be questioned in accordance with Section 55 of the IRR of RA 9184.

## ***Section III. Bid Data Sheet***

# Bid Data Sheet

ITB Clause	
1.1	<p>The Procuring Entity is <b>Bureau of Corrections</b></p> <p>The name of the Contract is <b>Supply and Delivery of Various Medicines for NBP and CIW 2019.</b></p> <p>The identification number of the Contract is _____.</p>
1.2	The Bid Reference _____
2	<p>The Funding Source is:</p> <p>The Government of the Philippines (GOP) through General Appropriation Act (GAA) of 2019 in the amount of <b>Two Hundred Three Million One Hundred Forty-Seven Thousand Two Hundred Three Pesos and 81/100 (₱203,147,203.81)</b></p> <p>The name of the Project is: <b>Supply and Delivery of Various Medicines for NBP and CIW 2019.</b></p>
3.1	No further instructions.
5.1	No further instructions.
5.2	Foreign bidders, except those falling under <b>ITB</b> Clause 5.2(b), may not participate in this Project.
5.4	<p>The Bidder must have completed, within the period specified in the Invitation to Bid and <b>ITB</b> Clause 12.1(a) (ii), a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC.</p> <p>For this purpose, similar contracts shall refer to <b>Medicines.</b></p>
7	No further instructions.
8.1	Subcontracting is not allowed
8.2	Not applicable.
9.1	The Procuring Entity will hold a pre-bid conference for this Project on July 04, 2019-01:00pm at BAC Conference Room NBP Reservation Muntinlupa City.
10.1	<p>The Procuring Entity's address is: <i>Bureau of Correction NBP Reservation Poblacion Muntinlupa City</i></p> <p>Name of BAC Chairman:</p>

	<p><b>CTCSUPT. MA. LOURDES M. RAZON, MD.</b>  <i>Chairperson, Bids and Awards Committee</i>  Telephone and fax number of BAC Secretariat:    Tel # 809-8587/478-0907</p>
12.1	<p><b>CLASS A DOCUMENTS:</b></p> <p>I. <b>Valid and current PhilGeps Certificate of Registration and Membership</b> in accordance with Section 8.5.2 of Revised IRR of RA 9184.</p> <p>II. <b>Valid and current Securities and Exchange Commission (SEC)</b> Registration for Corporation.</p> <p><b>Valid and current Department of Trade and Industry (DTI)</b> Registration for Sole Proprietorship and</p> <p><b>Valid and current Cooperative Development Authority (CDA)</b> Registration for cooperative.</p> <p>III. <b>Valid and current Mayor’s/Business Permit</b> issued by the city of municipality where the place of business of the prospective bidder is located.</p> <p>IV. <b>Valid and current Tax Clearance</b> per Executive Order 398, series of 2005 as finally reviewed and approved by the BIR.</p> <p>V. <b>Statement of prospective bidder of all its ongoing government and private contracts</b>, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid and;</p> <p><b>Statement identifying the bidder’s Single Largest Completed Contract (SLCC)</b>, similar to the contract to be bid within the last two (2) years from the date of submission and receipt of bids equivalent to at least twenty-five percent 25% of the ABC.</p> <p>Certificate of end-user’s acceptance (EUA) or Acceptance Report or official receipt (OR) or sales invoice (SI) issued for the contract, if completed, which shall be attached to the statement.</p> <p>VI. <b>Valid and current Audited Financial Statements</b>, showing, among others, the prospective bidder’s total and current assets and liabilities, stamped “received” by the BIR or its duly accredited and authorized institutions, for the preceding calendar year which should not be earlier than two (2) years from the date of bid submission.</p> <p>VII. <b>Net Financial Contracting Capacity (NFCC)</b> which must be at</p>



least equal to the ABC to be bid, and calculated as follows:

**NFCC** = [(Current assets minus current liabilities) (15)] minus the value of all outstanding or uncompleted portions of the projects under ongoing contracts, including awarded contracts yet to be started coinciding with the contract to be bid.

**Where:**

The values of the bidder’s current assets and current liabilities shall be based on the latest Audited Financial Statements submitted to the BIR, through its Electronic Filing and Payment System (EFPS).

In Lieu of the NFCC computation the bidder may submits a Committed Line of Credit (CLC) from a Universal or Commercial Bank, it must be at least equal to ten percent (10%) of the ABC to be bid in accordance with Sec 23.4.1.5 of the 2016 Revised IRR of RA 9184.

**CLASS “B” DOCUMENTS:**

VIII. **In case of Joint Venture:** A Valid Joint Venture Agreement (JVA ) for the project in case it is already in existence, or duly notarized statements from all the potential joint venture partners stating that they will enter into and abide by the provisions of the JVA in the instance that the bid is successful.

In case the joint venture is not yet in existence, the submission of a valid JVA shall be within ten (10) calendar days from receipt by the bidder of the notice from the BAC that the bidder is the Lowest Calculated Responsive Bid

IX. The Bidder shall have the option to post Bid Securing Declaration. Bid Securing Declaration must be duly notarized in accordance with the provisions of 2004 Rules on Notarial Practice or any form of Bid Security in which shall be not less than the percentage of the ABC in accordance with the following schedule:

Form of Bid Security	Amount of Bid Security (Not Less than the Percentage of the ABC)
(a) Cash or cashier’s/manager’s check issued by a Universal or Commercial Bank.	Two percent (2%)
(b) Bank draft/guarantee or irrevocable letter of credit issued by a Universal or Commercial Bank: Provided, however, that it shall be confirmed or authenticated by	

<p>a Universal or Commercial Bank, if issued by a foreign bank.</p>	
<p>(c) Surety bond callable upon demand issued by a surety or insurance company duly certified by the Insurance Commission as authorized to issue such security.</p>	<p>Five percent (5%)</p>
<p>Should the bidder opt to submit a Surety Bond as other form of Bid Security it must specify the additional grounds for forfeiture of bid security, to wit:</p> <ol style="list-style-type: none"> <li>1.) withdraws its bid during the period of bid validity specified in ITB Clause17;</li> <li>2.) does not accept the correction of errors pursuant to ITB Clause 18.3(b);</li> <li>3.) fails to submit the requirements within the prescribed period or a finding against their veracity as stated in ITB Clause 29.2;</li> <li>4.) submission of eligibility requirements containing false information or falsified documents;</li> <li>5.) submission of bids that contain false information or falsified documents, or the concealment of such information in the bids in order to influence the outcome of eligibility screening or any other stage of the public bidding;</li> <li>6.) allowing the use of one's name, or using the name of another for purposes of public bidding;</li> <li>7.) withdrawal of a bid, or refusal to accept an award, or enter into contract with the Government without justifiable cause, after the Bidder had been adjudged as having submitted the Lowest Calculated and Responsive Bid;</li> <li>8.) refusal or failure to post the required performance security within the prescribed time;</li> <li>9.) refusal to clarify or validate in writing its bid during post qualification within a period of seven (7) calendar days from receipt of the request for clarification;</li> <li>10.) any documented attempt by a bidder to unduly influence the outcome of the bidding in his favor;</li> </ol>	

	<p>11.) failure of the potential joint venture partners to enter into the joint venture after the bid is declared successful; or</p> <p>12.) all other acts that tend to defeat the purpose of the competitive bidding, such as habitually withdrawing from bidding, submitting late Bids or patently insufficient bid, for at least three (3) times within a year, except for valid reasons.</p> <p>or if the successful Bidder:</p> <p>1.) fails to sign the contract in accordance with ITB Clause32; or</p> <p>2.) fails to furnish performance security in accordance with ITB Clause 33.</p> <p>X. <b>Duly Conformed</b> Schedule of Requirements</p> <p>XI. <b>Duly Conformed</b> Technical specification</p> <p>XII. <b>Duly notarized</b> Omnibus Sworn Statement It must be supported by a Proof of Authority of the designated representative/s for the purposes of this bidding</p> <p>a) <b>Duly notarized</b> Special Power of Attorney –For sole proprietorship if owner opts to designate a representative/s;</p> <p>b) <b>Duly notarized</b> Secretary’s Certificate evidencing the authority of the designated representative/s, issued by the corporation, cooperative or the members of the joint venture;</p> <p>c) Provided that in the case of unincorporated joint venture, each member shall submit a separate <b>Duly notarized</b> Special Power of Attorney and/or <b>Duly notarized</b> Secretary’s Certificate evidencing the authority of the designated representative/s.</p>
13.1(a)	The Bidder shall submit the complete and signed Financial Bid Form inclusive of VAT and Schedule of Prices. The amount should not exceed the ABC of that particular item.
13.1(b)	No further instructions.
13.1(c)	No additional requirements.
13.2	The total ABC is <b>Two Hundred Three Million One Hundred Forty-Seven Thousand Two Hundred Three Pesos and 81/100 (₱203,147,203.81)</b> Any bid with a financial component exceeding the amount of the ABC to be bid shall not be accepted.
15.4(a)(iv)	No incidental services are required.”

15.4(b)	Not applicable
16.1(b)	The Bid prices for Goods supplied from outside of the Philippines shall be quoted in Philippine Pesos.
16.3	Not applicable
17.1	Bids will be valid for 120 calendar days from date of bid opening. Bids valid for a shorter period shall be rejected outright as non-responsive
18.1	The bid security shall be in the form of a Bid Securing Declaration, or any of the following forms and amounts:  1. The amount of not less than 2% of the total ABC to be bid, if bid security is in cash, cashier's/manager's check, bank draft/guarantee or irrevocable letter of credit; or  2. The amount of not less than 5% of the total ABC to be bid if bid security is in Surety Bond.
18.2	The bid security in the form of Surety Bond and callable upon demand shall be valid for 120 calendar days reckoned from the date of the opening of the bids.
20.1	Each Bidder shall submit the following in <i>one (1)</i> big envelope duly labelled containing two sets of envelopes:  <b>First envelope</b> must contain four (4) copies of Eligibility and Technical Documents duly marked as " <b>Original Technical Component</b> ", " <b>Copy No.1</b> ", " <b>Copy No.2</b> " and " <b>Copy No.3</b> "  <b>Second envelope</b> must contain four (4) copies of Financial Bid Form duly marked as " <b>Original Financial Component</b> ", " <b>Copy No.1</b> ", " <b>Copy No.2</b> " and " <b>Copy No.3</b> "  All envelopes and folders must be labeled as specify in <b>BDS 20.4</b>
20.3	Each Bidder shall submit one (1) original and three (3) copies of the first and second components of its bid.
20.4	All envelopes <b>shall</b> :  a.) Contain the name of the contract to be bid in CAPITAL LETTERS b.) Bear the name and address of the Bidder in CAPITAL LETTERS c.) Be addressed to the Procuring Entity's BAC in accordance with ITB Clause 1.1 d.) Bear the specific identification of this bidding process indicated in the ITB Clause 1.2 and e.) Bear the warning " <b>DO NOT OPEN BEFORE ....</b> " The date and time for the opening of bids in accordance with ITB Clause 21

	<div style="border: 1px solid black; padding: 10px; margin: 10px auto; width: fit-content;"> <p><b>TO</b> : THE BIDS AND AWARDS COMMITTEE  : BUREAU OF CORRECTIONS</p> <p><b>FROM</b> : _____  Name of Bidder in Capital Letter</p> <p><b>ADDRESS</b> : _____  Address of Bidder in Capital Letter</p> <p><b>PROJECT</b> : _____</p> <p><b>BID REF</b> : _____</p> <p>(In capital letters, indicate the phrase)  <b>“DO NOT OPEN BEFORE _____”</b></p> </div>
21	<p>The address for submission of bids is BAC Conference Room NBP Reservation Muntinlupa City.</p> <p>The deadline for submission of bids is July 17, 2019-9:00am.</p>
24.1	<p>The place of bid opening is BAC Conference Room NBP Reservation Muntinlupa City.</p> <p>The date and time of bid opening is July 17, 2019-9:00am.</p>
24.2	No further instructions.
24.3	No further instructions.
27.1	No further instructions.
28.3 (a)	<p><b>Grouping and Evaluation of Lots –</b></p> <p>Partial bids are allowed. All Goods are grouped in items listed below. Bidders shall have the option of submitting a proposal on any or all items and evaluation and contract award will be undertaken on a per line basis. Lots shall not be divided further into sub-lots for the purpose of bidding, evaluation, and contract award.</p> <p>In all cases, the NFCC computation, if applicable, must be sufficient for all the items or contracts to be awarded to the Bidder.</p> <p><i>Item No.            Contract Name</i></p> <p>1            8% w/v Amino Acid Soln w/ 3% w/v Branched Chain Amino Acids content 500ml</p> <p>2            A1(OH) 200 mg+ +Mg(OH)2 100 mg, 120 ml</p> <p>3            A1OH + MgOH mg, Simethicone 30 mg</p> <p>4            Aciclovir + Zinc Oxide Ointment 50mg/100mg</p>

5	Aciclovir 200 mg
6	Aciclovir 400 mg
7	Aciclovir 5%, 5 g
8	Ademetionine Butane Disulfonate 500mg
9	Ademetionine Butane Disulfonate 500mg IV/IM
10	Agmatine Sulfate
11	Alendronic Acid (as Alendronate Na Trihydrate) 70 mg
12	Allopurinol 300 mg
13	Alpha- lipoic Acid, Gamma-Linoleic Acid, Vit E & Selenium with Vit B Complex 920 mg
14	Alprazolam 250 mcg
15	Aluminum Magnesium Hydroxide 200/100
16	Ambroxol HCl 30 mg
17	Amino Acid + M-Vit + Mineral (Oral) 50 g
18	Amino Acid + Sorbitol Solution for I.V. 500 ml
19	Amino Acid and Glucose Inj. With Electrolytes and Vitamins B1, 1 L
20	Amino Acid and Glucose Inj. With Electrolytes and Vitamins B1, 500 ml
21	AminoLock Collagen
22	Amlodipine Besilate 10 mg
23	Amlodipine Besilate 5 mg
24	Amoxicillin 500 mg
25	Aripiprazole 10mg Discmelt ODT 30's
26	Aripiprazole 15mg Discmelt ODT 30's
27	Aripiprazole 400mg (box of 1)
28	Aspirin 80 mg
29	Atorvastatin 10 mg + Ezetimibe 10 mg FC

30	Atorvastatin 40 mg
31	Atorvastatin Calcium 20 mg
32	ATS 1,500 IU
33	Azelastine HCl 1mg/ml (0.1% w/v) Nasal Spray 14ml
34	Azithromycin Monohydrate 500 mg
35	Bacillus Clausii Oral Solution 5ml
36	Beclomethasone 100 mcg + Formoterol 6 mcg PMDI inhaler
37	Betahistine HCl 16 mg
38	Betamethasone Dipropionate 1ml
39	Betamethasone Dipropionate 640 mcg 5 g Ointment
40	Betamethasone Dipropionate 640mcg + Gentamicin 1mg 5 g Cream
41	Betamethasone Valerate 1mg/g, 1 g Cream
42	Biperiden 5mg
43	Biperiden HCl 2 mg
44	Biperiden Injection
45	Bisacodyl 10 mg (Adult)
46	Bisacodyl 5 mg
47	Blumea Balsamifera 500 mg
48	Brimonidine tabs 1.5 mg/ml topical ocular hypertensive agent solution
49	Bromhexine HCl 8 mg
50	Buclizine HCl + FeSO4 + MV
51	Budesonide + Formeterol 160 mcg + 4.5 mcg, 120 doses dry powder inhaler
52	Budesonide 500 mcg/ml, 2ml respiratory solution
53	Budesonide Swinghaler 200 mcg/dose
54	Butamirate Citrate 50 mg

55	Calamine plus Zinc Oxide 40/30 mg/g, 5g
56	Calcium with Vitamin D
57	Calcium with Vitamins and Minerals
58	Candesartan Cilexetil 8 mg
59	Captopril 25 mg
60	Captopril 50 mg
61	Carb Steady Renal Nutrition Formula for Dialysis Patient 237ml
62	Carb Steady Renal Nutrition Formula for Pre-Dialysis Patient w/ CKD 237ml
63	Carbamazepine 200 mg tab
64	Carbocisteine 500 mg
65	Carvedilol 25 mg
66	Castor Oil (Sweet Orange Flavor), 60 ml.
67	Cefaclor 500 mg
68	Cefalexin 500 mg
69	Ceftriaxone 1 g
70	Cefuroxime 500 mg
71	Cefuroxime 750 mg
72	Cefoxitin 1 g. IM/IV
73	Celecoxib 200 mg
74	Cetirizine 10 mg
75	Chloramphenicol Eyedrops 0.5% x 5 ml
76	Chlorphenamine Maleate 10mg/ml ,1 ml injection
77	Chlorphenamine Maleate 4 mg
78	Chlorpromazine HCl 100 mg
79	Chlorpromazine HCl 200 mg
80	Cilostazol 100 mg SR



81	Cimetidine 200 mg
82	Cinnarizine 25 mg
83	Ciprofloxacin 200 mg/100 ml I.V.
84	Ciprofloxacin 500 mg
85	Citicoline 1g/4ml Injection
86	Citicoline 500 mg
87	Citicoline Adult Oral Drops 100 mg/ml
88	Clarithromycin 500 mg
89	Clindamycin 300 mg
90	Clobetasol Propionate 0.05% Cream, 5 g
91	Clobetasol Propionate 0.05% Ointment 5 g
92	Clonidine HCl 75 mcg
93	Clopidrogel 75 mg
94	Clopidrogel Bisulfate 75mg, Aspirin 100mg
95	Clotrimazole 10 mg + Beclomethasone 250 mcg, 5 g
96	Clotrimazole 100 mg (vaginal tab)
97	Clotrimazole Cream 1.0%, 5 g
98	Cloxacillin 500 mg
99	Clozapine 100 mg
100	Co-Amoxiclav 1.2 g
101	Co-Amoxiclav 625 mg
102	Colchicine 500 mcg
103	Complete and Balanced Diabetes Nutrition Supplement Formula Powder with Sucromalt and Fibersol, 900 g
104	Complete and Balanced Nutrition Formula for Adult with HMB, 850 g
105	Cotrimoxazole 800/160mg

106	Dapagliflozin 10 mg
107	Dapagliflozin 10 mg / Metformin 1000 mg
108	Dapagliflozin 10 mg / Metformin 500 mg
109	Dapagliflozin 5 mg / Metformin 500 mg
110	Depotrust 50 mg/ml x 3 ml
111	Desloratidine 5 mg
112	Dexamethasone 1mg Neomycin SO4 3,500 IU mg Polymyxin B SO4 6,000u
113	Dexamethasone 500 mg
114	Dextrose + Vitamins for I.V. 500 ml
115	Dextrose 5% Lactated Ringer Solution 1L
116	Dextrose 5% Normal Saline Solution 1L
117	Dextrose 5% Water 1L
118	Dextrose 50%, 50 ml
119	Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate
120	Di-Alpha Tocopheryl Acetate (Vitamin E) + Selenium 400/IU 50mcg Softgel Capsule + Mineral (30cap / bot)
121	Diazepam 10 mg / 2 ml
122	Diazepam 5 mg
123	Diclofenac Sodium 25 mg/ml, 3 ml
124	Diclofenac Sodium 50 mg
125	Dicycloverine HCl 10 mg
126	Digoxin 0.25 mg
127	Digoxin 250 mcg/ml
128	Diltiazem 60 mg
129	Diosmin 450 mg + Hesperidin 50 mg
130	Diphenhydramine HCl 50 mg

131	Diphenhydramine HCl 50 mg/ml
132	Divalproex Na 250 mg IR (Immediate Release)
133	Divalproex Sodium 500 mg
134	Domperidone 10 mg
135	Donepezil 5mg
136	Dopamine 40 mg/ml, 5 ml
137	Doxofylline 400 mg
138	Doxycycline 100 mg
139	Drospirenone estradiol
140	Dutasteride 500 mcg + Tamsulosin HCl 400 mcg
141	Enalapril Maleate 10 mg
142	Energy Dense Nutritional Powder Formula w/ Increased Protein Content w/ Omega 3 EPA & Antioxidant 380g
143	Eperisone HCl 50 mg
144	Epinephrine SO4 1mg/ml, 1 ml
145	Epoetin Alpha, 4000 iu/ml
146	Epoetin Beta 5,000 IU/0.3 ml
147	Erythromycin 500 mg
148	Escitalopram Oxalate 10 mg
149	Esomeprazole 40 mg
150	Essential Phospholipids softgel 300 mg
151	Eterocoxib 60 mg
152	Ethambutol 300 mg
153	Ethambutol 400 mg
154	Etoricoxib 120 mg
155	Evening Primrose Oil Capsule
156	Eye Vitamins, Alpha Lipoic Acid 200 mg, Vit C 75 mg,

	Lutein powder 20 mg, Vie E 12 mg, Copper
157	Febuxostat 40 mg
158	Febuxostat 80 mg
159	Fenofibrate 145 mg
160	Ferrous Sulfate 300 mg + Folic Acid 250mg
161	Floucinolone cream 0.03%
162	Flucinolone 0.25%, Neomycin SO4 3.5 mg, Polymycin B SO4 10,000 Units Ear Drops
163	Fluconazole 150 mg
164	Flunarizine HCl 5 mg
165	Fluocinolone acetonide 250 mcg, neomycin sulfate 3.5 mg, polymyxin B sulfate 10,000 unit Otic, 5 ml
166	Fluoxetine HCl 20 mg
167	Fluticasone Propionate Nasal Spray 50 mcg
168	Formula powder with Glutamine, Argine & Fish Oil 400 g/can (vanilla/melon flavor)
169	Furosemide 10mg/ml, 2 ml
170	Furosemide 40 mg
171	Fusidate Sodium 10cm x 10cm Intertulle
172	Fusidate Sodium 2% Ointment 5 g
173	Fusidic Acid 2% + Betamethasone Dipropionate oint., 5 g
174	Fusidic Acid 2% Cream 5 g
175	Fusidic Acid 2% w/ Betamethasone w/ 0.064% Dip. Cream, 5 g
176	Gabapentin 100 mg
177	Gentamicin Sulfate 0.3% Ophthalmic/Otic drops, 5 ml
178	Gingko Biloba + Nattokinase Extract + Policosanol and fish Oil
179	Glibenclamide 5 mg
180	Gliclazide 30 mg

181	Gliclazide 60 mg MR
182	Glimiperide 2 mg
183	Glipizide 5 mg
184	Glucosamine HCl, Boswella Extract, Chondroitin SO <sub>4</sub> , Bioflavanoids & Vitamin C 620mg
185	Glucosamine Sulfate 495mg + Chondroitin Sulfate 400mg
186	Glucosamine Sulfate 500mg (Calcium Citrate, chondroitin, colecalciferol)
187	Glucosamine Sulfate, Sodium Chloride 1.884g
188	Guiafenesin 500mg
189	Guiafenesin 50mg / Salbutamol 1mg
190	Hydralazine HCl 20mg/ml
191	Hydrocortisone 1% Cream 5g
192	Hydrocortisone Sodium Succinate 100mg
193	Hydrocortisone Sodium Succinate 250mg
194	Hydroxyzine diHCl 10mg
195	Hyoscine N Butylbromide 10mg
196	Hyoscine N Butylbromide 20 mg/ml x 1ml
197	Hypromellose 0.3% x 10ml
198	Ibuprofen 400mg
199	Inosine Dipepranol Immunodin 500mg
200	Insulin 70/30 100 IU/ml
201	Insulin Biphasic Isophane Human (70/30) 100 IU/ml, 10ml
202	Insulin Glargine 100 U/ml, 10 ml
203	Insulin Glargine 100 U/ml, 3 ml
204	Insulin Glargine U 300
205	Insulin Glulisine 100 U/ml, 10 ml

206	Insulin N Isophane Human 100 IU/ml, 10 ml
207	Ipratropium B 20 mcg + Salbutamol 120 mcg inhaler
208	Ipratropium B 500 mcg + Salbutamol 120 mcg, 2.5 ml
209	Iron Sucrose 20 mg/ml
210	Isosorbide Dinitrate 1mg/1ml, 10 ml
211	Isosorbide Dinitrate 5 mg sublingual/oral
212	Isosorbide Mononitrate 60 mg MR
213	Itopride HCl 50mg
214	Itraconazole 100 mg
215	Ketoanalogues + Essential Amino Acids 630mg
216	Ketoconazole Cream 2%, 5 g
217	Ketorolac 30 mg/ml
218	Lactated Ringer Solution 1L
219	Lactulose 3.3g/5ml, 120 ml syrup
220	Lagundi 600 mg
221	Lansoprazole 30 mg
222	Levocetirizine 5 mg
223	Levodopa 250 mg + Carbidopa 25 mg
224	Levofloxacin 500 mg
225	Levothyroxine Na 100 mg
226	Lidocaine 2% + Epinephrine Injection
227	Lidocaine HCl 2%, 50 ml
228	Lidocaine HCl Topical Anesthesia
229	Linagliptin 2.5 mg + Metformin 500 mg
230	Linagliptin 5 mg
231	Loperamide 2 mg
232	Loratadine 10 mg

233	Losartan 50 mg
234	Losartan K 50mg + HCTZ 12.5mg
235	Losartan Potassium 50mg + Amlodipine Besylate 5 mg
236	Mannitol 20%, 250 ml
237	Mebendazole 100 mg
238	Mebendazole 500 mg
239	Meclizine HCl 25mg
240	Mecobalamin 500 mcg
241	Mefenamic Acid 500 mg
242	Meloxicam 15 mg
243	Memantine 10 mg
244	Metformin 500 mg
245	Methimazole 20 mg
246	Methimazole 5 mg
247	Methisoprinol 500 mg
248	Methylprednisolone 40 mg
249	Methylprednisolone 5 mg
250	Metoclopramide 5mg/ml, 2 ml
251	Metoclopramide HCl 10 mg
252	Metoprolol Tartrate 100 mg
253	Metoprolol Tartrate 50 mg
254	Metronidazole + Miconazole (vaginal suppository)
255	Metronidazole 500 mg
256	Metronidazole 500 mg/100 ml Infusion
257	Miconazole Nitrate + Hydrocortisone Cream 15 g
258	Miconazole Nitrate 2 cream, 5 g
259	Modular Amino Acid for healing and Immune Enchancing, Powder

	scht, 80 Kcal, Glutamine 10.0 G, CHO 9.6 G. Lipid 13.4 G with Fibre 1.2 g. Vitamin C 250mg, Vit E 83mg a-TE, Zn 3.4mg, Selenium 50 u.g. 22.4 g.
260	Mometasone Furoate 0.1% Ointment 5 g
261	Montelukast 10 mg + Levocetirizine 5 mg
262	Montelukast Na 10 mg
263	Muconase Nasal 60 ml
264	Multivitamins & Minerals Tablet with Natural Extract Amino Acid 820mg
265	Multivitamins / Minerals with Lecithin 50mg + Citrus Bioflavanoids 25mg L-lysine HCl 25mg
266	Multivitamins + Minerals + Iron
267	Mupirocin 2% Ointment 5 g
268	N-Acetylcysteine 600 mg
269	N-Acetylcysteine 600 mg
270	NaCl 0.65% Nasal Spray
271	Nalbuphine 10 mg/ml
272	Naphazoline HCl 0.12 mg/ml eye drops
273	Naproxen 500 mg
274	Neem, Glycyrrhiza Glabra Extract, Polyethylene Glycol, Ficus Infectoria Extract, Pongamia Pinnata Extract, Cassia Tora Extract, Zinc Oxide Celastrus Panniculatus Extract Cream 25g.
275	Nicardepine 1mg/ml, 2 ml
276	Nicotinamide + Phosphatidyl + B Complex Forte
277	Nifedipine 10 mg
278	Nifedipine 5 mg
279	Norfloxacin 400 mg
280	Normal Saline Solution 1L
281	Normal Saline Solution 1L (Irrigating Solution)
282	Nutritional Drink with Glutamine, Oligosaccharide, Dietary Fiber -



	Refreshing Lemon Flavor
283	Nystatin Oral Gel
284	Ofloxacin 200 mg
285	Ofloxacin 3mg/ml Ophthalmic/Otic Drops,5ml
286	Ofloxacin 400 mg
287	Olanzapine 10 mg
288	Olanzapine 5 mg oral dispersable
289	Olmesartan + Amlodipine 5 mg
290	Olmesartan 20 mg + Amlodipine 5 mg + HCTZ 12.5 mg
291	Olmesartan Medoxomil 20 mg
292	Omeprazole 20 mg
293	Omeprazole 40 mg powder
294	Oral Rehydration Salt, Powder for Oral Solution 5.125g
295	Oxymetazoline HCl 0.05%
296	Pantoprazole 40mg
297	Pantoprazole 40mg
298	Paracetamol 150 mg Injection
299	Paracetamol 325 mg + Ibuprofen 200 mg
300	Paracetamol 325 mg + Tramadol 37.5 mg
301	Paracetamol 500 mg
302	Paracetamol 650 mg + Orphenadine Citrate 50 mg
303	Permethrin Lotion 5%, 60 ml
304	Petroleum Jelly 200 g
305	Phenobarbital 60mg
306	Phenobarbital 90mg
307	Phenylpropanolamine 325mg + Paracetamol 25mg + Chlorphenamine Maleate 2mg

308	Phenytoin Sodium 100 mg
309	Phenytoin Sodium 50mg/ml 2ml
310	Phosphatidyl Choline 300mg, Nicotinamide 30mg, DL-A Tocopheryl Acetate 10mg + Vitamin B2 6mg, B6 10mg, B12 10mcg
311	Pinaverium Br 50mg
312	Pinene 17mg + Camphene 5mg + Cineol 2mg + Menthone 6mg + Methol 32mg + Borneol 5 mg + Olive Oil 33mg
313	Pinene 31mg + Camphene 15mg + Cineol 3mg + Frenchone 4mg + Borneol 10mg, Anethol 4mg, Olive Oil 33mg
314	Pioglitazone 15 mg
315	Pioglitazone 15 mg + Glimeperide 2mg
316	Pioglitazone 15 mg + Metformin 500 mg
317	Pioglitazone 30 mg
318	Pioglitazone 30 mg + Glimeperide 2mg
319	Pioglitazone 30 mg + Metformin 500 mg
320	Piperacillin Sodium 4g + Tazobactam Sodium 500mg
321	Piracetam 400 mg
322	Pirenoxine Na eye solution 0.85mg, 15ml solvent
323	Piroxicam 20mg
324	Pizotifen, Vit B, Nicotinamide
325	Policresulen 50mg, Cinchocaine HCl 10mg 20g ointment
326	Potassium Chloride 2 meq/ml, 20 ml injection
327	Potassium Chloride 600 mg
328	Potassium Citrate 10 mEq
329	Povidone Iodine gargle, 120 ml
330	Pramipexole diHCl 1mg
331	Prasugrel 10mg
332	Prednisolone Acetate Eye Drops 1%, 5 ml

333	Prednisone
334	Prednisone 10 mg
335	Prednisone 5 mg
336	Pregabalin 150 mg
337	Pregabalin 75 mg
338	Procaterol HCl 50 mcg Swinghaler 5 ml
339	Procaterol HCl 50 mcg
340	Propranolol 10mg
341	Propranolol 40mg
342	Propylthiouracil 50 mg
343	Protein 5 g, fat 2.3 g (saturated fatty acid 0.9 g), carbohydrate 15.7 g (dietary fiber 1.2 g), Na 177 mg (salt equiv 0.44 g), vit B1 0.32 mg, vit B2 0.35 mg, vit B6 0.45 mg, vit B12 0.45 mcg, vit C 80 mg, vit A 82 mcg-RE, vit E 3.5 mg $\alpha$ -TE, vit D 2 mcg, Cl 72 mg, K 156 mg, Ca 94 mg, P 75 mg, Fe 1.1 mg, Zn 1.8 mg. Energy: 100 kCal (Jelly Corn Flavor) 100g
344	Psyllium
345	Purified Vero Cell 0.5ml
346	Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated)
347	Quetiapine Fumarate 200mg
348	Racicadotril 100mg x 20's
349	Ranitidine 50 mg/ml
350	Ranitidine HCl 150 mg
351	Ranitidine HCl 300 mg
352	Ranitidine Injection
353	Rebamipide 100 mg
354	Rifaximin 200 mg
355	Risperidone 2 mg
356	Rosuvastatin 10 mg

357	Salbutamol + Ipratropium 2.5mg/500mg, 2.5ml
358	Salbutamol 100 mcg inhaler
359	Salbutamol 2 mg
360	Salbutamol 2.5 mg / 2.5 ml
361	Salmeterol + Fluticasone 25/125 mcg Inhaler
362	Salmeterol + Fluticasone 25/250 mcg Inhaler
363	Selegiline HCl 5mg
364	Serrapeptase 10 mg
365	Silver Sulfadiazine 1% Cream 20 g
366	Silymarine + Thiamine + Pyridoxine
367	Silymarine 125mg + Vit B (1.0000mg) + Vit B2 (1.0000mg) + Vit B6 (0.5000mg) + Vit B12 (0.0005mg)
368	Silymarine 150mg + Thiamine Mononitrate 4mg + Pyridoxine HCl 4mg + Cyanocobalamin 1.2mcg + Nicotinamide 12mg + Calcium Pantothenate 8mg + Lecithin 8mg (30cap / bot)
369	Simeticone 300 mg
370	Simvastatin 20 mg
371	Simvastatin 40 + Fenofibrate 145mg
372	Simvastatin 40 mg
373	Sitagliptin 100mg
374	Sitagliptin 50 mg + Metformin 1 g
375	Sitagliptin 50 mg + Metformin 500 mg
376	Sodium Ascorbate 568 mg
377	Sodium Bicarbonate 1 meq, 50 ml
378	Sodium Bicarbonate 1760mg Sodium Citrate 630mg Citric Acid 720mg Tartaric Acid
379	Sodium Bicarbonate 650 mg
380	Sodium Chloride 0.9% Solution for Irrigation 1L

381	Sodium Chloride 1 g
382	Spironolactone 25 mg
383	Spironolactone 25 mg / Butizide 2.5 mg
384	Spironolactone 50 mg
385	Standardized Senna Concentrate 374mg
386	Sterile Water for Injection, 100 cc
387	Sterile Water for Injection, 50 cc
388	Sucralfate 1 g
389	Sulfur Soap, 135 g
390	Sulodexide 250 mg
391	Sulodexide 600mg, 2 ml
392	Sultamicillin 1.5 g (Ampicillin + Sulbactam 1g/500mg)
393	Sultamicillin 750 mg
394	Tamsulosin 400 mg
395	Terazosin HCl 2 mg
396	Terazosin HCl 5 mg
397	Terbinafine Cream 10 g
398	Terbutaline 2.5 mg
399	Terbutaline 2.5 mg
400	Tetanus Toxoid 0.5 ml
401	Tetracycline 500 mg
402	Thiamine HCl Vit B1 (100mg) Riboflavin - 5 Phosphate Na Vit B25mg, Nicotinamide Vit B3 (100mg) Dexpanthenol 50mg, Pyridoxine HCl Vit B6 (100mg), Cyanocobalamin Vit B12 (1mg) 3ml
403	Tibolone pack (28's)
404	Timolol Maleate Ophthalmic Drops 0.5% x 5 ml
405	Tioconazole ointment 5 g

	406 Tiotropium 18 mcg inhaler
	407 Tobramycin 0.3% + Dexamethasone 0.5%, 5 ml Ophthalmic Drops
	408 Tobramycin Ophthalmic Drops 3mg/ml, 5 ml Ophthalmic Drops
	409 Tolnaftate 1% cream, 5 g
	410 Tolvaptan 15 mg
	411 Tramadol 50 mg
	412 Tramadol 50 mg/ml
	413 Tranexamic Acid 50 mg/5 ml
	414 Tranexamic Acid 500 mg
	415 Trimetazidine 20 mg
	416 Trimetazidine 35 mg
	417 Ursodeoxycholic Acid 300 mg
	418 Valproic Acid Solution for Injection 500mg / 5ml
	419 Valsartan 80 mg + Amlodipine 5 mg
	420 Valsartan 80 mg + HCTZ 12.5 mg
	421 Vildagliptin 50 mg tab
	422 Vildgliptin 50 mg + Metformin 1 g
	423 Vildgliptin 50 mg + Metformin 500 mg
	424 Vildgliptin 50 mg + Metformin 850 mg
	425 Vitamin B Complex 3 ml IV.
	426 Vitamin B1 250mg + B6 250mg + B12 1000mcg
	427 Vitamin C
	428 Vitamin D
	429 Vitamin E
	430 Zolpidem Tartrate 10 mg
28.4	No further instructions.
29.2	Within a non-extendible period of five (5) calendar days from receipt by

	<p>the bidder of the notice from the BAC that it submitted the LCB, the Bidder shall submit the following documentary requirements:</p> <p>I. Latest Income and Business Tax Return filed thru Electronic Filing and Payment System (EFPS) duly validated with the tax payments made thereon also refers to the Value Added tax (Form 2550M and 2550Q) or Percentage Tax Returns (Form 2551M) covering the previous six (6) months prior to submission and opening of bids.</p> <p>Only tax returns filed and taxes paid through the BIR Electronic Filing and Payments System (EFPS) shall be accepted</p> <p>II. License/permit:</p> <p>a.) Valid and current License to Operate (LTO) from FOOD and DRUG ADMINISTRATION (FDA)</p> <p>b.) Valid &amp; current copy of certification from the manufacturer/Distributor/dealer/trader that the supplier/bidder is an authorized/Exclusive Distributor/dealer/trader of the products/items</p> <p>c.) Valid and current Certificate of Product Registration of the products/items.</p> <p>Failure of the Bidder declared as LCB to duly submit the requirements stated above or a finding against the veracity of such shall be ground for forfeiture of the bid security and disqualify the Bidder for award.</p> <p>Furthermore, as part of the Post Qualification, the Eligibility and Technical Documents submitted by the LCB/SCB, shall be verify, validate and ascertain all statement made.</p>		
32.4(f)	No additional requirement.		
33	<p>To guarantee the faithful performance by the winning Bidder of its obligations under the contract, it shall post a performance security within a maximum period of ten (10) calendar days from the receipt of the Notice of Award from the Procuring Entity and in no case later than the signing of the contract.</p> <p>The Performance Security shall be denominated in Philippine Pesos and posted in favor of the Procuring Entity in an amount not less than the percentage of the total contract price in accordance with the following schedule:</p> <table border="1" data-bbox="406 1787 1313 1935"> <tr> <td data-bbox="406 1787 896 1935">Form of Performance Security</td> <td data-bbox="896 1787 1313 1935">Amount of Performance Security (Not less than the Percentage of the Total Contract Price)</td> </tr> </table>	Form of Performance Security	Amount of Performance Security (Not less than the Percentage of the Total Contract Price)
Form of Performance Security	Amount of Performance Security (Not less than the Percentage of the Total Contract Price)		

	<p>1. Cash or cashier's/manager's check issued by a Universal or Commercial Bank.</p>	<p>Five percent (5%)</p>
	<p>2. Bank draft/guarantee or irrevocable letter of credit issued by a Universal or Commercial Bank: Provided, however, that it shall be confirmed or authenticated by a Universal or Commercial Bank, if issued by a foreign bank.</p>	
	<p>3. Surety bond callable upon demand issued by a surety or insurance company duly certified by the Insurance Commission as authorized to issue such security.</p>	<p>Thirty percent (30%)</p>
<p>Failure of the successful Bidder to comply with the above-mentioned requirement shall constitute sufficient ground for the annulment of the award and forfeiture of the bid security, in which event the Procuring Entity shall have a fresh period to initiate and complete the post qualification of the second Lowest Calculated Bid. The procedure shall be repeated until the LCRB is identified and selected for recommendation of contract award. However if no Bidder passed post-qualification, the BAC shall declare the bidding a failure and conduct a re-bidding with re-advertisement, if necessary.</p>		



## ***Section IV. General Conditions of Contract***

# TABLE OF CONTENTS

1. DEFINITIONS.....	84
2. CORRUPT, FRAUDULENT, COLLUSIVE, AND COERCIVE PRACTICES .....	85
3. INSPECTION AND AUDIT BY THE FUNDING SOURCE.....	86
4. GOVERNING LAW AND LANGUAGE.....	86
5. NOTICES .....	86
6. SCOPE OF CONTRACT.....	87
7. SUBCONTRACTING.....	87
8. PROCURING ENTITY’S RESPONSIBILITIES .....	87
9. PRICES.....	87
10. PAYMENT.....	88
11. ADVANCE PAYMENT AND TERMS OF PAYMENT.....	88
12. TAXES AND DUTIES.....	89
13. PERFORMANCE SECURITY .....	89
14. USE OF CONTRACT DOCUMENTS AND INFORMATION.....	90
15. STANDARDS .....	90
16. INSPECTION AND TESTS.....	90
17. WARRANTY .....	91
18. DELAYS IN THE SUPPLIER’S PERFORMANCE .....	92
19. LIQUIDATED DAMAGES .....	92
20. SETTLEMENT OF DISPUTES.....	92
21. LIABILITY OF THE SUPPLIER .....	93
22. FORCE MAJEURE.....	93
23. TERMINATION FOR DEFAULT .....	93
24. TERMINATION FOR INSOLVENCY.....	94
25. TERMINATION FOR CONVENIENCE.....	94
26. TERMINATION FOR UNLAWFUL ACTS .....	95
27. PROCEDURES FOR TERMINATION OF CONTRACTS .....	95
28. ASSIGNMENT OF RIGHTS .....	96

**29. CONTRACT AMENDMENT .....97**  
**30. APPLICATION.....97**

## 1. Definitions

1.1. In this Contract, the following terms shall be interpreted as indicated:

- (a) “The Contract” means the agreement entered into between the Procuring Entity and the Supplier, as recorded in the Contract Form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.
- (b) “The Contract Price” means the price payable to the Supplier under the Contract for the full and proper performance of its contractual obligations.
- (c) “The Goods” means all of the supplies, equipment, machinery, spare parts, other materials and/or general support services which the Supplier is required to provide to the Procuring Entity under the Contract.
- (d) “The Services” means those services ancillary to the supply of the Goods, such as transportation and insurance, and any other incidental services, such as installation, commissioning, provision of technical assistance, training, and other such obligations of the Supplier covered under the Contract.
- (e) “GCC” means the General Conditions of Contract contained in this Section.
- (f) “SCC” means the Special Conditions of Contract.
- (g) “The Procuring Entity” means the organization purchasing the Goods, as named in the **SCC**.
- (h) “The Procuring Entity’s country” is the Philippines.
- (i) “The Supplier” means the individual contractor, manufacturer distributor, or firm supplying/manufacturing the Goods and Services under this Contract and named in the **SCC**.
- (j) The “Funding Source” means the organization named in the **SCC**.
- (k) “The Project Site,” where applicable, means the place or places named in the **SCC**.
- (l) “Day” means calendar day.
- (m) The “Effective Date” of the contract will be the date of signing the contract, however the Supplier shall commence performance of its obligations only upon receipt of the Notice to Proceed and copy of the approved contract.
- (n) “Verified Report” refers to the report submitted by the Implementing Unit to the HoPE setting forth its findings as to the existence of grounds

or causes for termination and explicitly stating its recommendation for the issuance of a Notice to Terminate.

## **2. Corrupt, Fraudulent, Collusive, and Coercive Practices**

2.1. Unless otherwise provided in the SCC, the Procuring Entity as well as the bidders, contractors, or suppliers shall observe the highest standard of ethics during the procurement and execution of this Contract. In pursuance of this policy, the Procuring Entity:

- (a) defines, for the purposes of this provision, the terms set forth below as follows:
  - (i) "corrupt practice" means behavior on the part of officials in the public or private sectors by which they improperly and unlawfully enrich themselves, others, or induce others to do so, by misusing the position in which they are placed, and it includes the offering, giving, receiving, or soliciting of anything of value to influence the action of any such official in the procurement process or in contract execution; entering, on behalf of the Government, into any contract or transaction manifestly and grossly disadvantageous to the same, whether or not the public officer profited or will profit thereby, and similar acts as provided in Republic Act 3019.
  - (ii) "fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Procuring Entity, and includes collusive practices among Bidders (prior to or after bid submission) designed to establish bid prices at artificial, non-competitive levels and to deprive the Procuring Entity of the benefits of free and open competition.
  - (iii) "collusive practices" means a scheme or arrangement between two or more Bidders, with or without the knowledge of the Procuring Entity, designed to establish bid prices at artificial, non-competitive levels.
  - (iv) "coercive practices" means harming or threatening to harm, directly or indirectly, persons, or their property to influence their participation in a procurement process, or affect the execution of a contract;
  - (v) "obstructive practice" is
    - (aa) deliberately destroying, falsifying, altering or concealing of evidence material to an administrative proceedings or investigation or making false statements to investigators in order to materially impede an administrative proceedings or investigation of the Procuring Entity or any foreign government/foreign or

international financing institution into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the administrative proceedings or investigation or from pursuing such proceedings or investigation; or

(bb) acts intended to materially impede the exercise of the inspection and audit rights of the Procuring Entity or any foreign government/foreign or international financing institution herein.

(b) will reject a proposal for award if it determines that the Bidder recommended for award has engaged in any of the practices mentioned in this Clause for purposes of competing for the contract.

2.2. Further the Funding Source, Borrower or Procuring Entity, as appropriate, will seek to impose the maximum civil, administrative and/or criminal penalties available under the applicable law on individuals and organizations deemed to be involved with any of the practices mentioned in **GCC** Clause 2.1(a).

### **3. Inspection and Audit by the Funding Source**

The Supplier shall permit the Funding Source to inspect the Supplier's accounts and records relating to the performance of the Supplier and to have them audited by auditors appointed by the Funding Source, if so required by the Funding Source.

### **4. Governing Law and Language**

4.1. This Contract shall be interpreted in accordance with the laws of the Republic of the Philippines.

4.2. This Contract has been executed in the English language, which shall be the binding and controlling language for all matters relating to the meaning or interpretation of this Contract. All correspondence and other documents pertaining to this Contract exchanged by the parties shall be written in English.

### **5. Notices**

5.1. Any notice, request, or consent required or permitted to be given or made pursuant to this Contract shall be in writing. Any such notice, request, or consent shall be deemed to have been given or made when received by the concerned party, either in person or through an authorized representative of the Party to whom the communication is addressed, or when sent by registered mail, telex, telegram, or facsimile to such Party at the address specified in the **SCC**, which shall be effective when delivered and duly received or on the notice's effective date, whichever is later.

- 5.2. A Party may change its address for notice hereunder by giving the other Party notice of such change pursuant to the provisions listed in the **SCC** for **GCC** Clause 5.1.

## **6. Scope of Contract**

- 6.1. The Goods and Related Services to be provided shall be as specified in Section VI. Schedule of Requirements.
- 6.2. This Contract shall include all such items, although not specifically mentioned, that can be reasonably inferred as being required for its completion as if such items were expressly mentioned herein. Any additional requirements for the completion of this Contract shall be provided in the **SCC**.

## **7. Subcontracting**

- 7.1. Subcontracting of any portion of the Goods, if allowed in the **BDS**, does not relieve the Supplier of any liability or obligation under this Contract. The Supplier will be responsible for the acts, defaults, and negligence of any subcontractor, its agents, servants or workmen as fully as if these were the Supplier's own acts, defaults, or negligence, or those of its agents, servants or workmen.
- 7.2. If subcontracting is allowed, the Supplier may identify its subcontractor during contract implementation. Subcontractors disclosed and identified during the bidding may be changed during the implementation of this Contract. In either case, subcontractors must submit the documentary requirements under **ITB** Clause 12 and comply with the eligibility criteria specified in the **BDS**. In the event that any subcontractor is found by the Procuring Entity to be ineligible, the subcontracting of such portion of the Goods shall be disallowed.

## **8. Procuring Entity's Responsibilities**

- 8.1. Whenever the performance of the obligations in this Contract requires that the Supplier obtain permits, approvals, import, and other licenses from local public authorities, the Procuring Entity shall, if so needed by the Supplier, make its best effort to assist the Supplier in complying with such requirements in a timely and expeditious manner.
- 8.2. The Procuring Entity shall pay all costs involved in the performance of its responsibilities in accordance with **GCC** Clause 6.

## **9. Prices**

- 9.1. For the given scope of work in this Contract as awarded, all bid prices are considered fixed prices, and therefore not subject to price escalation during contract implementation, except under extraordinary circumstances and upon prior approval of the GPPB in accordance with Section 61 of R.A. 9184 and its IRR or except as provided in this Clause.

- 9.2. Prices charged by the Supplier for Goods delivered and/or services performed under this Contract shall not vary from the prices quoted by the Supplier in its bid, with the exception of any change in price resulting from a Change Order issued in accordance with **GCC** Clause 29.

## **10. Payment**

- 10.1. Payments shall be made only upon a certification by the HoPE to the effect that the Goods have been rendered or delivered in accordance with the terms of this Contract and have been duly inspected and accepted. Except with the prior approval of the President no payment shall be made for services not yet rendered or for supplies and materials not yet delivered under this Contract. *At least one percent (1%) not to exceed five percent (5%)* of the amount of each payment shall be retained by the Procuring Entity to cover the Supplier's warranty obligations under this Contract as described in **GCC** Clause 17.
- 10.2. The Supplier's request(s) for payment shall be made to the Procuring Entity in writing, accompanied by an invoice describing, as appropriate, the Goods delivered and/or Services performed, and by documents submitted pursuant to the **SCC** provision for **GCC** Clause 6.2, and upon fulfilment of other obligations stipulated in this Contract.
- 10.3. Pursuant to **GCC** Clause 10.2, payments shall be made promptly by the Procuring Entity, but in no case later than sixty (60) days after submission of an invoice or claim by the Supplier. Payments shall be in accordance with the schedule stated in the **SCC**.
- 10.4. Unless otherwise provided in the **SCC**, the currency in which payment is made to the Supplier under this Contract shall be in Philippine Pesos.
- 10.5. Unless otherwise provided in the **SCC**, payments using Letter of Credit (LC), in accordance with the Guidelines issued by the GPPB, is allowed. For this purpose, the amount of provisional sum is indicated in the **SCC**. All charges for the opening of the LC and/or incidental expenses thereto shall be for the account of the Supplier.

## **11. Advance Payment and Terms of Payment**

- 11.1. Advance payment shall be made only after prior approval of the President, and shall not exceed fifteen percent (15%) of the Contract amount, unless otherwise directed by the President or in cases allowed under Annex "D" of RA 9184.
- 11.2. All progress payments shall first be charged against the advance payment until the latter has been fully exhausted.
- 11.3. For Goods supplied from abroad, unless otherwise indicated in the **SCC**, the terms of payment shall be as follows:
- (a) On Contract Signature: Fifteen Percent (15%) of the Contract Price shall be paid within sixty (60) days from signing of the Contract and upon submission of a claim and a bank guarantee for the equivalent amount



valid until the Goods are delivered and in the form provided in Section VIII. Bidding Forms.

- (b) On Delivery: Sixty-five percent (65%) of the Contract Price shall be paid to the Supplier within sixty (60) days after the date of receipt of the Goods and upon submission of the documents (i) through (vi) specified in the SCC provision on Delivery and Documents.
- (c) On Acceptance: The remaining twenty percent (20%) of the Contract Price shall be paid to the Supplier within sixty (60) days after the date of submission of the acceptance and inspection certificate for the respective delivery issued by the Procuring Entity's authorized representative. In the event that no inspection or acceptance certificate is issued by the Procuring Entity's authorized representative within forty five (45) days of the date shown on the delivery receipt, the Supplier shall have the right to claim payment of the remaining twenty percent (20%) subject to the Procuring Entity's own verification of the reason(s) for the failure to issue documents (vii) and (viii) as described in the SCC provision on Delivery and Documents.

## **12. Taxes and Duties**

The Supplier, whether local or foreign, shall be entirely responsible for all the necessary taxes, stamp duties, license fees, and other such levies imposed for the completion of this Contract.

## **13. Performance Security**

- 13.1. Within ten (10) calendar days from receipt of the Notice of Award from the Procuring Entity but in no case later than the signing of the contract by both parties, the successful Bidder shall furnish the performance security in any the forms prescribed in the **ITB** Clause 33.2.
- 13.2. The performance security posted in favor of the Procuring Entity shall be forfeited in the event it is established that the winning bidder is in default in any of its obligations under the contract.
- 13.3. The performance security shall remain valid until issuance by the Procuring Entity of the Certificate of Final Acceptance.
- 13.4. The performance security may be released by the Procuring Entity and returned to the Supplier after the issuance of the Certificate of Final Acceptance subject to the following conditions:
  - (a) There are no pending claims against the Supplier or the surety company filed by the Procuring Entity;
  - (b) The Supplier has no pending claims for labor and materials filed against it; and

(c) Other terms specified in the **SCC**.

13.5. In case of a reduction of the contract value, the Procuring Entity shall allow a proportional reduction in the original performance security, provided that any such reduction is more than ten percent (10%) and that the aggregate of such reductions is not more than fifty percent (50%) of the original performance security.

## **14. Use of Contract Documents and Information**

14.1. The Supplier shall not, except for purposes of performing the obligations in this Contract, without the Procuring Entity's prior written consent, disclose this Contract, or any provision thereof, or any specification, plan, drawing, pattern, sample, or information furnished by or on behalf of the Procuring Entity. Any such disclosure shall be made in confidence and shall extend only as far as may be necessary for purposes of such performance.

14.2. Any document, other than this Contract itself, enumerated in **GCC** Clause 14.1 shall remain the property of the Procuring Entity and shall be returned (all copies) to the Procuring Entity on completion of the Supplier's performance under this Contract if so required by the Procuring Entity.

## **15. Standards**

The Goods provided under this Contract shall conform to the standards mentioned in the Section VII. Technical Specifications; and, when no applicable standard is mentioned, to the authoritative standards appropriate to the Goods' country of origin. Such standards shall be the latest issued by the institution concerned.

## **16. Inspection and Tests**

16.1. The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Contract specifications at no extra cost to the Procuring Entity. The **SCC** and Section VII. Technical Specifications shall specify what inspections and/or tests the Procuring Entity requires and where they are to be conducted. The Procuring Entity shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

16.2. If applicable, the inspections and tests may be conducted on the premises of the Supplier or its subcontractor(s), at point of delivery, and/or at the goods' final destination. If conducted on the premises of the Supplier or its subcontractor(s), all reasonable facilities and assistance, including access to drawings and production data, shall be furnished to the inspectors at no charge to the Procuring Entity. The Supplier shall provide the Procuring Entity with results of such inspections and tests.

16.3. The Procuring Entity or its designated representative shall be entitled to attend the tests and/or inspections referred to in this Clause provided that the Procuring Entity shall bear all of its own costs and expenses incurred in

connection with such attendance including, but not limited to, all traveling and board and lodging expenses.

- 16.4. The Procuring Entity may reject any Goods or any part thereof that fail to pass any test and/or inspection or do not conform to the specifications. The Supplier shall either rectify or replace such rejected Goods or parts thereof or make alterations necessary to meet the specifications at no cost to the Procuring Entity, and shall repeat the test and/or inspection, at no cost to the Procuring Entity, upon giving a notice pursuant to **GCC** Clause 5.
- 16.5. The Supplier agrees that neither the execution of a test and/or inspection of the Goods or any part thereof, nor the attendance by the Procuring Entity or its representative, shall release the Supplier from any warranties or other obligations under this Contract.

## **17. Warranty**

- 17.1. The Supplier warrants that the Goods supplied under the Contract are new, unused, of the most recent or current models, and that they incorporate all recent improvements in design and materials, except when the technical specifications required by the Procuring Entity provides otherwise.
- 17.2. The Supplier further warrants that all Goods supplied under this Contract shall have no defect, arising from design, materials, or workmanship or from any act or omission of the Supplier that may develop under normal use of the supplied Goods in the conditions prevailing in the country of final destination.
- 17.3. In order to assure that manufacturing defects shall be corrected by the Supplier, a warranty shall be required from the Supplier for a minimum period specified in the **SCC**. The obligation for the warranty shall be covered by, at the Supplier's option, either retention money in an amount equivalent to *at least one percent (1%) not to exceed five percent (5%)* of every progress payment, or a special bank guarantee equivalent to *at least one percent (1%) not to exceed five percent (5%)* of the total Contract Price or other such amount if so specified in the **SCC**. The said amounts shall only be released after the lapse of the warranty period specified in the **SCC**; provided, however, that the Supplies delivered are free from patent and latent defects and all the conditions imposed under this Contract have been fully met.
- 17.4. The Procuring Entity shall promptly notify the Supplier in writing of any claims arising under this warranty. Upon receipt of such notice, the Supplier shall, within the period specified in the **SCC** and with all reasonable speed, repair or replace the defective Goods or parts thereof, without cost to the Procuring Entity.
- 17.5. If the Supplier, having been notified, fails to remedy the defect(s) within the period specified in **GCC** Clause 17.4, the Procuring Entity may proceed to take such remedial action as may be necessary, at the Supplier's risk and expense and without prejudice to any other rights which the Procuring Entity may have against the Supplier under the Contract and under the applicable law.

## **18. Delays in the Supplier's Performance**

- 18.1. Delivery of the Goods and/or performance of Services shall be made by the Supplier in accordance with the time schedule prescribed by the Procuring Entity in Section VI. Schedule of Requirements.
- 18.2. If at any time during the performance of this Contract, the Supplier or its Subcontractor(s) should encounter conditions impeding timely delivery of the Goods and/or performance of Services, the Supplier shall promptly notify the Procuring Entity in writing of the fact of the delay, its likely duration and its cause(s). As soon as practicable after receipt of the Supplier's notice, and upon causes provided for under GCC Clause 22, the Procuring Entity shall evaluate the situation and may extend the Supplier's time for performance, in which case the extension shall be ratified by the parties by amendment of Contract.
- 18.3. Except as provided under GCC Clause 22, a delay by the Supplier in the performance of its obligations shall render the Supplier liable to the imposition of liquidated damages pursuant to GCC Clause 19, unless an extension of time is agreed upon pursuant to GCC Clause 29 without the application of liquidated damages.

## **19. Liquidated Damages**

Subject to GCC Clauses 18 and 22, if the Supplier fails to satisfactorily deliver any or all of the Goods and/or to perform the Services within the period(s) specified in this Contract inclusive of duly granted time extensions if any, the Procuring Entity shall, without prejudice to its other remedies under this Contract and under the applicable law, deduct from the Contract Price, as liquidated damages, the applicable rate of one tenth (1/10) of one (1) percent of the cost of the unperformed portion for every day of delay until actual delivery or performance. The maximum deduction shall be ten percent (10%) of the amount of contract. Once the maximum is reached, the Procuring Entity may rescind or terminate the Contract pursuant to GCC Clause 23, without prejudice to other courses of action and remedies open to it.

## **20. Settlement of Disputes**

- 20.1. If any dispute or difference of any kind whatsoever shall arise between the Procuring Entity and the Supplier in connection with or arising out of this Contract, the parties shall make every effort to resolve amicably such dispute or difference by mutual consultation.
- 20.2. If after thirty (30) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the Procuring Entity or the Supplier may give notice to the other party of its intention to commence arbitration, as hereinafter provided, as to the matter in dispute, and no arbitration in respect of this matter may be commenced unless such notice is given.
- 20.3. Any dispute or difference in respect of which a notice of intention to commence arbitration has been given in accordance with this Clause shall be

settled by arbitration. Arbitration may be commenced prior to or after delivery of the Goods under this Contract.

- 20.4. In the case of a dispute between the Procuring Entity and the Supplier, the dispute shall be resolved in accordance with Republic Act 9285 (“R.A. 9285”), otherwise known as the “Alternative Dispute Resolution Act of 2004.”
- 20.5. Notwithstanding any reference to arbitration herein, the parties shall continue to perform their respective obligations under the Contract unless they otherwise agree; and the Procuring Entity shall pay the Supplier any monies due the Supplier.

## **21. Liability of the Supplier**

- 21.1. The Supplier’s liability under this Contract shall be as provided by the laws of the Republic of the Philippines, subject to additional provisions, if any, set forth in the SCC.
- 21.2. Except in cases of criminal negligence or willful misconduct, and in the case of infringement of patent rights, if applicable, the aggregate liability of the Supplier to the Procuring Entity shall not exceed the total Contract Price, provided that this limitation shall not apply to the cost of repairing or replacing defective equipment.

## **22. Force Majeure**

- 22.1. The Supplier shall not be liable for forfeiture of its performance security, liquidated damages, or termination for default if and to the extent that the Supplier’s delay in performance or other failure to perform its obligations under the Contract is the result of a *force majeure*.
- 22.2. For purposes of this Contract the terms “*force majeure*” and “fortuitous event” may be used interchangeably. In this regard, a fortuitous event or *force majeure* shall be interpreted to mean an event which the Supplier could not have foreseen, or which though foreseen, was inevitable. It shall not include ordinary unfavorable weather conditions; and any other cause the effects of which could have been avoided with the exercise of reasonable diligence by the Supplier. Such events may include, but not limited to, acts of the Procuring Entity in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions, and freight embargoes.
- 22.3. If a *force majeure* situation arises, the Supplier shall promptly notify the Procuring Entity in writing of such condition and the cause thereof. Unless otherwise directed by the Procuring Entity in writing, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the *force majeure*.

## **23. Termination for Default**

- 23.1. The Procuring Entity shall terminate this Contract for default when any of the following conditions attends its implementation:
- (a) Outside of *force majeure*, the Supplier fails to deliver or perform any or all of the Goods within the period(s) specified in the contract, or within any extension thereof granted by the Procuring Entity pursuant to a request made by the Supplier prior to the delay, and such failure amounts to at least ten percent (10%) of the contract price;
  - (b) As a result of *force majeure*, the Supplier is unable to deliver or perform any or all of the Goods, amounting to at least ten percent (10%) of the contract price, for a period of not less than sixty (60) calendar days after receipt of the notice from the Procuring Entity stating that the circumstance of force majeure is deemed to have ceased; or
  - (c) The Supplier fails to perform any other obligation under the Contract.
- 23.2. In the event the Procuring Entity terminates this Contract in whole or in part, for any of the reasons provided under GCC Clauses 23 to 26, the Procuring Entity may procure, upon such terms and in such manner as it deems appropriate, Goods or Services similar to those undelivered, and the Supplier shall be liable to the Procuring Entity for any excess costs for such similar Goods or Services. However, the Supplier shall continue performance of this Contract to the extent not terminated.
- 23.3. In case the delay in the delivery of the Goods and/or performance of the Services exceeds a time duration equivalent to ten percent (10%) of the specified contract time plus any time extension duly granted to the Supplier, the Procuring Entity may terminate this Contract, forfeit the Supplier's performance security and award the same to a qualified Supplier.

## **24. Termination for Insolvency**

The Procuring Entity shall terminate this Contract if the Supplier is declared bankrupt or insolvent as determined with finality by a court of competent jurisdiction. In this event, termination will be without compensation to the Supplier, provided that such termination will not prejudice or affect any right of action or remedy which has accrued or will accrue thereafter to the Procuring Entity and/or the Supplier.

## **25. Termination for Convenience**

- 25.1. The Procuring Entity may terminate this Contract, in whole or in part, at any time for its convenience. The HoPE may terminate a contract for the convenience of the Government if he has determined the existence of conditions that make Project Implementation economically, financially or technically impractical and/or unnecessary, such as, but not limited to, fortuitous event(s) or changes in law and national government policies.
- 25.2. The Goods that have been delivered and/or performed or are ready for delivery or performance within thirty (30) calendar days after the Supplier's receipt of Notice to Terminate shall be accepted by the Procuring Entity at the contract

terms and prices. For Goods not yet performed and/or ready for delivery, the Procuring Entity may elect:

- (a) to have any portion delivered and/or performed and paid at the contract terms and prices; and/or
- (b) to cancel the remainder and pay to the Supplier an agreed amount for partially completed and/or performed goods and for materials and parts previously procured by the Supplier.

25.3. If the Supplier suffers loss in its initial performance of the terminated contract, such as purchase of raw materials for goods specially manufactured for the Procuring Entity which cannot be sold in open market, it shall be allowed to recover partially from this Contract, on a *quantum meruit* basis. Before recovery may be made, the fact of loss must be established under oath by the Supplier to the satisfaction of the Procuring Entity before recovery may be made.

## **26. Termination for Unlawful Acts**

26.1. The Procuring Entity may terminate this Contract in case it is determined *prima facie* that the Supplier has engaged, before or during the implementation of this Contract, in unlawful deeds and behaviors relative to contract acquisition and implementation. Unlawful acts include, but are not limited to, the following:

- (a) Corrupt, fraudulent, and coercive practices as defined in **ITB** Clause 3.1(a);
- (b) Drawing up or using forged documents;
- (c) Using adulterated materials, means or methods, or engaging in production contrary to rules of science or the trade; and
- (d) Any other act analogous to the foregoing.

## **27. Procedures for Termination of Contracts**

27.1. The following provisions shall govern the procedures for termination of this Contract:

- (a) Upon receipt of a written report of acts or causes which may constitute ground(s) for termination as aforementioned, or upon its own initiative, the Implementing Unit shall, within a period of seven (7) calendar days, verify the existence of such ground(s) and cause the execution of a Verified Report, with all relevant evidence attached;
- (b) Upon recommendation by the Implementing Unit, the HoPE shall terminate this Contract only by a written notice to the Supplier conveying the termination of this Contract. The notice shall state:

- (i) that this Contract is being terminated for any of the ground(s) afore-mentioned, and a statement of the acts that constitute the ground(s) constituting the same;
  - (ii) the extent of termination, whether in whole or in part;
  - (iii) an instruction to the Supplier to show cause as to why this Contract should not be terminated; and
  - (iv) special instructions of the Procuring Entity, if any.
- (c) The Notice to Terminate shall be accompanied by a copy of the Verified Report;
  - (d) Within a period of seven (7) calendar days from receipt of the Notice of Termination, the Supplier shall submit to the HoPE a verified position paper stating why this Contract should not be terminated. If the Supplier fails to show cause after the lapse of the seven (7) day period, either by inaction or by default, the HoPE shall issue an order terminating this Contract;
  - (e) The Procuring Entity may, at any time before receipt of the Supplier's verified position paper described in item (d) above withdraw the Notice to Terminate if it is determined that certain items or works subject of the notice had been completed, delivered, or performed before the Supplier's receipt of the notice;
  - (f) Within a non-extendible period of ten (10) calendar days from receipt of the verified position paper, the HoPE shall decide whether or not to terminate this Contract. It shall serve a written notice to the Supplier of its decision and, unless otherwise provided, this Contract is deemed terminated from receipt of the Supplier of the notice of decision. The termination shall only be based on the ground(s) stated in the Notice to Terminate;
  - (g) The HoPE may create a Contract Termination Review Committee (CTRC) to assist him in the discharge of this function. All decisions recommended by the CTRC shall be subject to the approval of the HoPE; and
  - (h) The Supplier must serve a written notice to the Procuring Entity of its intention to terminate the contract at least thirty (30) calendar days before its intended termination. The Contract is deemed terminated if it is not resumed in thirty (30) calendar days after the receipt of such notice by the Procuring Entity.

## **28. Assignment of Rights**

The Supplier shall not assign his rights or obligations under this Contract, in whole or in part, except with the Procuring Entity's prior written consent.



**29. Contract Amendment**

Subject to applicable laws, no variation in or modification of the terms of this Contract shall be made except by written amendment signed by the parties.

**30. Application**

These General Conditions shall apply to the extent that they are not superseded by provisions of other parts of this Contract.

## *Section V. Special Conditions of Contract*

# Special Conditions of Contract

GCC Clause	
1.1(g)	The Procuring Entity is Bureau of Corrections.
1.1(i)	The Supplier is <i>[to be inserted at the time of contract award]</i> .
1.1(j)	<p>The Funding Source is</p> <p>The Government of the Philippines (GOP) through General Appropriation Act (GAA) of 2019 in the amount of <b>Two Hundred Three Million One Hundred Forty-Seven Thousand Two Hundred Three Pesos and 81/100 (₱203,147,203.81)</b></p>
1.1(k)	The Project Site is Supply Bodega NBP Reservation Muntinlupa City
2.1	No further instructions.
5.1	<p>The Procuring Entity’s address for Notices is: <b>Bureau of Corrections NBP Reservation Muntinlupa City Supply and Delivery of Various Medicines for NBP and CIW 2019</b></p> <p><i>Tel #809-85-87/478-09-07</i></p> <p>The Supplier’s address for Notices is: <i>[Insert address including, name of contact, fax and telephone number]</i></p>
6.2	<p><b>Delivery and Documents –</b></p> <p>For purposes of the Contract, “EXW,” “FOB,” “FCA,” “CIF,” “CIP,” “DDP” and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, Paris. The Delivery terms of this Contract shall be as follows:</p> <p>The delivery terms applicable to this Contract are delivered at Supply Bodega NBP Reservation Muntinlupa City. Risk and title will pass from the Supplier to the Procuring Entity upon receipt and final acceptance of the Goods at their final destination.</p> <p>Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in Section VI. Schedule of Requirements. The details of shipping and/or other documents to be furnished by the Supplier are as follows:</p> <p>Upon delivery of the Goods to the Project Site, the Supplier shall notify the Procuring Entity and present the following documents to the Procuring Entity:</p> <p>(i) Original and four copies of the Supplier’s invoice showing</p>

	<p>Goods' description, quantity, unit price, and total amount;</p> <p>(ii) Delivery receipt detailing number and description of items received signed by the authorized receiving personnel;</p> <p>(iii) Certificate of Acceptance/Inspection Report signed by the Procuring Entity's representative at the Project Site; and</p> <p>(iv) Four copies of the Invoice Receipt for Property signed by the Procuring Entity's representative at the Project Site.</p> <p>For purposes of this Clause the Procuring Entity's Representative at the Project Site is the Chief, NBP Hospital.</p> <p><b>Packaging –</b></p> <p>The Supplier shall provide such packaging of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in this Contract. The packaging shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage.</p> <p><b>Insurance –</b></p> <p>The Goods supplied under this Contract shall be fully insured by the Supplier in a freely convertible currency against loss or damage incidental to manufacture or acquisition, transportation, storage, and delivery. The Goods remain at the risk and title of the Supplier until their final acceptance by the Procuring Entity.</p> <p><b>Transportation –</b></p> <p>Deliveries. In the case of Goods supplied from within the Philippines or supplied by domestic Suppliers risk and title will not be deemed to have passed to the Procuring Entity until their receipt and final acceptance at the final destination.</p> <p><b>Patent Rights –</b></p> <p>The Supplier shall indemnify the Procuring Entity against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof.</p>
10.4	Not applicable
10.5	Payment using LC is not allowed.
11.3	Maintain the GCC Clause.
13.4(c)	No further instructions.
16.1	<p>The inspections and tests that will be conducted are:</p> <p>Partial or complete delivery of item/s shall be inspected and/or tested by</p>

the BuCor Inspection and Acceptance Committee (BIAC).

To be witnessed by:  
COA Representative

Inspection and acceptance will be conducted by the BuCor Inspection and Acceptance Committee (BIAC), to be witnessed by the COA Representative to the actual delivery at the Project Site. Goods with defect or non-compliant with the required specifications as stipulated in the approved Purchase Order/Technical Specifications shall be rejected and shall be replaced by the Supplier free of cost to the Procuring Entity within seven (7) calendar days

The Goods shall be accepted by the end user after passing the inspection of the BuCor Inspection and Acceptance Committee (BIAC).

The inspections and tests that will be conducted are;

1) Upon delivery, the Goods shall undergo physical inspection by the BuCor Inspection and Acceptance Committee (BIAC) of the PROCURING ENTITY to ascertain the physical condition and acceptability of the Goods.  
2.) However, if the end user requested for purposes of laboratory analysis a random samples shall be selected by the end user of its duly authorized representative and witnessed by a representative from supplier. The tests to be conducted by FDA (Food and Drug Administration) and sample sizes are as follows:

a) Physico-Chemical Test

- i. Tablet/capsule – 1 commercial presentation (min of 50 pcs.)
- ii. Liquid/Suspension Solution – 60mlx6 bottles; 120ml x 6 bottles
- iii. Granules/Powders for Suspension – 30ml x 6 bottles; 60ml x 6 bottles

b) Sterility Test

- i. Solid Preparations: Less than 50mg or more but 200mg or more – minimum of 20 bottles
- ii. Liquid Preparations: 1ml to 100ml – minimum of 20 bottles; 50ml to 1000ml- minimum of 6 bottles

c) Microbiological Test

- i. Tablet/capsule – number of tablets/capsules equivalent to at least 20g
- ii. Liquid Preparations – 500ml to 1000ml – minimum of 6 bottles

3) The supplier shall promptly replace the equivalent quantity of Goods taken as samples without cost to the PROCURING ENTITY.

4) Pending FDA analysis, said products should not be distributed to end-users nor shall it be used such time it is cleared by FDA laboratory testing.

5) If FDA inspection or results of laboratory analysis show major violations, the entire delivery shall be rejected and the company will not be allowed to participate in any future procurement activities of the agency.

17.3	Three (3) months after acceptance by the Procuring Entity of the delivered Goods or after the Goods are consumed, whichever is earlier.
17.4	The period for correction of defects in the warranty period is Seven (7) Calendar Days.
21.1	All partners to the joint venture shall be jointly and severally liable to the Procuring Entity.

## ***Section VI. Schedule of Requirements***



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## ***Section VI. Schedule of Requirements***

### ***Supply and Delivery of Various Medicines for NBP and CIW 2019***

#### **A. DELIVERY INSTRUCTIONS**

- Bureau of Corrections shall issue a Notice to Proceed and Purchase Order or Contract Agreement.
- Delivery shall commence within thirty (30) calendar days after the receipt of Notice to Proceed (NTP) and Purchase Order (P.O.) or Contract Agreement.
- Delivery shall be at Supply Bodega Bureau of Corrections NBP Reservation Muntinlupa City.

**I/We hereby commit to comply and deliver all the requirement in accordance with the above stated schedule.**

**CONFORME:**

---

Name of Company in Print

---

Signature Printed Name of Authorized Representative

---

Date



## ***Section VII. Technical Specifications***



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

Item No.	Qty.	Dosage Form	Agency Specification	Brand Name Offered	Bidder's Statement of Compliance
1	1,300	bot	8% w/v Amino Acid Soln w/ 3% w/v Branched Chain Amino Acids content 500ml		
2	100	susp	A1(OH) 200 mg+ +Mg(OH)2 100 mg, 120 ml		
3	46,000	chewable tab	A1OH + MgOH mg, Simethicone 30 mg		
4	1,400	tube	Aciclovir + Zinc Oxide Ointment 50mg/100mg		
5	1,500	tab	Aciclovir 200 mg		
6	6,000	tab	Aciclovir 400 mg		
7	1,500	tube	Aciclovir 5%, 5 g		
8	15,000	tab	Ademetionine Butane Disulfonate 500mg		
9	1,500	amp	Ademetionine Butane Disulfonate 500mg IV/IM		
10	6,000	cap	Agmatine Sulfate		
11	1,040	tab	Alendronic Acid (as Alendronate Na Trihydrate) 70 mg		
12	7,500	tab	Allopurinol 300 mg		
13	5,000	tab	Alpha- lipoic Acid, Gamma-Linoleic Acid, Vit E & Selenium with Vit B Complex 920 mg		
14	700	tab	Alprazolam 250 mcg		
15	17,400	tab	Aluminum Magnesium Hydroxide 200/100		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
16	31,400	tab	Ambroxol HCl 30 mg		
17	1,600	scht	Amino Acid + M-Vit + Mineral (Oral) 50 g		
18	2,000	bot	Amino Acid + Sorbitol Solution for I.V. 500 ml		
19	3,000	dual chamber	Amino Acid and Glucose Inj. With Electrolytes and Vitamins B1, 1 L		
20	3,000	dual chamber	Amino Acid and Glucose Inj. With Electrolytes and Vitamins B1, 500 ml		
21	16,000	cap	AminoLock Collagen		
22	227,000	tab	Amlodipine Besilate 10 mg		
23	227,000	tab	Amlodipine Besilate 5 mg		
24	30,000	cap	Amoxicillin 500 mg		
25	5,000	tab	Aripiprazole 10mg Discmelt ODT 30's		
26	5,000	tab	Aripiprazole 15mg Discmelt ODT 30's		
27	50	prefilled syringe	Aripiprazole 400mg (box of 1)		
28	58,000	tab	Aspirin 80 mg		
29	105,000	tab	Atorvastatin 10 mg + Ezetimibe 10 mg FC		
30	10,000	tab	Atorvastatin 40 mg		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
31	100,000	tab	Atorvastatin Calcium 20 mg		
32	15,160	amp	ATS 1,500 IU		
33	1,950	nasal spray	Azelastine HCl 1mg/ml (0.1% w/v) Nasal Spray14ml		
34	11,300	tab	Azithromycin Monohydrate 500 mg		
35	6,000	vial	Bacillus Clausii Oral Solution 5ml		
36	1,500	pcs	Beclomethasone 100 mcg + Formoterol 6 mcg PMDI inhaler		
37	21,100	tab	Betahistine HCl 16 mg		
38	100	amp	Betamethasone Dipropionate 1ml		
39	1,500	tube	Betamethasone Dipropionate 640 mcg 5 g Ointment		
40	1,000	tube	Betamethasone Dipropionate 640mcg + Gentamicin 1mg 5 g Cream		
41	3,000	tube	Betamethasone Valerate 1mg/g, 1 g Cream		
42	6,000	tab	Biperiden 5mg		
43	10,500	tab	Biperiden HCl 2 mg		
44	400	amp	Biperiden Injection		
45	1,500	supp	Bisacodyl 10 mg (Adult)		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
46	12,400	tab	Bisacodyl 5 mg		
47	6,000	tab	Blumea Balsamifera 500 mg		
48	60	bot	Brimonidine tabs 1.5 mg/ml topical ocular hypertensive agent solution		
49	28,000	tab	Bromhexine HCl 8 mg		
50	15,000	tab	Buclizine HCl + FeSO <sub>4</sub> + MV		
51	2,200	pcs	Budesonide + Formeterol 160 mcg + 4.5 mcg, 120 doses dry powder inhaler		
52	20,000	neb	Budesonide 500 mcg/ml, 2ml respiratory solution		
53	1,500	pcs	Budesonide Swinghaler 200 mcg/dose		
54	25,400	tab	Butamirate Citrate 50 mg		
55	1,900	scht	Calamine plus Zinc Oxide 40/30 mg/g, 5g		
56	101,000	tab	Calcium with Vitamin D		
57	26,000	tab	Calcium with Vitamins and Minerals		
58	10,000	tab	Candesartan Cilexetil 8 mg		
59	160,600	tab	Captopril 25 mg		
60	160,000	tab	Captopril 50 mg		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
61	3,000	can	Carb Steady Renal Nutrition Formula for Dialysis Patient 237ml		
62	5,500	can	Carb Steady Renal Nutrition Formula for Pre-Dialysis Patient w/ CKD 237ml		
63	26,500	tab	Carbamazepine 200 mg tab		
64	313,000	cap	Carbocisteine 500 mg		
65	20,000	tab	Carvedilol 25 mg		
66	250	bot	Castor Oil (Sweet Orange Flavor), 60 ml.		
67	10,000	cap	Cefaclor 500 mg		
68	35,600	cap	Cefalexin 500 mg		
69	10,500	vial	Ceftriaxone 1 g		
70	35,500	cap	Cefuroxime 500 mg		
71	20,070	vial	Cefuroxime 750 mg		
72	1,500	vial	Cefoxitin 1 g. IM/IV		
73	35,500	cap	Celecoxib 200 mg		
74	29,000	tab	Cetirizine 10 mg		
75	50	bot	Chloramphenicol Eyedrops 0.5% x 5 ml		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

Item No.	Qty.	Dosage Form	Agency Specification	Brand Name Offered	Bidder's Statement of Compliance
76	6,000	amp	Chlorphenamine Maleate 10mg/ml ,1 ml injection		
77	34,000	tab	Chlorphenamine Maleate 4 mg		
78	16,200	tab	Chlorpromazine HCl 100 mg		
79	16,200	tab	Chlorpromazine HCl 200 mg		
80	37,000	cap	Cilostazol 100 mg SR		
81	4,500	tab	Cimetidine 200 mg		
82	25,000	tab	Cinnarizine 25 mg		
83	20,020	vial	Ciprofloxacin 200 mg/100 ml I.V.		
84	23,000	tab	Ciprofloxacin 500 mg		
85	3,000	amp	Citicoline 1g/4ml Injection		
86	28,600	tab	Citicoline 500 mg		
87	3,200	bot	Citicoline Adult Oral Drops 100 mg/ml		
88	14,500	tab	Clarithromycin 500 mg		
89	34,000	cap	Clindamycin 300 mg		
90	6,700	tube	Clobetasol Propionate 0.05% Cream, 5 g		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

Item No.	Qty.	Dosage Form	Agency Specification	Brand Name Offered	Bidder's Statement of Compliance
91	6,000	tube	Clobetasol Propionate 0.05% Ointment 5 g		
92	5,900	tab	Clonidine HCl 75 mcg		
93	113,000	tab	Clopidrogel 75 mg		
94	5,000	tab	Clopidrogel Bisulfate 75mg, Aspirin 100mg		
95	3,300	tube	Clotrimazole 10 mg + Beclomethasone 250 mcg, 5 g		
96	200	tab	Clotrimazole 100 mg (vaginal tab)		
97	4,000	tube	Clotrimazole Cream 1.0%, 5 g		
98	32,000	tab	Cloxacillin 500 mg		
99	30,500	tab	Clozapine 100 mg		
100	5,000	vial	Co-Amoxiclav 1.2 g		
101	45,000	tab	Co-Amoxiclav 625 mg		
102	4,900	tab	Colchicine 500 mcg		
103	1,250	can	Complete and Balanced Diabetes Nutrition Supplement Formula Powder with Sucromalt and Fibersol, 900 g		
104	2,600	can	Complete and Balanced Nutrition Formula for Adult with HMB, 850 g		
105	23,300	tab	Cotrimoxazole 800/160mg		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date





Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
106	15,450	tab	Dapagliflozin 10 mg		
107	16,000	tab	Dapagliflozin 10 mg / Metformin 1000 mg		
108	15,000	tab	Dapagliflozin 10 mg / Metformin 500 mg		
109	15,000	tab	Dapagliflozin 5 mg / Metformin 500 mg		
110	40	vial	Depotrust 50 mg/ml x 3 ml		
111	6,000	tab	Desloratidine 5 mg		
112	280	bot	Dexamethasone 1mg Neomycin SO4 3,500 IU mg Polymyxin B SO4 6,000u		
113	5,000	tab	Dexamethasone 500 mg		
114	1,500	bot	Dextrose + Vitamins for I.V. 500 ml		
115	1,220	bot	Dextrose 5% Lactated Ringer Solution 1L		
116	1,600	bot	Dextrose 5% Normal Saline Solution 1L		
117	1,100	bot	Dextrose 5% Water 1L		
118	300	vial	Dextrose 50%, 50 ml		
119	1,120	bot	Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate		
120	5,200	bot	Di-Alpha Tocopheryl Acetate (Vitamin E) + Selenium 400/IU 50mcg Softgel Capsule + Mineral (30cap / bot)		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

Item No.	Qty.	Dosage Form	Agency Specification	Brand Name Offered	Bidder's Statement of Compliance
121	210	vial	Diazepam 10 mg / 2 ml		
122	640	tab	Diazepam 5 mg		
123	1,090	amp	Diclofenac Sodium 25 mg/ml, 3 ml		
124	23,000	tab	Diclofenac Sodium 50 mg		
125	8,000	tab	Dicycloverine HCl 10 mg		
126	12,500	tab	Digoxin 0.25 mg		
127	500	amp	Digoxin 250 mcg/ml		
128	50,300	tab	Diltiazem 60 mg		
129	10,300	tab	Diosmin 450 mg + Hesperidin 50 mg		
130	31,000	cap	Diphenhydramine HCl 50 mg		
131	1,620	amp	Diphenhydramine HCl 50 mg/ml		
132	10,000	tab	Divalproex Na 250 mg IR (Immediate Release)		
133	3,300	tab	Divalproex Sodium 500 mg		
134	11,700	tab	Domperidone 10 mg		
135	6,000	tab	Donepezil 5mg		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
136	10,000	amp	Dopamine 40 mg/ml, 5 ml		
137	25,600	tab	Doxofylline 400 mg		
138	10,800	cap	Doxycycline 100 mg		
139	20	packs	Drospirenone estradiol		
140	400	tab	Dutasteride 500 mcg + Tamsulosin HCl 400 mcg		
141	10,500	tab	Enalapril Maleate 10 mg		
142	1,000	can	Energy Dense Nutritional Powder Formula w/ Increased Protein Content w/ Omega 3 EPA & Antioxidant 380g		
143	16,400	tab	Eperisone HCl 50 mg		
144	10,100	amp	Epinephrine SO4 1mg/ml, 1 ml		
145	150	prefilled syringe	Epoetin Alpha, 4000 iu/ml		
146	250	pcs	Epoetin Beta 5,000 IU/0.3 ml		
147	2,300	cap	Erythromycin 500 mg		
148	10,000	tab	Escitalopram Oxalate 10 mg		
149	27,000	tab	Esomeprazole 40 mg		
150	37,000	cap	Essential Phospholipids softgel 300 mg		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
151	3,400	tab	Eterocoxib 60 mg		
152	1,800	tab	Ethambutol 300 mg		
153	5,000	tab	Ethambutol 400 mg		
154	3,250	tab	Etoricoxib 120 mg		
155	300	cap	Evening Primrose Oil Capsule		
156	9,000	softgel	Eye Vitamins, Alpha Lipoic Acid 200 mg, Vit C 75 mg, Lutein powder 20 mg, Vit E 12 mg, Copper		
157	2,500	tab	Febuxostat 40 mg		
158	25,000	tab	Febuxostat 80 mg		
159	31,000	cap	Fenofibrate 145 mg		
160	526,000	tab	Ferrous Sulfate 300 mg + Folic Acid 250mg		
161	650	bot	Floucinolone cream 0.03%		
162	1,060	bot	Flucinolone 0.25%, Neomycin SO4 3.5 mg, Polymycin B SO4 10,000 Units Ear Drops		
163	3,400	tab	Fluconazole 150 mg		
164	15,200	cap	Flunarizine HCl 5 mg		
165	1,534	bot	Fluocinolone acetonide 250 mcg, neomycin sulfate 3.5 mg, polymyxin B sulfate 10,000 unit Otic, 5 ml		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
166	400	tab	Fluoxetine HCl 20 mg		
167	320	bot	Fluticasone Propionate Nasal Spray 50 mcg		
168	4,500	can	Formula powder with Glutamine, Argine & Fish Oil 400 g/can (vanilla/melon flavor)		
169	3,200	amp	Furosemide 10mg/ml, 2 ml		
170	21,000	tab	Furosemide 40 mg		
171	2,400	pcs	Fusidate Sodium 10cm x 10cm Intertulle		
172	5,000	tube	Fusidate Sodium 2% Ointment 5 g		
173	6,000	tube	Fusidic Acid 2% + Betamethasone Dipropionate oint., 5 g		
174	6,150	tube	Fusidic Acid 2% Cream 5 g		
175	1,030	tube	Fusidic Acid 2% w/ Betamethasone w/ 0.064% Dip. Cream, 5 g		
176	2,500	tab	Gabapentin 100 mg		
177	2,000	bot	Gentamicin Sulfate 0.3% Ophthalmic/Otic drops, 5 ml		
178	80,000	softgel	Gingko Biloba + Nattokinase Extract + Policosanol and fish Oil		
179	7,000	tab	Glibenclamide 5 mg		
180	5,000	tab	Gliclazide 30 mg		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
181	22,000	tab	Glucophage 60 mg MR		
182	17,000	tab	Glimiperide 2 mg		
183	17,000	tab	Glipizide 5 mg		
184	50,000	cap	Glucosamine HCl, Boswella Extract, Chondroitin SO <sub>4</sub> , Bioflavanoids & Vitamin C 620mg		
185	16,000	tab	Glucosamine Sulfate 495mg + Chondroitin Sulfate 400mg		
186	25,300	tab	Glucosamine Sulfate 500mg (Calcium Citrate, chondroitin, colecalciferol)		
187	25,000	scht	Glucosamine Sulfate, Sodium Chloride 1.884g		
188	10,000	tab	Guafenesin 500mg		
189	13,600	tab	Guafenesin 50mg / Salbutamol 1mg		
190	3,000	amp	Hydralazine HCl 20mg/ml		
191	1,000	tube	Hydrocortisone 1% Cream 5g		
192	5,000	vial	Hydrocortisone Sodium Succinate 100mg		
193	11,600	vial	Hydrocortisone Sodium Succinate 250mg		
194	10,310	tab	Hydroxyzine diHCl 10mg		
195	33,000	tab	Hyoscine N Butylbromide 10mg		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
196	2,850	amp	Hyoscine N Butylbromide 20 mg/ml x 1ml		
197	5,450	bot	Hypromellose 0.3% x 10ml		
198	11,000	tab	Ibuprofen 400mg		
199	1,600	tab	Inosine Dipepranol Immunosin 500mg		
200	3,500	cart	Insulin 70/30 100 IU/ml		
201	6,510	vial	Insulin Biphasic Isophane Human (70/30) 100 IU/ml, 10ml		
202	650	vial	Insulin Glargine 100 U/ml, 10 ml		
203	3,010	vial	Insulin Glargine 100 U/ml, 3 ml		
204	500	pen	Insulin Glargine U 300		
205	600	vial	Insulin Glulisine 100 U/ml, 10 ml		
206	500	vial	Insulin N Isophane Human 100 IU/ml, 10 ml		
207	2,550	pcs	Ipatropium B 20 mcg + Salbutamol 120 mcg inhaler		
208	28,800	neb	Ipatropium B 500 mcg + Salbutamol 120 mcg, 2.5 ml		
209	300	amp	Iron Sucrose 20 mg/ml		
210	2,000	amp	Isosorbide Dinitrate 1mg/1ml, 10 ml		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
211	20,500	tab	Isosorbide Dinitrate 5 mg sublingual/oral		
212	56,500	tab	Isosorbide Mononitrate 60 mg MR		
213	6,000	tab	Itopride HCl 50mg		
214	200	cap	Itraconazole 100 mg		
215	32,800	tab	Ketoanalogues + Essential Amino Acids 630mg		
216	7,000	tube	Ketoconazole Cream 2%, 5 g		
217	300	amp	Ketorolac 30 mg/ml		
218	5,000	bot	Lactated Ringer Solution 1L		
219	500	bot	Lactulose 3.3g/5ml, 120 ml syrup		
220	12,500	tab	Lagundi 600 mg		
221	5,400	tab	Lansoprazole 30 mg		
222	10,000	tab	Levocetirizine 5 mg		
223	5,000	tab	Levodopa 250 mg + Carbidopa 25 mg		
224	8,000	tab	Levofloxacin 500 mg		
225	30	tab	Levothyroxine Na 100 mg		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date





Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
226	30,000	carp	Lidocaine 2% + Epinephrine Injection		
227	2,530	vial	Lidocaine HCl 2%, 50 ml		
228	100	tub	Lidocaine HCl Topical Anesthesia		
229	26,600	tab	Linagliptin 2.5 mg + Metformin 500 mg		
230	30,000	tab	Linagliptin 5 mg		
231	107,000	cap	Loperamide 2 mg		
232	21,500	tab	Loratadine 10 mg		
233	126,000	tab	Losartan 50 mg		
234	80,500	tab	Losartan K 50mg + HCTZ 12.5mg		
235	110,000	tab	Losartan Potassium 50mg + Amlodipine Besylate 5 mg		
236	1,000	bot	Mannitol 20%, 250 ml		
237	1,500	tab	Mebendazole 100 mg		
238	600	choco tab	Mebendazole 500 mg		
239	900	tab	Meclizine HCl 25mg		
240	5,000	tab	Mecobalamin 500 mcg		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
241	85,000	cap	Mefenamic Acid 500 mg		
242	5,000	tab	Meloxicam 15 mg		
243	5,000	tab	Memantine 10 mg		
244	240,000	tab	Metformin 500 mg		
245	4,000	tab	Methimazole 20 mg		
246	6,000	tab	Methimazole 5 mg		
247	10,000	tab	Methisoprinol 500 mg		
248	250	vial	Methylprednisolone 40 mg		
249	500	tab	Methylprednisolone 5 mg		
250	5,250	amp	Metoclopramide 5mg/ml, 2 ml		
251	11,300	tab	Metoclopramide HCl 10 mg		
252	10,500	tab	Metoprolol Tartrate 100 mg		
253	112,500	tab	Metoprolol Tartrate 50 mg		
254	800	pcs	Metronidazole + Miconazole (vaginal suppository)		
255	17,500	tab	Metronidazole 500 mg		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
256	1,000	pcs	Metronidazole 500 mg/100 ml Infusion		
257	100	tube	Miconazole Nitrate + Hydrocortisone Cream 15 g		
258	2,700	tube	Miconazole Nitrate 2 cream, 5 g		
259	500	scht	Modular Amino Acid for healing and Immune Enhancing, Powder scht, 80 Kcal, Glutamine 10.0 G, CHO 9.6 G. Lipid 13.4 G with Fibre 1.2 g. Vitamin C 250mg, Vit E 83mg a-TE, Zn 3.4mg, Selenium 50 u.g. 22.4 g.		
260	3,000	tube	Mometasone Furoate 0.1% Ointment 5 g		
261	20,700	tab	Montelukast 10 mg + Levocetirizine 5 mg		
262	25,800	tab	Montelukast Na 10 mg		
263	350	spray	Muconase Nasal 60 ml		
264	80,000	film coated	Multivitamins & Minerals Tablet with Natural Extract Amino Acid 820mg		
265	60,000	cap	Multivitamins / Minerals with Lecithin 50mg + Citrus Bioflavanoids 25mg L-lysine HCl 25mg		
266	1,190,000	tab	Multivitamins + Minerals + Iron		
267	8,400	tube	Mupirocin 2% Ointment 5 g		
268	26,300	scht	N-Acetylcysteine 600 mg		
269	25,000	tab	N-Acetylcysteine 600 mg		
270	150	bot	NaCl 0.65% Nasal Spray		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

Item No.	Qty.	Dosage Form	Agency Specification	Brand Name Offered	Bidder's Statement of Compliance
271	240	amp	Nalbuphine 10 mg/ml		
272	150	bot	Naphazoline HCl 0.12 mg/ml eye drops		
273	10,000	tab	Naproxen 500 mg		
274	4,500	tube	Neem, Glycyrrhiza Glabra Extract, Polyethylene Glycol, Ficus Infectoria Extract, Pongamia Pinnata Extract, Cassia Tora Extract, Zinc Oxide Celastrus Panniculatus Extract Cream 25g.		
275	3,010	amp	Nicardepine 1mg/ml, 2 ml		
276	8,000	cap	Nicotinamide + Phosphatidyl + B Complex Forte		
277	6,400	softgel	Nifedipine 10 mg		
278	6,300	softgel	Nifedipine 5 mg		
279	20,400	tab	Norfloxacin 400 mg		
280	5,010	bot	Normal Saline Solution 1L		
281	80	bot	Normal Saline Solution 1L (Irrigating Solution)		
282	35,500	scht	Nutritional Drink with Glutamine, Oligosaccharide, Dietary Fiber - Refreshing Lemon Flavor		
283	1,450	tube	Nystatin Oral Gel		
284	11,000	tab	Ofloxacin 200 mg		
285	1,650	bot	Ofloxacin 3mg/ml Ophthalmic/Otic Drops,5ml		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
286	10,000	tab	Ofloxacin 400 mg		
287	15,000	tab	Olanzapine 10 mg		
288	5,400	tab	Olanzapine 5 mg oral dispersable		
289	6,000	tab	Olmesartan + Amlodipine 5 mg		
290	20,500	tab	Olmesartan 20 mg + Amlodipine 5 mg + HCTZ 12.5 mg		
291	10,000	tab	Olmesartan Medoxomil 20 mg		
292	40,500	tab	Omeprazole 20 mg		
293	5,100	vial	Omeprazole 40 mg powder		
294	23,500	scht	Oral Rehydration Salt, Powder for Oral Solution 5.125g		
295	100	nasal spray	Oxymetazoline HCl 0.05%		
296	19,000	tab	Pantoprazole 40mg		
297	130	vial	Pantoprazole 40mg		
298	5,300	amp	Paracetamol 150 mg Injection		
299	10,000	tab	Paracetamol 325 mg + Ibuprofen 200 mg		
300	23,000	tab	Paracetamol 325 mg + Tramadol 37.5 mg		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
301	55,000	tab	Paracetamol 500 mg		
302	43,000	tab	Paracetamol 650 mg + Orphenadine Citrate 50 mg		
303	4,600	bot	Permethrin Lotion 5%, 60 ml		
304	1,800	jar	Petroleum Jelly 200 g		
305	2,000	tab	Phenobarbital 60mg		
306	2,000	tab	Phenobarbital 90mg		
307	90,000	tab	Phenylpropanolamine 325mg + Paracetamol 25mg + Chlorphenamine Maleate 2mg		
308	1,400	cap	Phenytoin Sodium 100 mg		
309	100	amp	Phenytoin Sodium 50mg/ml 2ml		
310	15,000	cap	Phosphatidyl Choline 300mg, Nicotinamide 30mg, DL-A Tocopheryl Acetate 10mg + Vitamin B2 6mg, B6 10mg, B12 10mcg		
311	250	cap	Pinaverium Br 50mg		
312	10,300	cap	Pinene 17mg + Camphene 5mg + Cineol 2mg + Menthone 6mg + Methol 32mg + Borneol 5 mg + Olive Oil 33mg		
313	10,500	cap	Pinene 31mg + Camphene 15mg + Cineol 3mg + Frenchone 4mg + Borneol 10mg, Anethol 4mg, Olive Oil 33mg		
314	20,000	tab	Pioglitazone 15 mg		
315	20,000	tab	Pioglitazone 15 mg + Glimeperide 2mg		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
316	25,000	tab	Pioglitazone 15 mg + Metformin 500 mg		
317	20,000	tab	Pioglitazone 30 mg		
318	20,000	tab	Pioglitazone 30 mg + Glimeperide 2mg		
319	20,000	tab	Pioglitazone 30 mg + Metformin 500 mg		
320	1,500	vial	Piperacillin Sodium 4g + Tazobactam Sodium 500mg		
321	2,000	tab	Piracetam 400 mg		
322	500	bot	Pirenoxine Na eye solution 0.85mg, 15ml solvent		
323	200	cap	Piroxicam 20mg		
324	25,000	cap	Pizotifen, Vit B, Nicotinamide		
325	280	tube	Policresulen 50mg, Cinchocaine HCl 10mg 20g ointment		
326	1,000	vial	Potassium Chloride 2 meq/ml, 20 ml injection		
327	22,000	tab	Potassium Chloride 600 mg		
328	6,800	tab	Potassium Citrate 10 mEq		
329	300	bot	Povidone Iodine gargle, 120 ml		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

Item No.	Qty.	Dosage Form	Agency Specification	Brand Name Offered	Bidder's Statement of Compliance
330	500	tab	Pramipexole diHCl 1mg		
331	22,000	tab	Prasugrel 10mg		
332	350	bot	Prednisolone Acetate Eye Drops 1%, 5 ml		
333	200	neb	Prednisone		
334	25,800	tab	Prednisone 10 mg		
335	50,800	tab	Prednisone 5 mg		
336	300	tab	Pregabalin 150 mg		
337	10,300	tab	Pregabalin 75 mg		
338	1,200	pcs	Procaterol HCl 50 mcg Swinghaler 5 ml		
339	45,000	tab	Procaterol HCl 50 mcg		
340	11,500	tab	Propranolol 10mg		
341	2,000	tab	Propranolol 40mg		
342	3,500	tab	Propylthiouracil 50 mg		
343	1,500	scht	Protein 5 g, fat 2.3 g (saturated fatty acid 0.9 g), carbohydrate 15.7 g (dietary fiber 1.2 g), Na 177 mg (salt equiv 0.44 g), vit B1 0.32 mg, vit B2 0.35 mg, vit B6 0.45 mg, vit B12 0.45 mcg, vit C 80 mg, vit A 82 mcg-RE, vit E 3.5 mg α-TE, vit D 2 mcg, Cl 72 mg, K 156 mg, Ca 94 mg, P 75 mg, Fe 1.1 mg, Zn 1.8 mg. Energy: 100 kCal (Jelly Corn Flavor) 100g		
344	3,600	scht	Psyllium		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date





Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
345	500	amp	Purified Vero Cell 0.5ml		
346	1,500	prefilled syringe	Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated)		
347	400	tab	Quetiapine Fumarate 200mg		
348	500	tab	Racicadotril 100mg x 20's		
349	500	amp	Ranitidine 50 mg/ml		
350	300	tab	Ranitidine HCl 150 mg		
351	4,000	tab	Ranitidine HCl 300 mg		
352	300	amp	Ranitidine Injection		
353	10,000	tab	Rebamipide 100 mg		
354	6,500	coated tab	Rifaximin 200 mg		
355	16,300	tab	Risperidone 2 mg		
356	20,000	tab	Rosuvastatin 10 mg		
357	20,000	polyamp	Salbutamol + Ipratropium 2.5mg/500mg, 2.5ml		
358	5,400	pcs	Salbutamol 100 mcg inhaler		
359	503,500	tab	Salbutamol 2 mg		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
360	64,500	neb	Salbutamol 2.5 mg / 2.5 ml		
361	10,100	pcs	Salmeterol + Fluticasone 25/125 mcg Inhaler		
362	5,210	pcs	Salmeterol + Fluticasone 25/250 mcg Inhaler		
363	1,000	tab	Selegiline HCl 5mg		
364	15,000	tab	Serrapeptase 10 mg		
365	1,052	tube	Silver Sulfadiazine 1% Cream 20 g		
366	2,000	tab	Silymarine + Thiamine + Pyridoxine		
367	220,000	softgel	Silymarine 125mg + Vit B (1.0000mg) + Vit B2 (1.0000mg) + Vit B6 (0.5000mg) + Vit B12 (0.0005mg)		
368	6,000	bot	Silymarine 150mg + Thiamine Mononitrate 4mg + Pyridoxine HCl 4mg + Cyanocobalamin 1.2mcg + Nicotinamide 12mg + Calcium Pantothenate 8mg + Lecithin 8mg (30cap / bot)		
369	800	cap	Simeticone 300 mg		
370	2,600	tab	Simvastatin 20 mg		
371	12,000	tab	Simvastatin 40 + Fenofibrate 145mg		
372	54,000	tab	Simvastatin 40 mg		
373	10,000	tab	Sitagliptin 100mg		
374	20,000	tab	Sitagliptin 50 mg + Metformin 1 g		

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
375	25,000	tab	Sitagliptin 50 mg + Metformin 500 mg		
376	1,045,000	tab	Sodium Ascorbate 568 mg		
377	1,000	vial	Sodium Bicarbonate 1 meq, 50 ml		
378	45,000	scht	Sodium Bicarbonate 1760mg Sodium Citrate 630mg Citric Acid 720mg Tartaric Acid		
379	5,800	tab	Sodium Bicarbonate 650 mg		
380	2,010	bot	Sodium Chloride 0.9% Solution for Irrigation 1L		
381	10,000	tab	Sodium Chloride 1 g		
382	5,800	tab	Spironolactone 25 mg		
383	500	tab	Spironolactone 25 mg / Butizide 2.5 mg		
384	6,000	tab	Spironolactone 50 mg		
385	600	tab	Standardized Senna Concentrate 374mg		
386	5,000	vial	Sterile Water for Injection, 100 cc		
387	5,005	vial	Sterile Water for Injection, 50 cc		
388	2,500	tab	Sucralfate 1 g		
389	35,000	pcs	Sulfur Soap, 135 g		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

Item No.	Qty.	Dosage Form	Agency Specification	Brand Name Offered	Bidder's Statement of Compliance
390	27,000	soft gel	Sulodexide 250 mg		
391	500	amp	Sulodexide 600mg, 2 ml		
392	500	vial	Sultamicillin 1.5 g (Ampicillin + Sulbactam 1g/500mg)		
393	5,000	tab	Sultamicillin 750 mg		
394	10,000	tab	Tamsulosin 400 mg		
395	11,000	tab	Terazosin HCl 2 mg		
396	35,000	tab	Terazosin HCl 5 mg		
397	400	tube	Terbinafine Cream 10 g		
398	2,000	amp	Terbutaline 2.5 mg		
399	20,000	tab	Terbutaline 2.5 mg		
400	5,550	amp	Tetanus Toxoid 0.5 ml		
401	500	cap	Tetracycline 500 mg		
402	1,600	amp	Thiamine HCl Vit B1 (100mg) Riboflavin - 5 Phospate Na Vit B25mg, Nicotinamide Vit B3 (100mg) Dexpanthenol 50mg, Pyridoxine HCl Vit B6 (100mg), Cynocobalamin Vit b12 (1mg) 3ml		
403	150	pack	Tibolone pack (28's)		
404	500	bot	Timolol Maleate Ophthalmic Drops 0.5% x 5 ml		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

<b>Item No.</b>	<b>Qty.</b>	<b>Dosage Form</b>	<b>Agency Specification</b>	<b>Brand Name Offered</b>	<b>Bidder's Statement of Compliance</b>
405	200	tube	Tioconazole ointment 5 g		
406	5,000	pcs	Tiotropium 18 mcg inhaler		
407	7,880	bot	Tobramycin 0.3% + Dexamethasone 0.5%, 5 ml Ophthalmic Drops		
408	4,090	bot	Tobramycin Ophthalmic Drops 3mg/ml, 5 ml Ophthalmic Drops		
409	100	tube	Tolnaftate 1% cream, 5 g		
410	4,000	tab	Tolvaptan 15 mg		
411	12,200	cap	Tramadol 50 mg		
412	2,500	amp	Tramadol 50 mg/ml		
413	2,300	amp	Tranexamic Acid 50 mg/5 ml		
414	105,400	cap	Tranexamic Acid 500 mg		
415	21,000	tab	Trimetazidine 20 mg		
416	2,000	tab	Trimetazidine 35 mg		
417	13,100	tab	Ursodeoxycholic Acid 300 mg		
418	250	vial	Valproic Acid Solution for Injection 500mg / 5ml		
419	20,000	tab	Valsartan 80 mg + Amlodipine 5 mg		

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



## *Section VII. Technical Specifications*

### *Supply and Delivery of Various Medicines for NBP and CIW 2019*

Item No.	Qty.	Dosage Form	Agency Specification	Brand Name Offered	Bidder's Statement of Compliance
420	20,000	tab	Valsartan 80 mg + HCTZ 12.5 mg		
421	31,000	tab	Vildagliptin 50 mg tab		
422	25,000	tab	Vildgliptin 50 mg + Metformin 1 g		
423	26,000	tab	Vildgliptin 50 mg + Metformin 500 mg		
424	25,000	tab	Vildgliptin 50 mg + Metformin 850 mg		
425	2,000	amp	Vitamin B Complex 3 ml IV.		
426	95,000	tab	Vitamin B1 250mg + B6 250mg + B12 1000mcg		
427	700	amp	Vitamin C		
428	1,000	tab	Vitamin D		
429	1,000	tab	Vitamin E		
430	300	tab	Zolpidem Tartrate 10 mg		
<ul style="list-style-type: none"> <li>• <b>SHELF LIFE:</b>            Medicines to be delivered must be of fresh commercial stock as indicated in the Certificate of Product Registration upon receipt at the designated delivery place. The acceptable remaining shelf-life is 18 months from date of delivery.</li> </ul>					

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date

## ***Section VIII. Bidding Forms***

COMPANY LETTERHEAD

**Statement of ongoing government & private contracts**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Statement of all its ongoing government and or private contracts including contracts awarded but not yet started, if any whether similar or not similar in nature.

Name of Contract	Date of contract	Contract Duration	Owner's Name and Address	Kind of Goods	Amount of Contract	Value of Outstanding Contract
Total Value of Outstanding Contract:						

**CERTIFIED CORRECT:**

\_\_\_\_\_  
Name and Signature of Authorized Representative

\_\_\_\_\_  
Position

\_\_\_\_\_  
Date



COMPANY LETTERHEAD

**Statement of Single Largest Completed Contract**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Statement of Single (1) Largest Completed Contract of Similar in nature within the last two (2) years from the date of submission and receipt of bids amounting to at least twenty-five percent (25%) of the Approved Budget of the Contract (ABC)

Name of Contract	Date of contract	Contract Duration	Owner's Name and Address	Kind of Goods	Amount of Contract	Amount of completed contracts, adjusted by the Bidder to current prices using PSA's consumer price index, if necessary	Date of Delivery	end user's acceptance or official receipt(s) or sales invoice issued for the contract, (Attached Copy)

**CERTIFIED CORRECT:**

\_\_\_\_\_  
Name and Signature of Authorized Representative

\_\_\_\_\_  
Position

\_\_\_\_\_  
Date

COMPANY LETTERHEAD

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

**Certificate of Net Financial Contracting Capacity**

(Please show figures at how you arrived at the NFCC)

This is to certify that our Net Financial Contracting Capacity (NFCC) is \_\_\_\_\_ (P\_\_\_\_\_ ) which is at least equal to the total ceiling price we are bidding. The amount is computed as follows: (Please show computation of NFCC)

$$\text{NFCC} = (\text{CA}-\text{CL}) (15) - \text{C}$$

Where:

CA = Current Assets

CL = Current Liabilities

C = value of all outstanding or uncompleted portions of the  
Projects under going contracts, including awarded contracts  
Yet to be started coinciding with the contract for this Project

**NOTE:**

**The values of the bidder's current assets and current liabilities shall be based on the Audited Financial Statement submitted to the BIR.**

Issued this \_\_\_\_\_ day of \_\_\_\_\_, 2019

\_\_\_\_\_  
Name & Signature of Authorized Representative

\_\_\_\_\_  
Position

\_\_\_\_\_  
Date

COMPANY LETTERHEAD

*Supply and Delivery of Various Medicines for NBP and CIW 2019*

**Joint Venture Agreement**

This **PROTOCOL/UNDERTAKING OF AGREEMENT TO ENTER INTO JOINT**

**VENTURE**, executed by:

.....a sole proprietorship/partnership/corporation duly organized and existing under and by virtue of the laws of the Philippines, with offices located at .....,  
....., represented herein by its ....., ....., hereinafter referred to as  
“.....”;

-and-

..... a sole proprietorship/partnership/corporation duly organized and existing under and by virtue of the laws of the Philippines, with offices located at .....,  
....., represented herein by its ....., ....., hereinafter referred to as  
“.....”;

-and-

..... a sole proprietorship/partnership/corporation duly organized and existing under and by virtue of the laws of the Philippines, with offices located at .....,  
....., represented herein by its ....., ....., hereinafter referred to as  
“.....”; (hereinafter referred to collectively as “Parties”)

For submission to the **Bids and Awards Committee** of the **Bureau of Corrections, NBP**, pursuant to **Section 23.1 (b)** of the Revised Implementing Rules and Regulations (IRR) of Republic Act (RA) No. 9184.

WITNESSETH That:

WHEREAS, the Parties desire to participate as a joint venture in the public bidding that will be conducted by the **Bureau of Corrections, NBP** pursuant to Republic Act No. 9184 and its implementing rules and regulations, with the following particulars:

Bid Reference No.	
Name/Title of Procurement Project	
Approved Budget for the Contract	

NOW, THEREFORE, in consideration of the foregoing, the Parties undertake to enter into a **JOINT VENTURE** and sign a **Joint Venture Agreement** relative to their joint cooperation for this bid project, in the event that their bid is successful, furnishing the BuCor BAC a duly signed and

notarized copy thereof within **ten (10) calendar days** from receipt of Notice from the BAC that our bid has the lowest calculated responsive bid or highest rated responsive bid (as the case may be).

That furthermore, the parties agree to be jointly and severally under the said Joint Venture Agreement;

THAT finally, failure on our part of enter into the Joint Venture and/or sign the Joint Venture Agreement for any reason after the Notice of Award has been issued by shall be a ground for non-issuance of the

Notice to Proceed, forfeiture of our bid security and such other administrative and/or civil liabilities as may be imposed by BuCor under the provisions of R.A. 9184 and its Revised IRR, without any liability on the part of BuCor.

This undertaking shall form an integral part of our Eligibility documents for the above-cited project.

IN WITNESS WHEREOF, the parties have signed this Protocol/Undertaking on the date first above-written.

Bidder's Representative/Authorized Signatory

SUBSCRIBED AND SWORN TO BEFORE ME this \_\_\_\_\_ day of \_\_\_\_\_ at \_\_\_\_\_, Philippines. Affiant exhibited to me his/her competent Evidence of Identity (as defined by 2004 Rules on Notarial Practice issued \_\_\_\_\_ at \_\_\_\_\_, Philippines.

Doc. No. \_\_\_\_\_  
Page No. \_\_\_\_\_  
Book No. \_\_\_\_\_  
Series of \_\_\_\_\_

COMPANY LETTERHEAD

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

REPUBLIC OF THE PHILIPPINES)  
CITY OF \_\_\_\_\_) S.S.

X-----X

**BID SECURING DECLARATION**  
**Invitation to Bid:** *[Insert Reference number]*

To: **Bureau of Corrections**

I/We, the undersigned, declare that:

1. I/We understand that, according to your conditions, bids must be supported by a Bid Security, which may be in the form of a Bid-Securing Declaration.
2. I/We accept that: (a) I/we will be automatically disqualified from bidding for any contract with any procuring entity for a period of two (2) years upon receipt of your Blacklisting order; and, (b) I/we will pay the applicable fine provided under Section 6 of the Guidelines on the Use of Bid Securing Declaration, within fifteen (15) days from receipt of the written demand by the procuring entity for the commission of acts resulting to the enforcement of the bid securing declaration under Sections 23.1(b), 34.2, 40.1 and 69.1, except 69.1(f), of the IRR of RA 9184; without prejudice to other legal action the government may undertake.
3. I/We understand that this Bid Securing Declaration shall cease to be valid on the following circumstances:
  - (a) Upon expiration of the bid validity period, or any extension thereof pursuant to your request;
  - (b) I am/we are declared ineligible or post-disqualified upon receipt of your notice to such effect, and (i) I/we failed to timely file a request for reconsideration or (ii) I/we filed a waiver to avail of said right;
  - (c) I am/we are declared the bidder with the Lowest Calculated Responsive Bid, and I/we have furnished the performance security and signed the Contract.

IN WITNESS WHEREOF, I/We have hereunto set my/our hand/s this \_\_\_\_ day of [month] [year] at [place of execution].

\_\_\_\_\_  
*[Insert NAME OF BIDDER'S AUTHORIZED REPRESENTATIVE]*

\_\_\_\_\_  
*[Insert Signatory's Legal Capacity]*  
Affiant

**SUBSCRIBED AND SWORN** to before me this \_\_\_\_ day of *[month]* *[year]* at *[place of execution]*, Philippines. Affiant/s is/are personally known to me and was/were identified by me through competent evidence of identity as defined in the 2004 Rules on Notarial Practice (A.M. No. 02-8-13-SC). Affiant/s exhibited to me his/her *[insert type of government identification card used]*, with his/her photograph and signature appearing thereon, with no. \_\_\_\_\_ issued on \_\_\_\_\_ at \_\_\_\_\_.

Witness my hand and seal this \_\_\_\_ day of *[month]* *[year]*.

**NAME OF NOTARY PUBLIC**

Serial No. of Commission \_\_\_\_\_

Notary Public for \_\_\_\_\_ until \_\_\_\_\_

Roll of Attorneys No. \_\_\_\_\_

PTR No. \_\_\_\_\_ *[date issued]*, *[place issued]*

IBP No. \_\_\_\_\_ *[date issued]*, *[place issued]*

Doc. No. \_\_\_\_\_

Page No. \_\_\_\_\_

Book No. \_\_\_\_\_

Series of \_\_\_\_\_

COMPANY LETTERHEAD  
***Supply and Delivery of Various Medicines for NBP and CIW 2019***

**Omnibus Sworn Statement**

---

REPUBLIC OF THE PHILIPPINES )  
CITY/MUNICIPALITY OF \_\_\_\_\_ ) S.S.

**AFFIDAVIT**

I, *[Name of Affiant]*, of legal age, *[Civil Status]*, *[Nationality]*, and residing at *[Address of Affiant]*, after having been duly sworn in accordance with law, do hereby depose and state that:

1. ***Select one, delete the other:***

*If a sole proprietorship:* I am the sole proprietor or authorized representative of *[Name of Bidder]* with office address at *[address of Bidder]*;

*If a partnership, corporation, cooperative, or joint venture:* I am the duly authorized and designated representative of *[Name of Bidder]* with office address at *[address of Bidder]*;

2. ***Select one, delete the other:***

*If a sole proprietorship:* As the owner and sole proprietor, or authorized representative of *[Name of Bidder]*, I have full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for **Supply and Delivery of Various Medicines for NBP and CIW 2019** of the **Bureau of Corrections**, as shown in the attached duly notarized *Special Power of Attorney*;

*If a partnership, corporation, cooperative, or joint venture:* I am granted full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for **Supply and Delivery of Various Medicines for NBP and CIW 2019** of the **Bureau of Corrections**, as shown in the attached *[state title of attached document showing proof of authorization (e.g., duly notarized Secretary's Certificate, Board/Partnership Resolution, or Special Power of Attorney, whichever is applicable)]*;

3. *[Name of Bidder]* is not "blacklisted" or barred from bidding by the Government of the Philippines or any of its agencies, offices, corporations, or Local Government Units, foreign government/foreign or international financing institution whose blacklisting rules have been recognized by the Government Procurement Policy Board;

4. Each of the documents submitted in satisfaction of the bidding requirements is an authentic copy of the original, complete, and all statements and information provided therein are true and correct;
5. *[Name of Bidder]* is authorizing the Head of the Procuring Entity or its duly authorized representative(s) to verify all the documents submitted;
6. **Select one, delete the rest:**

*If a sole proprietorship:* The owner or sole proprietor is not related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

*If a partnership or cooperative:* None of the officers and members of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

*If a corporation or joint venture:* None of the officers, directors, and controlling stockholders of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

7. *[Name of Bidder]* complies with existing labor laws and standards; and
8. *[Name of Bidder]* is aware of and has undertaken the following responsibilities as a Bidder:
  - a) Carefully examine all of the Bidding Documents;
  - b) Acknowledge all conditions, local or otherwise, affecting the implementation of the Contract;
  - c) Made an estimate of the facilities available and needed for the contract to be bid, if any; and
  - d) Inquire or secure Supplemental/Bid Bulletin(s) issued for the **Supply and Delivery of Various Medicines for NBP and CIW 2019**.
9. *[Name of Bidder]* did not give or pay directly or indirectly, any commission, amount, fee, or any form of consideration, pecuniary or otherwise, to any person or official, personnel or representative of the government in relation to any procurement project or activity.



IN WITNESS WHEREOF, I have hereunto set my hand this \_\_\_ day of \_\_\_, 20\_\_ at \_\_\_\_\_, Philippines.

\_\_\_\_\_  
Bidder's Representative/Authorized Signatory

**SUBSCRIBED AND SWORN** to before me this \_\_\_ day of [month] [year] at [place of execution], Philippines. Affiant/s is/are personally known to me and was/were identified by me through competent evidence of identity as defined in the 2004 Rules on Notarial Practice (A.M. No. 02-8-13-SC). Affiant/s exhibited to me his/her [insert type of government identification card used], with his/her photograph and signature appearing thereon, with no. \_\_\_\_\_ issued on \_\_\_\_\_ at \_\_\_\_\_.

Witness my hand and seal this \_\_\_ day of [month] [year].

**NAME OF NOTARY PUBLIC**

Serial No. of Commission \_\_\_\_\_

Notary Public for \_\_\_\_\_ until \_\_\_\_\_

Roll of Attorneys No. \_\_\_\_\_

PTR No. \_\_\_\_\_ [date issued], [place issued]

IBP No. \_\_\_\_\_ [date issued], [place issued]

Doc. No. \_\_\_\_\_

Page No. \_\_\_\_\_

Book No. \_\_\_\_\_

Series of \_\_\_\_\_

COMPANY LETTERHEAD

**Supply and Delivery of Various Medicines for NBP and CIW 2019  
Bid Form**

Date: \_\_\_\_\_  
Invitation to Bid N<sup>o</sup>: \_\_\_\_\_

To: **Bureau of Corrections**  
NBP Reservation Muntinlupa City

Gentlemen and/or Ladies:

Having examined the Bidding Documents including Bid Bulletin Numbers [*insert numbers*], the receipt of which is hereby duly acknowledged, we, the undersigned, offer to **Supply and Delivery of Various Medicines for NBP and CIW 2019** in conformity with the said Bidding Documents for the sum of \_\_\_\_\_ ₱ \_\_\_\_\_ or such other sums as may be ascertained in accordance with the Schedule of Prices attached herewith and made part of this Bid.

We undertake, if our Bid is accepted, to deliver the goods in accordance with the delivery schedule specified in the Schedule of Requirements.

If our Bid is accepted, we undertake to provide a performance security in the form, amounts, and within the times specified in the Bidding Documents.

We agree to abide by this Bid for the Bid Validity Period specified in **BDS** provision for **ITB** Clause 17.1 and it shall remain binding upon us and may be accepted at any time before the expiration of that period.

Commissions or gratuities, if any, paid or to be paid by us to agents relating to this Bid, and to contract execution if we are awarded the contract, are listed below:

Name and address of agent	Amount and Currency	Purpose of Commission or gratuity
_____	_____	_____
_____	_____	_____
_____	_____	_____

(if none, state "None")

Until a formal Contract is prepared and executed, this Bid, together with your written acceptance thereof and you're Notice of Award, shall be binding upon us.

We understand that you are not bound to accept the Lowest Calculated Bid or any Bid you may receive.

We certify/confirm that we comply with the eligibility requirements as per **ITB** Clause 5 of the Bidding Documents.

We likewise certify/confirm that the undersigned, [*for sole proprietorships, insert: as the owner and sole proprietor or authorized representative of Name of Bidder*], has the full

power and authority to participate, submit the bid, and to sign and execute the ensuing contract, on the latter's behalf for the **Supply and Delivery of Various Medicines for NBP and CIW 2019** of the **Bureau of Corrections** *[for partnerships, corporations, cooperatives, or joint ventures, insert: is granted full power and authority by the Name of Bidder, to participate, submit the bid, and to sign and execute the ensuing contract on the latter's behalf for **Supply and Delivery of Various Medicines for NBP and CIW 2019** of the **Bureau of Corrections**.*

We acknowledge that failure to sign each and every page of this Bid Form, including the attached Schedule of Prices, shall be a ground for the rejection of our bid.

Dated this \_\_\_\_\_ day of \_\_\_\_\_ 20\_\_\_\_\_.

\_\_\_\_\_  
*[signature]*

\_\_\_\_\_  
*[in the capacity of]*

Duly authorized to sign Bid for and on behalf of \_\_\_\_\_



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
1	1,300	8% w/v Amino Acid Soln w/ 3% w/v Branched Chain Amino Acids content 500ml			<b>1,391,390.00</b>
2	100	A1(OH) 200 mg+ +Mg(OH)2 100 mg, 120 ml			<b>5,280.00</b>
3	46,000	A1OH + MgOH mg, Simethicone 30 mg			<b>231,380.00</b>
4	1,400	Aciclovir + Zinc Oxide Ointment 50mg/100mg			<b>1,228,920.00</b>
5	1,500	Aciclovir 200 mg			<b>8,310.00</b>
6	6,000	Aciclovir 400 mg			<b>240,000.00</b>
7	1,500	Aciclovir 5%, 5 g			<b>447,000.00</b>
8	15,000	Ademetionine Butane Disulfonate 500mg			<b>1,230,000.00</b>
9	1,500	Ademetionine Butane Disulfonate 500mg IV/IM			<b>525,000.00</b>
10	6,000	Agmatine Sulfate			<b>202,500.00</b>
11	1,040	Alendronic Acid (as Alendronate Na Trihydrate) 70 mg			<b>206,960.00</b>
12	7,500	Allopurinol 300 mg			<b>45,375.00</b>
13	5,000	Alpha- lipoic Acid, Gamma-Linoleic Acid, Vit E & Selenium with Vit B Complex 920 mg			<b>412,500.00</b>
14	700	Alprazolam 250 mcg			<b>11,200.00</b>
15	17,400	Aluminum Magnesium Hydroxide 200/100			<b>1,052,700.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
16	31,400	Ambroxol HCl 30 mg			<b>19,468.00</b>
17	1,600	Amino Acid + M-Vit + Mineral (Oral) 50 g			<b>528,000.00</b>
18	2,000	Amino Acid + Sorbitol Solution for I.V. 500 ml			<b>1,800,000.00</b>
19	3,000	Amino Acid and Glucose Inj. With Electrolytes and Vitamins B1, 1 L			<b>4,200,000.00</b>
20	3,000	Amino Acid and Glucose Inj. With Electrolytes and Vitamins B1, 500 ml			<b>2,526,000.00</b>
21	16,000	AminoLock Collagen			<b>336,000.00</b>
22	227,000	Amlodipine Besilate 10 mg			<b>220,190.00</b>
23	227,000	Amlodipine Besilate 5 mg			<b>115,770.00</b>
24	30,000	Amoxicillin 500 mg			<b>41,400.00</b>
25	5,000	Aripiprazole 10mg Discmelt ODT 30's			<b>1,300,000.00</b>
26	5,000	Aripiprazole 15mg Discmelt ODT 30's			<b>1,300,000.00</b>
27	50	Aripiprazole 400mg (box of 1)			<b>388,550.00</b>
28	58,000	Aspirin 80 mg			<b>33,060.00</b>
29	105,000	Atorvastatin 10 mg + Ezetimibe 10 mg FC			<b>3,360,000.00</b>
30	10,000	Atorvastatin 40 mg			<b>93,500.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
31	100,000	Atorvastatin Calcium 20 mg			<b>600,000.00</b>
32	15,160	ATS 1,500 IU			<b>1,250,700.00</b>
33	1,950	Azelastine HCl 1mg/ml (0.1% w/v) Nasal Spray 14ml			<b>1,560,000.00</b>
34	11,300	Azithromycin Monohydrate 500 mg			<b>136,730.00</b>
35	6,000	Bacillus Clausii Oral Solution 5ml			<b>240,000.00</b>
36	1,500	Beclomethasone 100 mcg + Formoterol 6 mcg PMDI inhaler			<b>1,741,500.00</b>
37	21,100	Betahistine HCl 16 mg			<b>234,210.00</b>
38	100	Betamethasone Dipropionate 1ml			<b>45,300.00</b>
39	1,500	Betamethasone Dipropionate 640 mcg 5 g Ointment			<b>580,500.00</b>
40	1,000	Betamethasone Dipropionate 640mcg + Gentamicin 1mg 5 g Cream			<b>457,000.00</b>
41	3,000	Betamethasone Valerate 1mg/g, 1 g Cream			<b>525,000.00</b>
42	6,000	Biperiden 5mg			<b>120,000.00</b>
43	10,500	Biperiden HCl 2 mg			<b>51,765.00</b>
44	400	Biperiden Injection			<b>88,000.00</b>
45	1,500	Bisacodyl 10 mg (Adult)			<b>35,790.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
46	12,400	Bisacodyl 5 mg			<b>23,188.00</b>
47	6,000	Blumea Balsamifera 500 mg			<b>35,880.00</b>
48	60	Brimonidine tabs 1.5 mg/ml topical ocular hypertensive agent solution			<b>37,290.00</b>
49	28,000	Bromhexine HCl 8 mg			<b>154,000.00</b>
50	15,000	Buclizine HCl + FeSO4 + MV			<b>154,350.00</b>
51	2,200	Budesonide + Formeterol 160 mcg + 4.5 mcg, 120 doses dry powder inhaler			<b>1,588,400.00</b>
52	20,000	Budesonide 500 mcg/ml, 2ml respiratory solution			<b>890,000.00</b>
53	1,500	Budesonide Swinghaler 200 mcg/dose			<b>248,325.00</b>
54	25,400	Butamirate Citrate 50 mg			<b>293,370.00</b>
55	1,900	Calamine plus Zinc Oxide 40/30 mg/g, 5g			<b>133,000.00</b>
56	101,000	Calcium with Vitamin D			<b>333,300.00</b>
57	26,000	Calcium with Vitamins and Minerals			<b>201,500.00</b>
58	10,000	Candesartan Cilexetil 8 mg			<b>151,800.00</b>
59	160,600	Captopril 25 mg			<b>199,144.00</b>
60	160,000	Captopril 50 mg			<b>523,200.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
61	3,000	Carb Steady Renal Nutrition Formula for Dialysis Patient 237ml			<b>510,000.00</b>
62	5,500	Carb Steady Renal Nutrition Formula for Pre-Dialysis Patient w/ CKD 237ml			<b>1,045,000.00</b>
63	26,500	Carbamazepine 200 mg tab			<b>81,620.00</b>
64	313,000	Carbocisteine 500 mg			<b>338,040.00</b>
65	20,000	Carvedilol 25 mg			<b>77,000.00</b>
66	250	Castor Oil (Sweet Orange Flavor), 60 ml.			<b>27,500.00</b>
67	10,000	Cefaclor 500 mg			<b>347,000.00</b>
68	35,600	Cefalexin 500 mg			<b>234,960.00</b>
69	10,500	Ceftriaxone 1 g			<b>177,135.00</b>
70	35,500	Cefuroxime 500 mg			<b>421,385.00</b>
71	20,070	Cefuroxime 750 mg			<b>363,869.10</b>
72	1,500	Cefoxitin 1 g. IM/IV			<b>300,000.00</b>
73	35,500	Celecoxib 200 mg			<b>98,335.00</b>
74	29,000	Cetirizine 10 mg			<b>60,610.00</b>
75	50	Chloramphenicol Eyedrops 0.5% x 5 ml			<b>5,500.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date





Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
76	6,000	Chlorphenamine Maleate 10mg/ml ,1 ml injection			<b>61,260.00</b>
77	34,000	Chlorphenamine Maleate 4 mg			<b>11,560.00</b>
78	16,200	Chlorpromazine HCl 100 mg			<b>51,192.00</b>
79	16,200	Chlorpromazine HCl 200 mg			<b>76,140.00</b>
80	37,000	Cilostazol 100 mg SR			<b>3,223,440.00</b>
81	4,500	Cimetidine 200 mg			<b>4,950.00</b>
82	25,000	Cinnarizine 25 mg			<b>27,500.00</b>
83	20,020	Ciprofloxacin 200 mg/100 ml I.V.			<b>11,011,000.00</b>
84	23,000	Ciprofloxacin 500 mg			<b>107,640.00</b>
85	3,000	Citicoline 1g/4ml Injection			<b>858,000.00</b>
86	28,600	Citicoline 500 mg			<b>913,484.00</b>
87	3,200	Citicoline Adult Oral Drops 100 mg/ml			<b>563,200.00</b>
88	14,500	Clarithromycin 500 mg			<b>159,500.00</b>
89	34,000	Clindamycin 300 mg			<b>205,700.00</b>
90	6,700	Clobetasol Propionate 0.05% Cream, 5 g			<b>469,000.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
91	6,000	Clobetasol Propionate 0.05% Ointment 5 g			<b>420,000.00</b>
92	5,900	Clonidine HCl 75 mcg			<b>32,450.00</b>
93	113,000	Clopidrogel 75 mg			<b>171,760.00</b>
94	5,000	Clopidrogel Bisulfate 75mg, Aspirin 100mg			<b>295,300.00</b>
95	3,300	Clotrimazole 10 mg + Beclomethasone 250 mcg, 5 g			<b>544,500.00</b>
96	200	Clotrimazole 100 mg (vaginal tab)			<b>20,400.00</b>
97	4,000	Clotrimazole Cream 1.0%, 5 g			<b>266,000.00</b>
98	32,000	Cloxacillin 500 mg			<b>77,440.00</b>
99	30,500	Clozapine 100 mg			<b>244,000.00</b>
100	5,000	Co-Amoxiclav 1.2 g			<b>440,000.00</b>
101	45,000	Co-Amoxiclav 625 mg			<b>450,000.00</b>
102	4,900	Colchicine 500 mcg			<b>9,800.00</b>
103	1,250	Complete and Balanced Diabetes Nutrition Supplement Formula Powder with Sucromalt and Fibersol, 900 g			<b>2,458,750.00</b>
104	2,600	Complete and Balanced Nutrition Formula for Adult with HMB, 850 g			<b>4,498,000.00</b>
105	23,300	Cotrimoxazole 800/160mg			<b>24,465.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
106	15,450	Dapagliflozin 10 mg			<b>540,750.00</b>
107	16,000	Dapagliflozin 10 mg / Metformin 1000 mg			<b>912,000.00</b>
108	15,000	Dapagliflozin 10 mg / Metformin 500 mg			<b>855,000.00</b>
109	15,000	Dapagliflozin 5 mg / Metformin 500 mg			<b>600,000.00</b>
110	40	Depotrust 50 mg/ml x 3 ml			<b>5,280.00</b>
111	6,000	Desloratidine 5 mg			<b>92,400.00</b>
112	280	Dexamethasone 1mg Neomycin SO4 3,500 IU mg Polymyxin B SO4 6,000u			<b>82,600.00</b>
113	5,000	Dexamethasone 500 mg			<b>6,900.00</b>
114	1,500	Dextrose + Vitamins for I.V. 500 ml			<b>1,200,000.00</b>
115	1,220	Dextrose 5% Lactated Ringer Solution 1L			<b>67,868.60</b>
116	1,600	Dextrose 5% Normal Saline Solution 1L			<b>89,008.00</b>
117	1,100	Dextrose 5% Water 1L			<b>61,193.00</b>
118	300	Dextrose 50%, 50 ml			<b>18,450.00</b>
119	1,120	Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium			<b>98,000.00</b>
120	5,200	Di-Alpha Tocopheryl Acetate (Vitamin E) + Selenium 400/IU 50mcg Softgel Capsule + Mineral (30cap / bot)			<b>3,120,000.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
121	210	Diazepam 10 mg / 2 ml			<b>19,966.80</b>
122	640	Diazepam 5 mg			<b>7,040.00</b>
123	1,090	Diclofenac Sodium 25 mg/ml, 3 ml			<b>12,796.60</b>
124	23,000	Diclofenac Sodium 50 mg			<b>14,030.00</b>
125	8,000	Dicycloverine HCl 10 mg			<b>3,520.00</b>
126	12,500	Digoxin 0.25 mg			<b>50,875.00</b>
127	500	Digoxin 250 mcg/ml			<b>117,975.00</b>
128	50,300	Diltiazem 60 mg			<b>241,440.00</b>
129	10,300	Diosmin 450 mg + Hesperidin 50 mg			<b>237,930.00</b>
130	31,000	Diphenhydramine HCl 50 mg			<b>162,130.00</b>
131	1,620	Diphenhydramine HCl 50 mg/ml			<b>38,005.20</b>
132	10,000	Divalproex Na 250 mg IR (Immediate Release)			<b>149,600.00</b>
133	3,300	Divalproex Sodium 500 mg			<b>55,110.00</b>
134	11,700	Domperidone 10 mg			<b>41,886.00</b>
135	6,000	Donepezil 5mg			<b>444,000.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
136	10,000	Dopamine 40 mg/ml, 5 ml			<b>377,600.00</b>
137	25,600	Doxofylline 400 mg			<b>253,440.00</b>
138	10,800	Doxycycline 100 mg			<b>11,340.00</b>
139	20	Drospirenone estradiol			<b>23,694.00</b>
140	400	Dutasteride 500 mcg + Tamsulosin HCl 400 mcg			<b>14,080.00</b>
141	10,500	Enalapril Maleate 10 mg			<b>58,695.00</b>
142	1,000	Energy Dense Nutritional Powder Formula w/ Increased Protein Content w/ Omega 3 EPA & Antioxidant 380g			<b>800,000.00</b>
143	16,400	Eperisone HCl 50 mg			<b>246,000.00</b>
144	10,100	Epinephrine SO4 1mg/ml, 1 ml			<b>85,345.00</b>
145	150	Epoetin Alpha, 4000 iu/ml			<b>165,000.00</b>
146	250	Epoetin Beta 5,000 IU/0.3 ml			<b>295,625.00</b>
147	2,300	Erythromycin 500 mg			<b>10,373.00</b>
148	10,000	Escitalopram Oxalate 10 mg			<b>34,300.00</b>
149	27,000	Esomeprazole 40 mg			<b>675,000.00</b>
150	37,000	Essential Phospholipids softgel 300 mg			<b>814,000.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
151	3,400	Eterocoxib 60 mg			<b>91,800.00</b>
152	1,800	Ethambutol 300 mg			<b>7,920.00</b>
153	5,000	Ethambutol 400 mg			<b>17,500.00</b>
154	3,250	Etoricoxib 120 mg			<b>276,250.00</b>
155	300	Evening Primrose Oil Capsule			<b>7,383.00</b>
156	9,000	Eye Vitamins, Alpha Lipoic Acid 200 mg, Vit C 75 mg, Lutein powder 20 mg, Vit E 12 mg, Copper			<b>252,000.00</b>
157	2,500	Febuxostat 40 mg			<b>30,250.00</b>
158	25,000	Febuxostat 80 mg			<b>325,000.00</b>
159	31,000	Fenofibrate 145 mg			<b>1,050,280.00</b>
160	526,000	Ferrous Sulfate 300 mg + Folic Acid 250mg			<b>725,880.00</b>
161	650	Floucinolone cream 0.03%			<b>97,500.00</b>
162	1,060	Fluocinolone 0.25%, Neomycin SO4 3.5 mg, Polymyxin B SO4 10,000 Units Ear Drops			<b>226,840.00</b>
163	3,400	Fluconazole 150 mg			<b>187,000.00</b>
164	15,200	Flunarizine HCl 5 mg			<b>577,600.00</b>
165	1,534	Fluocinolone acetonide 250 mcg, neomycin sulfate 3.5 mg, polymyxin B sulfate 10,000 unit Otic, 5 ml			<b>460,200.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
166	400	Fluoxetine HCl 20 mg			<b>18,800.00</b>
167	320	Fluticasone Propionate Nasal Spray 50 mcg			<b>84,480.00</b>
168	4,500	Formula powder with Glutamine, Arginine & Fish Oil 400 g/can (vanilla/melon flavor)			<b>4,293,000.00</b>
169	3,200	Furosemide 10mg/ml, 2 ml			<b>212,960.00</b>
170	21,000	Furosemide 40 mg			<b>33,600.00</b>
171	2,400	Fusidate Sodium 10cm x 10cm Intertulle			<b>224,400.00</b>
172	5,000	Fusidate Sodium 2% Ointment 5 g			<b>750,000.00</b>
173	6,000	Fusidic Acid 2% + Betamethasone Dipropionate oint., 5 g			<b>2,164,800.00</b>
174	6,150	Fusidic Acid 2% Cream 5 g			<b>293,109.00</b>
175	1,030	Fusidic Acid 2% w/ Betamethasone w/ 0.064% Dip. Cream, 5 g			<b>371,624.00</b>
176	2,500	Gabapentin 100 mg			<b>19,625.00</b>
177	2,000	Gentamicin Sulfate 0.3% Ophthalmic/Otic drops, 5 ml			<b>600,000.00</b>
178	80,000	Gingko Biloba + Nattokinase Extract + Policosanol and fish Oil			<b>3,200,000.00</b>
179	7,000	Glibenclamide 5 mg			<b>46,900.00</b>
180	5,000	Gliclazide 30 mg			<b>30,800.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
181	22,000	Gliclazide 60 mg MR			<b>176,220.00</b>
182	17,000	Glimiperide 2 mg			<b>31,790.00</b>
183	17,000	Glipizide 5 mg			<b>112,200.00</b>
184	50,000	Glucosamine HCl, Boswella Extract, Chondroitin SO4, Bioflavanoids & Vitamin C 620mg			<b>1,500,000.00</b>
185	16,000	Glucosamine Sulfate 495mg + Chondroitin Sulfate 400mg			<b>512,000.00</b>
186	25,300	Glucosamine Sulfate 500mg (Calcium Citrate, chondroitin, coledalciferol)			<b>619,850.00</b>
187	25,000	Glucosamine Sulfate, Sodium Chloride 1.884g			<b>1,215,000.00</b>
188	10,000	Guiafenesin 500mg			<b>35,800.00</b>
189	13,600	Guiafenesin 50mg / Salbutamol 1mg			<b>32,232.00</b>
190	3,000	Hydralazine HCl 20mg/ml			<b>52,440.00</b>
191	1,000	Hydrocortisone 1% Cream 5g			<b>113,300.00</b>
192	5,000	Hydrocortisone Sodium Succinate 100mg			<b>114,900.00</b>
193	11,600	Hydrocortisone Sodium Succinate 250mg			<b>556,800.00</b>
194	10,310	Hydroxyzine diHCl 10mg			<b>147,433.00</b>
195	33,000	Hyoscine N Butylbromide 10mg			<b>149,160.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date





Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
196	2,850	Hyoscine N Butylbromide 20 mg/ml x 1ml			<b>66,861.00</b>
197	5,450	Hypromellose 0.3% x 10ml			<b>637,432.00</b>
198	11,000	Ibuprofen 400mg			<b>12,980.00</b>
199	1,600	Inosine Dipepranol Immunosin 500mg			<b>36,256.00</b>
200	3,500	Insulin 70/30 100 IU/ml			<b>385,000.00</b>
201	6,510	Insulin Biphasic Isophane Human (70/30) 100 IU/ml, 10ml			<b>651,000.00</b>
202	650	Insulin Glargine 100 U/ml, 10 ml			<b>1,833,000.00</b>
203	3,010	Insulin Glargine 100 U/ml, 3 ml			<b>1,354,500.00</b>
204	500	Insulin Glargine U 300			<b>649,995.00</b>
205	600	Insulin Glulisine 100 U/ml, 10 ml			<b>1,140,000.00</b>
206	500	Insulin N Isophane Human 100 IU/ml, 10 ml			<b>54,500.00</b>
207	2,550	Ipatropium B 20 mcg + Salbutamol 120 mcg inhaler			<b>1,822,204.50</b>
208	28,800	Ipatropium B 500 mcg + Salbutamol 120 mcg, 2.5 ml			<b>364,320.00</b>
209	300	Iron Sucrose 20 mg/ml			<b>231,000.00</b>
210	2,000	Isosorbide Dinitrate 1mg/1ml, 10 ml			<b>572,000.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
211	20,500	Isosorbide Dinitrate 5 mg sublingual/oral			<b>451,000.00</b>
212	56,500	Isosorbide Mononitrate 60 mg MR			<b>254,250.00</b>
213	6,000	Itopride HCl 50mg			<b>210,000.00</b>
214	200	Itraconazole 100 mg			<b>44,000.00</b>
215	32,800	Ketoanalogues + Essential Amino Acids 630mg			<b>463,792.00</b>
216	7,000	Ketoconazole Cream 2%, 5 g			<b>525,000.00</b>
217	300	Ketorolac 30 mg/ml			<b>26,400.00</b>
218	5,000	Lactated Ringer Solution 1L			<b>230,350.00</b>
219	500	Lactulose 3.3g/5ml, 120 ml syrup			<b>60,000.00</b>
220	12,500	Lagundi 600 mg			<b>41,250.00</b>
221	5,400	Lansoprazole 30 mg			<b>106,920.00</b>
222	10,000	Levocetirizine 5 mg			<b>220,000.00</b>
223	5,000	Levodopa 250 mg + Carbidopa 25 mg			<b>52,000.00</b>
224	8,000	Levofloxacin 500 mg			<b>64,000.00</b>
225	30	Levothyroxine Na 100 mg			<b>148.50</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
226	30,000	Lidocaine 2% + Epinephrine Injection			<b>600,000.00</b>
227	2,530	Lidocaine HCl 2%, 50 ml			<b>98,670.00</b>
228	100	Lidocaine HCl Topical Anesthesia			<b>35,000.00</b>
229	26,600	Linagliptin 2.5 mg + Metformin 500 mg			<b>1,463,000.00</b>
230	30,000	Linagliptin 5 mg			<b>1,500,000.00</b>
231	107,000	Loperamide 2 mg			<b>58,850.00</b>
232	21,500	Loratadine 10 mg			<b>52,030.00</b>
233	126,000	Losartan 50 mg			<b>108,360.00</b>
234	80,500	Losartan K 50mg + HCTZ 12.5mg			<b>72,450.00</b>
235	110,000	Losartan Potassium 50mg + Amlodipine Besylate 5 mg			<b>770,000.00</b>
236	1,000	Mannitol 20%, 250 ml			<b>200,000.00</b>
237	1,500	Mebendazole 100 mg			<b>11,550.00</b>
238	600	Mebendazole 500 mg			<b>60,720.00</b>
239	900	Meclizine HCl 25mg			<b>9,405.00</b>
240	5,000	Mecobalamin 500 mcg			<b>69,650.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
241	85,000	Mefenamic Acid 500 mg			<b>210,800.00</b>
242	5,000	Meloxicam 15 mg			<b>46,750.00</b>
243	5,000	Memantine 10 mg			<b>67,950.00</b>
244	240,000	Metformin 500 mg			<b>129,600.00</b>
245	4,000	Methimazole 20 mg			<b>92,000.00</b>
246	6,000	Methimazole 5 mg			<b>106,020.00</b>
247	10,000	Methisoprinol 500 mg			<b>217,300.00</b>
248	250	Methylprednisolone 40 mg			<b>87,500.00</b>
249	500	Methylprednisolone 5 mg			<b>3,025.00</b>
250	5,250	Metoclopramide 5mg/ml, 2 ml			<b>25,042.50</b>
251	11,300	Metoclopramide HCl 10 mg			<b>12,430.00</b>
252	10,500	Metoprolol Tartrate 100 mg			<b>17,325.00</b>
253	112,500	Metoprolol Tartrate 50 mg			<b>99,000.00</b>
254	800	Metronidazole + Miconazole (vaginal suppository)			<b>161,920.00</b>
255	17,500	Metronidazole 500 mg			<b>53,025.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
256	1,000	Metronidazole 500 mg/100 ml Infusion			<b>16,230.00</b>
257	100	Miconazole Nitrate + Hydrocortisone Cream 15 g			<b>34,430.00</b>
258	2,700	Miconazole Nitrate 2 cream, 5 g			<b>270,000.00</b>
259	500	Modular Amino Acid for healing and Immune Enchancing, Powder scht, 80 Kcal, Glutamine 10.0 G, CHO 9.6 G. Lipid 13.4 G with Fibre 1.2 g. Vitamin C 250mg, Vit E 83mg a-TE, Zn 3.4mg, Selenium 50 u.g. 22.4 g.			<b>100,500.00</b>
260	3,000	Mometasone Furoate 0.1% Ointment 5 g			<b>870,000.00</b>
261	20,700	Montelukast 10 mg + Levocetirizine 5 mg			<b>612,720.00</b>
262	25,800	Montelukast Na 10 mg			<b>198,660.00</b>
263	350	Muconase Nasal 60 ml			<b>120,505.00</b>
264	80,000	Multivitamins & Minerals Tablet with Natural Extract Amino Acid 820mg			<b>2,800,000.00</b>
265	60,000	Multivitamins / Minerals with Lecithin 50mg + Citrus Bioflavanoids 25mg L-lysine HCl 25mg			<b>600,000.00</b>
266	1,190,000	Multivitamins + Minerals + Iron			<b>1,416,100.00</b>
267	8,400	Mupirocin 2% Ointment 5 g			<b>418,824.00</b>
268	26,300	N-Acetylcysteine 600 mg			<b>376,090.00</b>
269	25,000	N-Acetylcysteine 600 mg			<b>907,500.00</b>
270	150	NaCl 0.65% Nasal Spray			<b>9,750.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
271		Nalbuphine 10 mg/ml			15,369.60
272		Naphazoline HCl 0.12 mg/ml eye drops			18,000.00
273		Naproxen 500 mg			26,400.00
274		Neem, Glycyrrhiza Glabra Extract, Polyethylene Glycol, Ficus Infectoria Extract, Pongamia Pinnata Extract, Cassia Tora Extract, Zinc Oxide Celastrus Panniculatus Extract Cream 25g.			1,125,000.00
275		Nicardepine 1mg/ml, 2 ml			275,535.40
276		Nicotinamide + Phosphatidyl + B Complex Forte			220,000.00
277		Nifedipine 10 mg			211,200.00
278		Nifedipine 5 mg			13,860.00
279		Norfloxacin 400 mg			33,456.00
280		Normal Saline Solution 1L			256,762.50
281		Normal Saline Solution 1L (Irrigating Solution)			4,840.00
282		Nutritional Drink with Glutamine, Oligosaccharide, Dietary Fiber - Refreshing Lemon Flavor			3,834,000.00
283		Nystatin Oral Gel			66,192.50
284		Ofloxacin 200 mg			49,830.00
285		Ofloxacin 3mg/ml Ophthalmic/Otic Drops,5ml			417,450.00

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
286	10,000	Ofloxacin 400 mg			<b>77,000.00</b>
287	15,000	Olanzapine 10 mg			<b>69,300.00</b>
288	5,400	Olanzapine 5 mg oral dispersable			<b>197,100.00</b>
289	6,000	Olmesartan + Amlodipine 5 mg			<b>90,000.00</b>
290	20,500	Olmesartan 20 mg + Amlodipine 5 mg + HCTZ 12.5 mg			<b>360,595.00</b>
291	10,000	Olmesartan Medoxomil 20 mg			<b>172,400.00</b>
292	40,500	Omeprazole 20 mg			<b>38,475.00</b>
293	5,100	Omeprazole 40 mg powder			<b>137,088.00</b>
294	23,500	Oral Rehydration Salt, Powder for Oral Solution 5.125g			<b>162,855.00</b>
295	100	Oxymetazoline HCl 0.05%			<b>23,364.00</b>
296	19,000	Pantoprazole 40mg			<b>179,550.00</b>
297	130	Pantoprazole 40mg			<b>87,750.00</b>
298	5,300	Paracetamol 150 mg Injection			<b>35,563.00</b>
299	10,000	Paracetamol 325 mg + Ibuprofen 200 mg			<b>65,000.00</b>
300	23,000	Paracetamol 325 mg + Tramadol 37.5 mg			<b>47,610.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
301		Paracetamol 500 mg			<b>60,500.00</b>
302		Paracetamol 650 mg + Orphenadine Citrate 50 mg			<b>1,032,000.00</b>
303		Permethrin Lotion 5%, 60 ml			<b>1,031,550.00</b>
304		Petroleum Jelly 200 g			<b>283,140.00</b>
305		Phenobarbital 60mg			<b>11,000.00</b>
306		Phenobarbital 90mg			<b>12,100.00</b>
307		Phenylpropanolamine 325mg + Paracetamol 25mg + Chlorphenamine Maleate 2mg			<b>495,000.00</b>
308		Phenytoin Sodium 100 mg			<b>53,200.00</b>
309		Phenytoin Sodium 50mg/ml 2ml			<b>11,365.00</b>
310		Phosphatidyl Choline 300mg, Nicotinamide 30mg, DL-A Tocopheryl Acetate 10mg + Vitamin B2 6mg, B6 10mg, B12 10mcg			<b>375,000.00</b>
311		Pinaverium Br 50mg			<b>4,020.00</b>
312		Pinene 17mg + Camphene 5mg + Cineol 2mg + Menthone 6mg + Methol 32mg + Borneol 5 mg + Olive Oil 33mg			<b>296,434.00</b>
313		Pinene 31mg + Camphene 15mg + Cineol 3mg + Frenchone 4mg + Borneol 10mg, Anethol 4mg, Olive Oil 33mg			<b>231,000.00</b>
314		Pioglitazone 15 mg			<b>300,000.00</b>
315		Pioglitazone 15 mg + Glimeperide 2mg			<b>340,000.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date





Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
316	25,000	Pioglitazone 15 mg + Metformin 500 mg			<b>175,000.00</b>
317	20,000	Pioglitazone 30 mg			<b>360,000.00</b>
318	20,000	Pioglitazone 30 mg + Glimeperide 2mg			<b>420,000.00</b>
319	20,000	Pioglitazone 30 mg + Metformin 500 mg			<b>170,000.00</b>
320	1,500	Piperacillin Sodium 4g + Tazobactam Sodium 500mg			<b>211,744.50</b>
321	2,000	Piracetam 400 mg			<b>11,000.00</b>
322	500	Pirenoxine Na eye solution 0.85mg, 15ml solvent			<b>137,500.00</b>
323	200	Piroxicam 20mg			<b>15,400.00</b>
324	25,000	Pizotifen, Vit B, Nicotinamide			<b>1,093,750.00</b>
325	280	Policresulen 50mg, Cinchocaine HCl 10mg 20g ointment			<b>233,590.00</b>
326	1,000	Potassium Chloride 2 meq/ml, 20 ml injection			<b>44,000.00</b>
327	22,000	Potassium Chloride 600 mg			<b>236,280.00</b>
328	6,800	Potassium Citrate 10 mEq			<b>59,840.00</b>
329	300	Povidone Iodine gargle, 120 ml			<b>44,700.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
330		Pramipexole diHCl 1mg			<b>91,000.00</b>
331		Prasugrel 10mg			<b>2,420,000.00</b>
332		Prednisolone Acetate Eye Drops 1%, 5 ml			<b>52,500.00</b>
333		Prednisone			<b>18,920.00</b>
334		Prednisone 10 mg			<b>110,166.00</b>
335		Prednisone 5 mg			<b>32,004.00</b>
336		Pregabalin 150 mg			<b>24,750.00</b>
337		Pregabalin 75 mg			<b>283,250.00</b>
338		Procaterol HCl 50 mcg Swinghaler 5 ml			<b>1,560,000.00</b>
339		Procaterol HCl 50 mcg			<b>810,000.00</b>
340		Propranolol 10mg			<b>88,550.00</b>
341		Propranolol 40mg			<b>33,220.00</b>
342		Propylthiouracil 50 mg			<b>52,500.00</b>
343		Protein 5 g, fat 2.3 g (saturated fatty acid 0.9 g), carbohydrate 15.7 g (dietary fiber 1.2 g), Na 177 mg (salt equiv 0.44 g), vit B1 0.32 mg, vit B2 0.35 mg, vit B6 0.45 mg, vit B12 0.45 mcg, vit C 80 mg, vit A 82 mcg-RE, vit E 3.5 mg α-TE, vit D 2 mcg, Cl 72 mg, K 156 mg, Ca 94 mg, P 75 mg, Fe 1.1 mg, Zn 1.8 mg. Energy: 100 kCal (Jelly Corn Flavor) 100g			<b>439,500.00</b>
344		Psyllium			<b>54,000.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>ABC</b>
345	500	Purified Vero Cell 0.5ml		<b>750,000.00</b>
346	1,500	Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated)		<b>1,500,000.00</b>
347	400	Quetiapine Fumarate 200mg		<b>66,000.00</b>
348	500	Racicotril 100mg x 20's		<b>19,315.00</b>
349	500	Ranitidine 50 mg/ml		<b>1,925.00</b>
350	300	Ranitidine HCl 150 mg		<b>225.00</b>
351	4,000	Ranitidine HCl 300 mg		<b>30,800.00</b>
352	300	Ranitidine Injection		<b>24,750.00</b>
353	10,000	Rebamipide 100 mg		<b>310,000.00</b>
354	6,500	Rifaximin 200 mg		<b>513,500.00</b>
355	16,300	Risperidone 2 mg		<b>163,000.00</b>
356	20,000	Rosuvastatin 10 mg		<b>420,000.00</b>
357	20,000	Salbutamol + Ipratropium 2.5mg/500mg, 2.5ml		<b>230,000.00</b>
358	5,400	Salbutamol 100 mcg inhaler		<b>1,254,150.00</b>
359	503,500	Salbutamol 2 mg		<b>166,155.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
360	64,500	Salbutamol 2.5 mg / 2.5 ml			<b>453,435.00</b>
361	10,100	Salmeterol + Fluticasone 25/125 mcg Inhaler			<b>2,161,400.00</b>
362	5,210	Salmeterol + Fluticasone 25/250 mcg Inhaler			<b>1,276,450.00</b>
363	1,000	Selegiline HCl 5mg			<b>27,000.00</b>
364	15,000	Serrapeptase 10 mg			<b>525,000.00</b>
365	1,052	Silver Sulfadiazine 1% Cream 20 g			<b>73,408.56</b>
366	2,000	Silymarine + Thiamine + Pyridoxine			<b>44,000.00</b>
367	220,000	Silymarine 125mg + Vit B (1.0000mg) + Vit B2 (1.0000mg) + Vit B6 (0.5000mg) + Vit B12 (0.0005mg)			<b>4,400,000.00</b>
368	6,000	Silymarine 150mg + Thiamine Mononitrate 4mg + Pyridoxine HCl 4mg + Cyanocobalamin 1.2mcg + Nicotinamide 12mg + Calcium Pantothenate 8mg + Lecithin 8mg (30cap / bot)			<b>4,500,000.00</b>
369	800	Simeticone 300 mg			<b>10,472.00</b>
370	2,600	Simvastatin 20 mg			<b>4,628.00</b>
371	12,000	Simvastatin 40 + Fenofibrate 145mg			<b>420,000.00</b>
372	54,000	Simvastatin 40 mg			<b>176,580.00</b>
373	10,000	Sitagliptin 100mg			<b>300,000.00</b>
374	20,000	Sitagliptin 50 mg + Metformin 1 g			<b>700,000.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
375	25,000	Sitagliptin 50 mg + Metformin 500 mg			<b>850,000.00</b>
376	1,045,000	Sodium Ascorbate 568 mg			<b>4,598,000.00</b>
377	1,000	Sodium Bicarbonate 1 meq, 50 ml			<b>66,000.00</b>
378	45,000	Sodium Bicarbonate 1760mg Sodium Citrate 630mg Citric Acid 720mg Tartaric Acid			<b>900,000.00</b>
379	5,800	Sodium Bicarbonate 650 mg			<b>6,380.00</b>
380	2,010	Sodium Chloride 0.9% Solution for Irrigation 1L			<b>92,600.70</b>
381	10,000	Sodium Chloride 1 g			<b>55,000.00</b>
382	5,800	Spirolactone 25 mg			<b>91,814.00</b>
383	500	Spirolactone 25 mg / Butizide 2.5 mg			<b>4,265.00</b>
384	6,000	Spirolactone 50 mg			<b>156,420.00</b>
385	600	Standardized Senna Concentrate 374mg			<b>12,000.00</b>
386	5,000	Sterile Water for Injection, 100 cc			<b>312,500.00</b>
387	5,005	Sterile Water for Injection, 50 cc			<b>281,531.25</b>
388	2,500	Sucralfate 1 g			<b>141,625.00</b>
389	35,000	Sulfur Soap, 135 g			<b>1,470,000.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICES**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

Item No.	Qty.	Agency Specification	Unit Price	Total Bid Price Inclusive of VAT	ABC
390	27,000	Sulodexide 250 mg			<b>1,323,000.00</b>
391	500	Sulodexide 600mg, 2 ml			<b>169,400.00</b>
392	500	Sultamicillin 1.5 g (Ampicillin + Sulbactam 1g/500mg)			<b>107,800.00</b>
393	5,000	Sultamicillin 750 mg			<b>165,000.00</b>
394	10,000	Tamsulosin 400 mg			<b>174,700.00</b>
395	11,000	Terazosin HCl 2 mg			<b>550,000.00</b>
396	35,000	Terazosin HCl 5 mg			<b>2,405,900.00</b>
397	400	Terbinafine Cream 10 g			<b>132,000.00</b>
398	2,000	Terbutaline 2.5 mg			<b>549,000.00</b>
399	20,000	Terbutaline 2.5 mg			<b>44,000.00</b>
400	5,550	Tetanus Toxoid 0.5 ml			<b>349,650.00</b>
401	500	Tetracycline 500 mg			<b>605.00</b>
402	1,600	Thiamine HCl Vit B1 (100mg) Riboflavin - 5 Phosphate Na Vit B25mg, Nicotinamide Vit B3 (100mg) Dexpanthenol 50mg, Pyridoxine HCl Vit B6 (100mg), Cynocobalamin Vit b12 (1mg) 3ml			<b>240,000.00</b>
403	150	Tibolone pack (28's)			<b>84,975.00</b>
404	500	Timolol Maleate Ophthalmic Drops 0.5% x 5 ml			<b>187,500.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



Republic of the Philippines  
 Department of Justice  
**BUREAU OF CORRECTIONS**  
 Muntinlupa City



**SCHEDULE OF PRICE**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
405	200	Tioconazole ointment 5 g			<b>34,100.00</b>
406	5,000	Tiotropium 18 mcg inhaler			<b>875,000.00</b>
407	7,880	Tobramycin 0.3% + Dexamethasone 0.5%, 5 ml Ophthalmic Drops			<b>1,497,200.00</b>
408	4,090	Tobramycin Ophthalmic Drops 3mg/ml, 5 ml Ophthalmic Drops			<b>695,300.00</b>
409	100	Tolnaftate 1% cream, 5 g			<b>33,000.00</b>
410	4,000	Tolvaptan 15 mg			<b>3,080,000.00</b>
411	12,200	Tramadol 50 mg			<b>24,156.00</b>
412	2,500	Tramadol 50 mg/ml			<b>36,350.00</b>
413	2,300	Tranexamic Acid 50 mg/5 ml			<b>34,868.00</b>
414	105,400	Tranexamic Acid 500 mg			<b>579,700.00</b>
415	21,000	Trimetazidine 20 mg			<b>114,450.00</b>
416	2,000	Trimetazidine 35 mg			<b>33,260.00</b>
417	13,100	Ursodeoxycholic Acid 300 mg			<b>563,300.00</b>
418	250	Valproic Acid Solution for Injection 500mg / 5ml			<b>461,500.00</b>
419	20,000	Valsartan 80 mg + Amlodipine 5 mg			<b>185,000.00</b>

Name of Company

Signature over Printed Name  
 of Authorized Representative

Date



Republic of the Philippines  
Department of Justice  
**BUREAU OF CORRECTIONS**  
Muntinlupa City



**SCHEDULE OF PRICE**

***Supply and Delivery of Various Medicines for NBP and CIW 2019***

<b>Item No.</b>	<b>Qty.</b>	<b>Agency Specification</b>	<b>Unit Price</b>	<b>Total Bid Price Inclusive of VAT</b>	<b>ABC</b>
420	20,000	Valsartan 80 mg + HCTZ 12.5 mg			<b>240,000.00</b>
421	31,000	Vildagliptin 50 mg tab			<b>868,000.00</b>
422	25,000	Vildgliptin 50 mg + Metformin 1 g			<b>900,000.00</b>
423	26,000	Vildgliptin 50 mg + Metformin 500 mg			<b>936,000.00</b>
424	25,000	Vildgliptin 50 mg + Metformin 850 mg			<b>900,000.00</b>
425	2,000	Vitamin B Complex 3 ml IV.			<b>300,000.00</b>
426	95,000	Vitamin B1 250mg + B6 250mg + B12 1000mcg			<b>1,615,000.00</b>
427	700	Vitamin C			<b>9,240.00</b>
428	1,000	Vitamin D			<b>6,550.00</b>
429	1,000	Vitamin E			<b>6,600.00</b>
430	300	Zolpidem Tartrate 10 mg			<b>17,958.00</b>

Name of Company

Signature over Printed Name  
of Authorized Representative

Date



## Contract Agreement Form

---

THIS AGREEMENT made the \_\_\_\_ day of \_\_\_\_\_ 20\_\_\_\_ between;

The **BUREAU OF CORRECTIONS (BuCor)**, a government agency organized under and by virtue of the laws of the Republic of the Philippines, under the Department of Justice, with principal office at NBP Reservation, Muntinlupa City, *herein* represented by **USEC. NICANOR E. FAELDON** his capacity as Director General, BuCor, hereinafter referred to as the **ENTITY**.

and

Name of Company registered with the Registration Certificate, with principal office address at \_\_\_\_\_ herein represented by \_\_\_\_\_ in his/her capacity as Proprietor/Authorized Representative, hereinafter referred to as the **SUPPLIER**.

WHEREAS the Entity invited Bids for certain goods and ancillary services, viz., **Supply and Delivery of Various Medicines for NBP and CIW 2019**, and has accepted a Bid by the Supplier for the supply of those goods and services in the sum of *Bid Price* (hereinafter called “the Contract Price”).

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to.
2. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz.:
  - (a) The Supplier’s Bid, including the Technical and Financial Proposals, and all other documents/statements submitted (e.g. bidder’s response to clarifications on the bid), including corrections to the bid resulting from the Procuring Entity’s bid evaluation;
  - (b) the Bid Data Sheets;
  - (c) the Schedule of Requirements;
  - (d) the Technical Specifications;
  - (e) the General Conditions of Contract;
  - (f) the Special Conditions of Contract;
  - (g) the Entity’s Notification of Award; and
  - (h) the Performance Security;
3. In consideration of the payments to be made by the Entity to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Entity to provide the goods and services and to remedy defects therein in conformity in all respects with the provisions of the Contract
4. The Entity hereby covenants to pay the Supplier in consideration of the provision of the goods and services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the contract at the time and in the manner prescribed by the contract.

IN WITNESS whereof the parties hereto have caused this Agreement to be executed in accordance with the laws of the Republic of the Philippines on the day and year first above written.

**ENTITY**

**SUPPLIER**

**USEC. NICANOR E. FAELDON**  
Director General, BuCor

*Supplier's Name*  
Designation

**SIGNED IN THE PRESENCE OF:**

\_\_\_\_\_

\_\_\_\_\_

**ACKNOWLEDGEMENT**

REPUBLIC OF THE PHILIPPINES )  
\_\_\_\_\_ ) SS

BEFORE ME, a notary public for \_\_\_\_\_ City, personally appeared this \_\_\_\_\_ the following persons with their competent proofs of identity as indicated below:

NAME	COMPETENT PROOF OF IDENTIFICATION
USEC NICANOR E. FAELDON	

Known to me and to me known to be the same persons who executed the foregoing Contract Agreement and acknowledgement to me that same is their own free and voluntary act and deed and that of the respective entities that they represent.

This instrument consisting of two (2) pages, including this page whereon the acknowledgement is written has been signed by the parties and witnesses on each and every page thereof.

WITNESS MY HAND AND SEAL on this \_\_\_\_\_ day of \_\_\_\_\_, 2019 in the \_\_\_\_\_, Philippines.

Doc. No. \_\_\_\_\_  
Page No. \_\_\_\_\_  
Book No. \_\_\_\_\_  
Series of 20\_\_\_\_\_

